US20150157586A1 - Penetrating pharmaceutical foam - Google Patents

Penetrating pharmaceutical foam Download PDF

Info

Publication number
US20150157586A1
US20150157586A1 US14/528,038 US201414528038A US2015157586A1 US 20150157586 A1 US20150157586 A1 US 20150157586A1 US 201414528038 A US201414528038 A US 201414528038A US 2015157586 A1 US2015157586 A1 US 2015157586A1
Authority
US
United States
Prior art keywords
composition
carrier
active agent
foam
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/528,038
Inventor
Dov Tamarkin
Doron Friedman
Meir Eini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vyne Pharmaceuticals Ltd
Original Assignee
Foamix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46302609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20150157586(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IL15248602A external-priority patent/IL152486A0/en
Priority claimed from PCT/IB2003/005527 external-priority patent/WO2004037225A2/en
Priority claimed from US10/911,367 external-priority patent/US20050069566A1/en
Application filed by Foamix Pharmaceuticals Ltd filed Critical Foamix Pharmaceuticals Ltd
Priority to US14/528,038 priority Critical patent/US20150157586A1/en
Assigned to FOAMIX PHARMACEUTICALS LTD. reassignment FOAMIX PHARMACEUTICALS LTD. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: FOAMIX LTD.
Assigned to FOAMIX LTD. reassignment FOAMIX LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FRIEDMAN, DORON, TAMARKIN, DOV, EINI, MEIR
Publication of US20150157586A1 publication Critical patent/US20150157586A1/en
Assigned to PERCEPTIVE CREDIT HOLDINGS II, LP reassignment PERCEPTIVE CREDIT HOLDINGS II, LP PATENT SECURITY AGREEMENT Assignors: FOAMIX PHARMACEUTICALS LTD.
Assigned to VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.) reassignment VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.) RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: PERCEPTIVE CREDIT HOLDINGS II, LP
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/16—Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/062—Oil-in-water emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/31—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/02—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings containing insect repellants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Definitions

  • the invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a surface-active agent and a gelling agent.
  • the foam carrier further comprises active agents and excipients providing beneficial therapeutic properties.
  • Foam products are used for topical applications of drugs and cosmetics. Aerosol products and particularly foams are complicated physical-chemical structures that do not form under arbitrary circumstances. In particular, a special balance between the foam-forming components is important. Slight shifts in the composition may already result in a collapse of the foam; thus, a formulation of per se active substances may not be capable of being formulated as a foam without further provisions.
  • the inventors of the present invention have developed a series of novel emulsion-based foam formulations. See, for example, commonly assigned, co-pending application WO 2004/037225.
  • U.S. Pat. No. 6,423,323 describes a foam skin cream, which optionally contains urea and lactic acid.
  • the skin cream formulation is limited to a very specific list of ingredients that are not contemplated in the present invention.
  • U.S. Pat. No. 4,145,411 describes shaving foam compositions with low levels of mineral oil (0.25-1% by weight) and urea (0.001-0.006% by weight).
  • a shaving foam is, by definition, not breakable and thus cannot readily facilitate topical administration of an active ingredient and especially is not well-suited for topical administration of compositions geared towards skin penetration.
  • an alcohol-free cosmetic or pharmaceutical foamable composition containing at least one active component, selected from the group of: (1) urea, in a concentration of at least 2%; (2) a hydroxy acid in a concentration of at least 1%; and (3) a therapeutic enhancer is provided, which upon admixing with a liquefied gas propellant in an aerosol container releases a breakable foam that is suitable for topical administration.
  • the alcohol-free foam composition is suitable for inclusion of both water-soluble and oil-soluble active agents.
  • a foamable composition includes formulations that are capable of forming a foam when dispensed from an aerosol container.
  • the cosmetic or pharmaceutical foamable composition includes water, a hydrophobic solvent, a surface-active agent and a gelling agent and at least one active component selected from the group of (1) urea in a concentration of at least 2%; (2) a hydroxy acid in a concentration of at least 1%; and (3) a therapeutic enhancer in a concentration of at least 2%; and a liquefied gas propellant in the amount of about 3-18% by weight of the total composition.
  • composition creates an oil-in-water emulsion that is stable in its pre-dispensed state.
  • the composition Upon release from the aerosol container, the composition forms a breakable foam product, which is suitable for topical or mucosal administration.
  • the hydrophobic solvent is included in the foamable composition at a concentration of 5% to about 10% (Class A), or 10% to about 20% (Class B), or about 20% to about 50% (Class C).
  • the surface-active agent concentration is about 0.1% to about 5%; the concentration of the gelling agent is 0.01% to about 5% by weight and the liquefied gas propellant is included at a concentration of about 3% to about 18% of the total composition.
  • Water and optional ingredients are added to complete the total mass to 100%.
  • the hydrophobic solvent content can be between 0% and 5%.
  • each of the above compositions further optionally comprises a foam adjuvant in the concentration range of 0.1% to 5%.
  • the foamable composition does not contain short chain aliphatic alcohols, making it non-irritant and non-drying.
  • a foamable composition in one or more embodiments, includes a foamable composition as described herein and further includes at least one active agent at a therapeutically effective concentration.
  • the foam carrier is suitable for inclusion of both water-soluble and oil-soluble active agents, as well as suspended active agents.
  • Such a composition is suitable for topical treatment of human and animal skin and mucosal disorders or diseases.
  • the composition is suitable for cosmetic treatment, for example, for cleansing, beautifying, promoting attractiveness or altering the appearance without affecting the body structure or function.
  • the foam carrier or composition according to one or more embodiments of the present invention provides various advantages over current foam compositions.
  • the term “about” when used to refer to weight % in a composition means ⁇ 10% of the reported weight %. As used herein, the term “about” when used to refer to measured characteristics of the composition means ⁇ 20% of the reported value.
  • the foamable composition includes a hydrophobic solvent.
  • the hydrophobic solvent includes a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, or less than about 0.5 gm per 100 mL, or less than about 0.1 gm per 100 mL.
  • the hydrophobic solvent is a liquid at ambient (room) temperature, e.g., about 20-30° C.
  • composition Classes A-C The total content of hydrophobic solvent may vary from 5% to 50% (w/w). However, different ranges (herein “composition Classes A-C”) have been designated, in order to facilitate a choice of an appropriate class, according to the anticipated cosmetic or pharmaceutical need. As a rule of thumb, higher hydrophobic solvent concentrations are more appropriate for the treatment of dry skin, and/or for the treatment of a disease, which is more responsive to drugs, delivered in an oily vehicle and regulating the residence of an active ingredient in the target area. Another consideration relates to the usability and tolerability of the product, whereby very high concentration of the hydrophobic solvent (from about 25% of the composition) would leave an oily feeling subsequent to application, which is undesirable in the product. Thus, when using a foamable composition, the hydrophobic solvent concentration is selected in view of the target treated population and the specific needs of the intended treated population.
  • the hydrophobic solvent is mineral oil.
  • Mineral oil (Chemical Abstracts Service Registry number 8012-95-1) is a mixture of aliphatic, naphthalenic, and aromatic liquid hydrocarbons that derive from petroleum. They are typically liquid, their viscosity is in the range of between about 35 CST and about 100 CST (at 40° C.), and their pour point (the lowest temperature at which an oil can be handled without excessive amounts of wax crystals forming so preventing flow) is below 0° C.
  • white petrolatum also termed “Vaseline”
  • white petrolatum is disadvantageous, due to the waxy nature of petrolatum. It is known to leave waxy and sticky feeling after application and occasionally stain cloths. Thus, white petrolatum is not a preferred hydrophobic solvent according to the present invention.
  • hydrophobic solvents include, but are not limited to, liquid oils from vegetable, marine or animal sources.
  • the unsaturated oil is selected from the group consisting of an olive oil, a corn oil, a soybean oil, a canola oil, a cottonseed oil, a coconut oil, a sesame oil, a sunflower oil, a borage seed oil, an syzigium aromaticum oil, a hempseed oil, a herring oil, a cod-liver oil, a salmon oil, a flaxseed oil, a wheat germ oil, an evening primrose oil and any mixtures thereof, at any proportion.
  • a particular class of oils includes polyunsaturated oils, containing omega-3 and omega-6 fatty acids.
  • polyunsaturated fatty acids are linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
  • GLA gamma-linoleic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • the unsaturated oil contains at least 6% of an oil selected from omega-3 oil, omega-6 oil, and mixtures thereof.
  • oils are considered “therapeutic oils” containing active biologically occurring molecules, which, upon topical application, exert a therapeutic effect.
  • examples of such oils are rosehip oil, which contain retinoids and is known to reduce acne and post-acne scars, tea tree oil, which possesses antibacterial, antifungal and antiviral properties.
  • essential oils are basil, camphor, cardamom, carrot, citronella, clary sage, clove, cypress, frankincense, ginger, grapefruit, hyssop, jasmine, lavender, lemon, mandarin, marjoram, myrrh, neroli, nutmeg, petitgrain, sage, tangerine, vanilla, verbena, as well as any other therapeutically beneficial oil, know in the art of herbal medication.
  • solvents includes, but is not limited to, liquid hydrophobic plant-derived oils, which are known to possess therapeutic benefits when applied topically.
  • a further class of hydrophobic solvents is known as the group of “emollients”.
  • suitable emollients for use include isostearic acid derivatives, isopropyl palmitate, lanolin oil, diisopropyl dimerate, maleated soybean oil, octyl palmitate, isopropyl isostearate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, propylene glycol ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycerides, arachidyl propionat
  • the hydrophobic solvent comprises a mixture of mineral oil and an emollient in a ratio between 2:8 and 8:2 on a weight basis.
  • Silicone oils are known for their skin protective properties and may be used as a hydrophobic solvent.
  • the silicone oil is either a volatile silicon oil or a non-volatile silicone oil, wherein water-soluble silicones, such as dimethicone copolyol are not included in the definition of silicone oils (as hydrophobic solvents).
  • the hydrophobic solvent includes at least 2% silicone oil.
  • One or more hydrophobic solvents in any combination can be used.
  • the foamable composition includes a surface-active agent.
  • Surface-active agents include any agent that alters the surface properties of the oil and water components in the composition to aid in the formation of an emulsion.
  • a surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil.
  • the HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics.
  • Lipophilic emulsifiers tend to form water-in-oil (w/o) emulsions; hydrophilic surfactants tend to form oil-in-water (o/w) emulsions.
  • the HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average).
  • any surface-active agent selected from anionic, cationic, non-ionic, zwitterionic, amphoteric and ampholytic surfactants, or combinations thereof may be used as surface-active agent.
  • the surface-active agent has a hydrophilic lipophilic balance (HLB) between about 9 and about 14, which is the required HLB (the HLB required to stabilize an O/W emulsion of a given oil) of most oils and hydrophobic solvents.
  • HLB hydrophilic lipophilic balance
  • the composition is a single surface active agent having an HLB value between about 9 and 14, and in one or more embodiments, the foam composition contains more than one surface active agent and the weighted average of their HLB values is between about 9 and about 14.
  • Non-limiting examples of surfactants include polysorbates, such as polyoxyethylene (20) sorbitan monostearate (Tween 60) and polyoxyethylene (20) sorbitan monooleate (Tween 80); Polyoxyethylene (POE) fatty acid esters, such as Myrj 45, Myrj 49 and Myrj 59; poly(oxyethylene) alkylyl ethers, such as poly(oxyethylene) cetyl ether, poly(oxyethylene) palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1; sucrose esters, partial esters of sorbitol and sorbitol anhydrides, such as sorbitan monolaurate and sorbitan monolaurate-mono or diglycerides, isoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sul
  • the surface-active agent is a non-ionic surfactant.
  • exemplary non-ionic surfactants include mono-, di- and tri-esters of sucrose with food fatty acids (sucrose esters), prepared from sucrose and methyl and ethyl esters of food fatty acids or by extraction from sucroglycerides. Further examples are sucrose esters with high monoester content, which have higher HLB values.
  • a combination of a non-ionic surfactant and an ionic surfactant may be used.
  • a non-ionic surfactant and an ionic surfactant are present in the foam carrier or composition at a ratio of between 1:1 and 20:1 or between 4:1 and 10:1.
  • the ratio between the surface active agent and the hydrophobic solvent is between about 1:8 and about 1:16 or between about 1:16 and about 1:32.
  • Foam adjuvants may optionally be included in the foam composition and include fatty alcohols having 15 or more carbons in their carbon chain, such as cetyl alcohol and stearyl alcohol (or mixtures thereof).
  • fatty alcohols are arachidyl alcohol (C20), behenyl alcohol (C22), 1-triacontanol (C30), as well as alcohols with longer carbon chains (up to C50).
  • concentration of the fatty alcohol, required to support the foam system is inversely related to the length of its carbon chains.
  • Fatty alcohols derived from beeswax including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, are especially well suited as foam adjuvants.
  • foam adjuvants includes fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof.
  • fatty acids having 16 or more carbons in their carbon chain such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof.
  • the carbon atom chain of the fatty alcohol or the fatty acid may have at least one double bond.
  • a further class of foam adjuvant includes a long chain fatty alcohol or fatty acid, wherein the carbon atom chain is branched.
  • the carbon chain of the fatty acid is substituted with a hydroxyl group, such as 12-hydroxy stearic acid.
  • the foam adjuvant may include a mixture of fatty alcohols, fatty acids and hydroxy fatty acids and derivatives thereof in any proportion, providing that the total amount is 0.1% to 5% (w/w) of the carrier mass.
  • the total amount can be 0.4%-2.5% (w/w) of the carrier mass.
  • Long chain saturated and mono unsaturated fatty alcohols e.g., stearyl alcohol, erycyl alcohol, arachidyl alcohol and docosanol have been reported to possess antiviral, anti infective, anti-proliferative and anti-inflammatory properties (U.S. Pat. No. 4,874,794).
  • Longer chain fatty alcohols e.g., tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol, etc. are also known for their metabolism modifying properties and tissue energizing properties.
  • Long chain fatty acids have also been reported to possess anti-infective characteristics.
  • the pharmaceutical or cosmetic composition containing therapeutic foam adjuvant provides an extra therapeutic benefit in comparison with currently used vehicles, which are inert and non-active.
  • Gelling agents include, but are not limited to, naturally-occurring polymeric materials such as, locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum sodium alginate, xanthan gum, quince seed extract, tragacanth gum, starch, chemically modified starches and the like, semi-synthetic polymeric materials such as cellulose ethers (e.g.
  • mixtures of the above compounds are contemplated.
  • gelling agents such as the acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold, for example, by the B.F. Goodrich Company under the trademark of Carbopol RegisteredTM resins.
  • These resins consist essentially of a colloidally water-soluble polyalkenyl polyether crosslinked polymer of acrylic acid crosslinked with from 0.75% to 2% of a crosslinking agent such as polyallyl sucrose or polyallyl pentaerythritol. Examples include Pemulene TR1 and TR2, Carbopol 934, Carbopol 940, Carbopol 950, Carbopol 980, Carbopol 951 and Carbopol 981.
  • Carbopol 934 is a water-soluble polymer of acrylic acid crosslinked with about 1% of a polyallyl ether of sucrose having an average of about 5.8 allyl groups for each sucrose molecule.
  • the gelling agent is selected from the class of amphiphilic copolymers.
  • Amphiphilic copolymers include polymers having hydrophobic groups and hydrophilic groups or regions. These materials are referred to alternatively as “polymeric surfactants” because the hydrophilic and hydrophobic regions of the polymers serve to interact with and stabilize hydrophilic and lipophilic components, respectively, of a composition.
  • the copolymer may be a random copolymer, a block copolymer of a graft or comb copolymer.
  • Exemplary amphiphilic copolymers include di-, tri- or multi-block copolymer or graft copolymer of a biodegradable polymer.
  • the Amphiphilic copolymer may be an acrylate copolymer, in which hydrophobic moieties are chemically linked to hydrophilic polymer or hydrophilic moieties are attached to hydrophobic polymers to produce amphiphilic surface active and surface stabilizing agent.
  • suitable amphiphilic copolymers include cross linked copolymers of acrylic acid and a hydrophobic comonomer, such as Pemulen TR-1 and Pemulen TR-2, ETD 2020 and Carbopol 1382 (all, Acrylates/C10-30 alkyl acrylate crosspolymer), Natrosol CS Plus 330 and 430 and Polysurf 67 (all, cetyl hydroxyethyl cellulose), Aculyn 22 (acrylates/steareth-20 methacrylate copolymer), Aculyn 25 (acrylates/laureth-25 methacrylate copolymer), Aculyn 28 (acrylates/beheneth-25 methacrylate copolymer), Aculyn 46 (PEG-150/stearyl alcohol/SMDI copolymer), Stabylen 30 (acrylates/vinyl isodecanoate), Structure 2001 (acrylates/steareth-20 itaconate copolymer), Structure 3001 (acrylates/ceteth-20
  • amphiphilic copolymers include silicone polymers such as amphiphilic silicone polyols or copolyol, for example cetyl dimethicone copolyol and dimethicone copolyol PPG-3 oleyl ether, acetylated starch derivatives, amphiphilic modified starches, and amphiphilic block copolymers of ethylene oxide, propylene oxide and/or propylene glycol (also known as “poloxamer”).
  • silicone polymers such as amphiphilic silicone polyols or copolyol, for example cetyl dimethicone copolyol and dimethicone copolyol PPG-3 oleyl ether, acetylated starch derivatives, amphiphilic modified starches, and amphiphilic block copolymers of ethylene oxide, propylene oxide and/or propylene glycol (also known as “poloxamer”).
  • One or more gelling agents in any combination can be used.
  • the gelling agent is present in the foam composition in an amount of about 0.1% to 5.0%. In one or more embodiments, the gelling agent included in the foamable composition can be less than 1% of the foamable composition.
  • urea is included in the foam composition as an active component.
  • Urea has been long recognized as a cosmetic ingredient in formulations acting as a humectant and moisturizer. There have been reports of keratolytic activity attributed to urea with the ability at high concentrations to solubilize and denature protein. High concentrations of urea are also known to have a mild, antimicrobial effect. Urea further possesses skin exfoliating properties, which are useful in the control of passage of active agents through the dermal barrier.
  • Urea preparations especially those containing high urea concentration are provided in gels, creams, lotions and pastes, but not in foam. Foam is preferable in many cases where urea is needed for therapy. For example, xerosis, which is a common indication for high concentration urea preparations, is disseminated over large skin areas, and thus, the foam of the present invention, having low specific gravity and excellent spreading and absorption properties is advantageous.
  • urea is contained in the foam composition in an amount from about 1% to about 50% of the total composition.
  • compositions contain from about 10% to about 20%, and from about 20% to about 50%, depending on the intended use.
  • urea can serve as means to induce dermal penetration of a variety of drugs or cosmetic active agents. Furthermore, in many dermatological disorders, having urea, with its beneficial properties as mentioned above and a drug or cosmetic active agent provides a synergistic therapeutic effect. This is also the case when urea, which is known for its antibacterial and antifungal effects, is combined with another anti-infective agent.
  • the foamable composition includes urea and at least one pharmaceutical or cosmetic active agent, as defined hereinbelow.
  • the penetration of the active agent is enhanced due to the urea present in the foam composition.
  • a foam according to the present invention includes a foamable composition containing urea in a therapeutically—effective concentration.
  • the foamable composition forms an emulsion of oil and water including a hydrophobic solvent at a level described herein as Class A, Class B, or Class C.
  • a hydroxy acid is included in the foam composition as an active component.
  • Hydroxy acids are useful in increasing the clarity of the skin surface, increasing cellular turnover, and increasing skin radiance and smoothness. They further possess skin exfoliating properties, which are useful in the control of passage of active agents through the dermal barrier.
  • Suitable hydroxy acids include alpha- or beta-hydroxy acids, poly-hydroxy acids, or any combinations of any of the foregoing.
  • the hydroxy acid can be an alpha-hydroxy acid.
  • alpha hydroxy acids include, but are not limited to, glycolic acid, lactic acid, malic acid, citric acid, alpha-hydroxyethanoic acid, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic acidglycolic acid, tartaric acid, pyuric acid, citric acid, as well as their corresponding salts and pharmaceutically-acceptable derivatives; or any combination of any of the foregoing.
  • Beta-hydroxy acids include, but are not limited to, salicylic acid, beta hydroxybutanoic acid, tropic acid and trethocanic acid.
  • hydroxy acids can serve as means to induce dermal penetration of a variety of drugs or cosmetic active agents. Furthermore, in many dermatological disorders, having urea, with its beneficial properties as mentioned above and a drug or cosmetic active agent provides a synergistic therapeutic effect.
  • the foamable composition comprises a hydroxy acid and at least one pharmaceutical or cosmetic active agent, as defined hereinbelow.
  • the hydroxy acid is contained in the foamable composition in an amount from about 1% to about 30% of the total composition.
  • the compositions can contain from about 1% to about 10% and from about 10% to about 30%, depending on their designated use.
  • a therapeutic enhancer is included in the foam composition as an active component.
  • a therapeutic enhancer is a material that facilitates an enhanced delivery of an active agent into a target site of treatment, thus enabling an improved therapeutic effect.
  • Suitable therapeutic enhancers include polyhydric alcohols having at least two hydroxy groups, or at least three hydroxy groups, or a derivative of a polyhydric alcohol.
  • Non-limiting examples are propylene glycol, butylene glycols, glycerol, pentaerythritol, sorbitol, mannitol, oligosaccharides, dimethyl isosorbide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), polyethylene glycol 200-600, transcutol (diethylene glycol monoethyl ether) and glycofurol (tetrahydrofurfuryl alcohol PEG ether).
  • the therapeutic enhancer can further comprise at least cyclodextrins a related compounds. Cyclodextrins are structurally related cyclic oligomaltoses, which form a new group of pharmaceutical excipients.
  • Cyclodextrins are capable of forming water-soluble inclusion complexes with a wide variety of lipophilic water-insoluble drugs by taking up a whole drug molecule, or some part of it, into the cavity.
  • the cyclodextrin molecules are relatively large (molecular weight ranging from almost 1000 to over 1500), with a hydrated outer surface, and under normal conditions, cyclodextrin molecules will only permeate the skin barrier with considerable difficulty. It is generally believed that the cyclodextrin molecules act as true carriers by keeping lipophilic drug molecules in solution and deliver them to the skin surface where they partition from the cyclodextrin cavity into the skin.
  • the therapeutic enhancer is contained in the foamable composition in an amount from about 2% to about 30% of the total composition.
  • the compositions can contain from about 2% to about 10% and from about 10% to about 30%, depending on their designated use.
  • the foam composition is useful and advantageous for the treatment of skin disorders and for skin care and cosmetic care.
  • the addition of an oil having refatting, protective and moisture-retaining properties in a spreadable foam form can substitute for currently available dermatological and cosmetic creams, lotions, gels, etc.
  • the foam composition includes an active agent directed to the treatment of a medical disorder or a cosmetic disorder.
  • the active agent can be categorized by the benefit it provides or by its postulated mode of action.
  • the active agents can in some instances provide more than one benefit or operate via more than one mode of action. Therefore, classifications are made for the sake of convenience and are not intended to limit the active to that particular application or applications listed.
  • foam compositions, with or without further active ingredients are suitable for the application as “cosmeceutical” preparations.
  • antibacterial agents include, but is not limited to, any substance being destructive to or inhibiting the growth of bacteria or any substance having the capacity to inhibit the growth of or to destroy bacteria and other microorganisms, and are used in the treatment of infectious diseases. It is well known that bacterial infections are involved in a variety of superficial disorders of the skin, eye, mucosal membrane, oral cavity, vagina and rectum.
  • the antibacterial drug can be active against gram positive and gram-negative bacteria, protozoa, aerobic bacteria and unaerobic ones.
  • the antibacterial drug is selected from the group consisting of chloramphenicol, tetracyclines, synthetic and semi-synthetic penicillins, beta-lactams, quinolones, fluoroquinolnes, macrolide antibiotics, metronidazole and metronidazole derivatives and analogs, dicarboxylic acids, such as azelaic acid, silicylates, peptide antibiotics, cyclosporines and any combination thereof at a therapeutically effective concentration.
  • Another group of antibacterial agents is non-specific and includes strong oxidants and free radical liberating compounds, such as hydrogen peroxide, bleaching agents (e.g., sodium, calcium or magnesium hypochlorite and the like) iodine, chlorohexidine and benzoyl peroxide.
  • bleaching agents e.g., sodium, calcium or magnesium hypochlorite and the like
  • iodine e.g., sodium, calcium or magnesium hypochlorite and the like
  • chlorohexidine e.g., benzoyl peroxide.
  • Exemplary foamable compositions are particularly useful and beneficial in the prevention and treatment of secondary infections, accompanying skin-structure damage, such as in cuts, wounds, burns and ulcers.
  • the present formulation is easy to use, being in foam state when applied and becoming liquid upon rubbing onto the skin.
  • the antibacterial foam is also applicable for decontaminating areas, afflicted with bacterial warfare organisms, such as anthrax and smallpox.
  • Fungal infections are another object of treatment using the foamable composition.
  • Superficial fungal infection of the skin is one of the commonest skin diseases seen in general practice. Dermatophytosis is probably the most common superficial fungal infection of the skin. Dermatophytosis is caused by a group of fungi capable of metabolizing the keratin of human epidermis, nails or hair. There are three genera of dermatophytes causing dermatophytosis, i.e., microsporum, trichophyton and epidermophyton.
  • Candidiasis is an infection caused by the yeast like fungus candida albicans or occasionally other species of candida .
  • Clinical syndromes of candidiasis include: (a) oral candidiasis (oral thrush); (b) candidiasis of the skin and genital mucous membrane; (c) candida paronychia , which inflicts the nail; and (d) genital and vaginal candida , which inflict genitalia and the vagina.
  • the pharmaceutical composition can include an antifungal drug that is effective against dermatophytes and candida .
  • the antifungal drug is selected from the group consisting of azoles, diazoles, triazoles, miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B, potassium iodide, flucytosine (5FC) and any combination thereof at a therapeutically effective concentration.
  • the foam composition according to one or more embodiments of the present invention is useful, for example, for the treatment of tinea corporis, tinea pedis, tinea rubrum, tinea unguium, tinea cruris, tinea barbae and tinea versicolor, as well as yeast Infections, such as candidiasis, and candidal vaginitis.
  • any known antiviral drugs in a therapeutically effective concentration, can be incorporated into the foam composition.
  • Exemplary compositions are particularly beneficial in the case of viral infections.
  • Cold sores are caused by the herpes simplex Type 1 virus and are sometimes referred to as facial herpes.
  • Mollusca are small viral growths that appear singly or in groups on the face, trunk, lower abdomen, pelvis, inner thighs, or penis.
  • Shingles (herpes zoster) usually occurs only once in a lifetime, appears as a rash (clusters of blisters with a red base). Shingles is caused by the same virus that is responsible for chickenpox. Warts are a common, benign skin tumor caused by viral infection.
  • the active agent can be an anti-inflammatory or antiallergic agent.
  • anti-inflammatory or antiallergic agents include corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), anti-histamines, immunosuppressants and any combination thereof at a therapeutically effective concentration.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • anti-histamines anti-histamines
  • immunosuppressants any combination thereof at a therapeutically effective concentration.
  • the anti-inflammatory active agent is a corticosteroid.
  • the corticosteroid can be selected from the group consisting of clobetasol proprionate, halobetasol proprionate, betamethasone diproprionate, betamethasone valerate, fluocinolone acetonide, halcinonide, betamethasone valerate, fluocinolone acetonide, hydrocortisone valerate, triamcinolone acetonide, hydrocortisone and any combination thereof at a therapeutically effective concentration.
  • corticosteroid drugs are typically hydrophobic
  • suitable foam carriers include high levels of a hydrophobic solvent. The hydrophobic solvent facilitates topical distribution and enhances the rate of penetration of any of the corticosteroid drugs.
  • the composition may include active agents for the treatment of psoriasis.
  • Corticosteroid ointments greasy preparations containing little or no water, are commonly used for treating psoriasis.
  • Their main disadvantage is in a sticky feeling subsisting for extended periods subsequent to treatment being completed thereby creating a latent inconvenience and possible discomfort to the treatment recipient.
  • the foam composition according to one or more embodiments of the present invention containing high levels of an oil (hydrophobic solvent) spreads very easily throughout the afflicted area and absorbs into the skin without leaving any unpleasant sensation or look.
  • Examples of other inflammatory disorders that are treatable by a foamable composition including a steroid as an active agent are atopic dermatitis, seborrhea, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis (gravitational eczema; varicose eczema), exfoliative dermatitis (erythroderma), lichen simplex chronicus, pityriasis rosea and pemphigus.
  • Topical antihistaminic preparations currently available include 1% and 2% diphenhydramine (Benadryl® and Caladryl®), 5% doxepin (Zonalon®) cream, phrilamine maleate, chlorpheniramine and tripelennamine, phenothiazines, promethazine hydrochloride (Phenergan®) and dimethindene maleate. These drugs, as well as additional antihistamines, can also be used.
  • Polyunsaturated fatty acids containing omega-3 and omega-6 fatty acids e.g., linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also are beneficial in the treatment of psoriasis and other skin inflammation conditions and may be included in the foamable composition.
  • omega-3 and omega-6 fatty acids e.g., linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
  • GLA gamma-linoleic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • Nonsteroidal anti-inflammatory agents are useful against skin and systemic bio-abnormalities and can be added to the foam composition.
  • NSAIDs include, but are not limited to oxicams, such as piroxicam, isoxicam, tenoxicam, sudoxicam; salicylates, such as salicylic acid, ethyl salicylate, methyl salycilate, aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal; acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac,
  • Any other steroidal and nonsteroidal compounds having the capacity to prevent, alleviate the symptoms of, treat or cure inflammation processes, may be generally included as anti-inflammatory agents.
  • the pharmaceutical composition may include an anti-inflammatory and/or an antiallergic agent that reduces the occurrence of pro-inflammatory cytokines or inhibits the effect of pro-inflammatory cytokines.
  • compositions can be used in the composition, as well as the dermatologically acceptable salts, esters, amides, prodrugs and derivatives of these agents.
  • Topical application of a foam, comprising a safe and effective dose of an NSAID can be useful in the prevention and/or alleviation of the symptoms of rheumatoid arthritis, osteoarthritis and pain.
  • Topical NSAIDs, incorporated in the foam composition can be also used in the treatment of dermatological disorders such as acne, rosacea, hair growth disorders, actinic keratosis and certain skin cancer conditions.
  • the foam compositions may include an effective amount of a topical anesthetic.
  • the topical anesthetic can be selected from the group consisting of benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine, phenol, any pharmaceutically acceptable salts thereof and mixtures of such anesthetic agents. Any mixture of synergistically beneficial anesthetic agents is contemplated
  • a keratolytic agent may be included as an active agent of a foamable composition.
  • the term “keratolytically active agent” as used herein includes a compound that loosens and removes the stratum corneum of the skin, or alters the structure of the keratin layers of skin. Keratolytically active agents are used in the treatment of dermatological disorders that involve dry skin, hyperkeratinization (such as psoriasis), skin itching (such as xerosis), acne and rosacea.
  • Suitable keratolytically active agents include phenol and substituted phenolic compounds. Such compounds are known to dissolve and loosen the intracellular matrix of the hyperkeratinized tissue. As such, they are used in the treatment of dermatological disorders. Dihydroxybenzene and derivatives thereof have been recognized as potent keratolytic agents. Resorcinol (m-dihydroxybenzene) and derivatives thereof are used in anti-acne preparations. In addition to hydroquinone (p-dihydroxybenzene) having anti-pigmentation properties, hydroquinone is also known to be keratolytic. These compounds also exhibit antiseptic properties. Cresols also possess bactericidal and keratolytic properties.
  • Vitamin A and vitamin A derivatives also termed herein “retinoids”, such as retinoic acid, isoretinoic acid, retinol and retinal are another class of keratolytically active agents.
  • keratolytically active agents include alpha-hydroxy acids, such as lactic acid and glycolic acid and their respective salts and derivatives; and beta-hydroxy acids, such as salicylic acid (o-hydroxybenzoic acid) and salicylic acid salts and pharmaceutically acceptable derivatives.
  • alpha-hydroxy acids such as lactic acid and glycolic acid and their respective salts and derivatives
  • beta-hydroxy acids such as salicylic acid (o-hydroxybenzoic acid) and salicylic acid salts and pharmaceutically acceptable derivatives.
  • retinoids include retinol, retinal, all trans retinoic acid and derivatives, isomers and analogs thereof, collectively termed “retinoids”.
  • Etretinate, actiretin, isotretinoin, adapalene and tazarotene are further examples of said retinoid isomers and analogs.
  • Foamable compositions containing retinoids as the active drug can be used for the treatment of acne, seborrhea, various dermatoses, inflammation of the skin, mucosal membranes, vagina and the rectum, psoriasis, actinic keratosis and skin cancers, by application onto the affected area.
  • Insects such as mosquitoes, biting flies, mites, gnats, fleas, chiggers, punkies, sand flies, lice and ticks can be annoying and sometimes pose a serious risk to human and animal health.
  • mosquitoes can transmit diseases like equine and St. Louis encephalitis.
  • Biting flies can inflict a painful bite that can persist for days, swell, and become infected.
  • Ticks can transmit serious diseases like Lyme disease and Rocky Mountain spotted fever.
  • Insect repellents may be added to the foamable composition to protect people and animals from flying or biting insects, spiders, ticks and mites.
  • insect repellants include, but are not limited to, DEET (N, N-diethyl-m-toluamide), dimethyl phthalate, piperonyl butoxide and permethrin. Insect repelling terpenoids, have been reported by Hwang, et al, J. Chem. Ecol., 11, 1297 (1985); and Ruledge, J. Am. Mosquito Control Assoc. 4, 414 (1988).
  • a particular group of insect repellents includes the terpenoid compounds, described in U.S. Pat. No. 5,411,992, including:
  • Terpenoid-alcohol or terpene-ols are terpenoids which have at least one hydroxyl group.
  • terpene-ols include: C10H16O compounds, perillyl alcohol, carveol, myrtenol, and cis-verbenol; C10H18O compounds, myrtanol, iso-pinocampheol, dihydrocarveol, isopulegol, terpineol, terpinen-4-ol, nerol, geraniol, and linalool, and C10H20O compounds, menthol, beta-citronellol, and dihydro-myrcenol.
  • Terpenoid-esters are terpenoids, which have at least one ester group which is the product of the bonding of the hydroxyl group of a terpene-ol with an aliphatic carboxylic acid that can contain functional groups such as the hydroxyl or amine on the aliphatic chain.
  • suitable aliphatic carboxylic acids include acetic acid, propionic acid, lactic acid, and various amino acids.
  • terpenoid-esters include: carvyl acetate, carvyl propionate, and menthyl lactate.
  • Essential oils which contain terpenoids and perfumes which contain terpenoids include bergamot (62% terpenoids); sage (>50% terpenoids); styrax (>50% terpenoids); peppermint (>50% terpenoids); and pine Siberian (75% terpenoids %).
  • Terpenes, aldehydes and ketones vary in their usefulness but as a general group have potential as insect-repellent.
  • the foamable composition is particularly suitable for the effective uniform spreading of an insect repellent agent onto large areas of the skin of humans and animals.
  • the hydrophobic solvent present in the foam composition helps retain the insect repellent on the skin surface for an extended period of time.
  • the foamable composition is suitable for delivery of insect-killing agents (insecticides) to an afflicted external surface area of humans and animals.
  • insect-killing agents insect-killing agents
  • the pharmaceutical or cosmetic composition includes an insecticide selected from the group consisting of permethrin, hexachlorobenzene, carbamate, naturally occurring pyrethroids, permethrin, allethrin, malathion, piperonyl butoxide and any combination thereof at a therapeutically effective concentration.
  • the application of the composition is very convenient and it spreads easily, even over hairy areas.
  • the hydrophobic solvent present in the foam composition helps retain the insecticide on the treated area for an extended period of time. Furthermore, the presence of a hydrophobic solvent in the foam eases mechanical removal of lice and nits with a comb.
  • Anti-cancer drugs can also be used as the drug of choice for the treatment of skin malignant tumors such as basal cell carcinoma, squamous sell carcinoma, melanoma and Kaposi's sarcoma, as well as the pre-cancerous condition actinic keratosis.
  • topical cytotoxic and antiproliferative drugs are used to treat or prevent such cancers, including 5-fluorouracil, also called 5-FU.
  • 5-FU as well as any other anti-cancer agents, know in the art of cancer medicine, can be incorporated in the foam at therapeutically effective levels.
  • An exemplary family of anticancer drugs, suitable for usage in the foam of the present formulation comprises antiestrogens, such as tamoxifen.
  • a photosensitizer can be selected from the group consisting of poephyrins, modified porphyrins, psoralen, 8-methoxypsoralen, 5-methoxypsoralen, psoralen derivatives, chlorins, bacteriochlorins, phthalocyanines, naphthalocyanines, pheophorbides, purpurins, m-THPC, mono-L-aspartyl chlorin e6, bacteriochlorins, phthalocyanines, benzoporphyrin derivatives and photosensitizer precursors, such as aminolevulinic acid (ALA).
  • ALA aminolevulinic acid
  • the treatment of burns, wounds, cuts and ulcers using a foamable composition is particularly advantageous.
  • the foam can include both anti-infective agents (against bacteria, fungi and/or viruses), antiinflammatory agents (steroidal and/or NSAIDs) and pain relieving components. Upon application, the foam spreads easily, covering the surface of the affected area, and without causing pain.
  • the foam composition is useful and advantageous for skin care and cosmetic care.
  • the combination of oil and water having moisture-retaining properties in a spreadable foam form can be used to substitute currently used cosmetic skin care creams, lotions, gels, etc.
  • the cosmetic foam compositions are suitable for the further application as “cosmeceutical” preparation (cosmetic products with therapeutic benefit), to treat “cosmetic” skin disorders, such as aging skin, wrinkles, hyperpigmentation (melasma, chloasma, freckles, etc.), scaly skin and other skin undesirable properties.
  • CTFA Cosmetic Ingredient Handbook describes a wide variety of nonlimiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention.
  • these ingredient classes include: abrasives, absorbents, aesthetic components such as fragrances, pigments, colorings/colorants, essential oils, astringents, etc.
  • anti-acne agents e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate
  • anti-acne agents e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate
  • antimicrobial agents e.g., iodopropyl butylcarbamate
  • antioxidants e.g., iodopropyl butylcarbamate
  • binders biological additives, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film formers or materials, e.g., polymers, for aiding the film-forming properties and substantivity of the composition (e.g., copolymer of
  • An anti-acne agent can be included in the foamable composition.
  • the anti-acne agent can be selected from the group consisting of resorcinol, sulfur, salicylic acid and salicylates, alpha-hydroxy acids, nonsteroidal anti-inflammatory agents, benzoyl peroxide, retinoic acid, isoretinoic acid and other retinoid compounds, adapalene, tazarotene, azelaic acid and azelaic acid derivatives, antibiotic agents, such as erythromycin and clyndamycin, zinc salts and complexes, and combinations thereof, in a therapeutically effective concentration.
  • Anti-Wrinkle Active Agents/Anti-Atrophy Active Agents and Agents to Treat Dry and Scaly Skin Xerosis and Ichthyosis
  • the foamable composition may also include an effective amount of an anti-wrinkle active and/or at least one anti-atrophy active.
  • anti-wrinkle/anti-atrophy active agents suitable for use in the foamable compositions include sulfur-containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives; thiols; hydroxy acids (e.g., alpha-hydroxy acids such as lactic acid and glycolic acid and their derivatives and salts; or beta-hydroxy acids such as salicylic acid and salicylic acid salts and derivatives), urea, hyaluronic acid, phytic acid, lipoic acid; lysophosphatidic acid, skin peel agents (e.g., phenol, resorcinol and the like), vitamin B3 compounds (e.g., niacinamide, nicotinic acid and nicotinic acid salts and esters, including non-vasodilating esters of nicotinic acid (such as tocop
  • an effective amount of an anti-oxidant/radical scavenger can be added to the foamable compositions, for example, in an amount from about 0.1% to about 10% (w/w), or from about 1% to about 5% (w/w).
  • Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and ascorbic acid salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the tradename Trolox.®), gallic acid and gallic acid alkyl esters, especially propyl gallate, uric acid and uric acid salts and alkyl esters, sorbic acid and sorbic acid salts, lipoic acid, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydryl
  • the foam is suitable for delivering skin protecting and revitalizing anti-oxidants/radical scavengers.
  • Polyunsaturated fatty acids containing omega-3 and omega-6 fatty acids e.g., linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
  • GLA gamma-linoleic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • emollients and silicone oils exert moisture-retaining and skin protective effects on the skin.
  • a skin protective foam wherein the hydrophobic solvent comprises in full or in part, a solvent, selected from the group of emollients, silicone oil and oils, rich in unsaturated fatty acids, thus, affording a synergistic therapeutic effect of the anti-oxidants/radical scavenger agent and the vehicle components.
  • a solvent selected from the group of emollients, silicone oil and oils, rich in unsaturated fatty acids, thus, affording a synergistic therapeutic effect of the anti-oxidants/radical scavenger agent and the vehicle components.
  • the foam composition is particularly suitable for the uniform delivery of a tanning active agent onto large areas of the skin.
  • the compositions contain from about 0.1% to about 20%, or from about 2% to about 7%, or even from about 3% to about 6% of dihydroxyacetone or any other compound know in the art as an artificial tanning active agent.
  • the foam composition may be formulated to provide a composition for the uniform delivery of a skin lightening agent.
  • the composition contains from about 0.1% to about 10%, or from about 0.2% to about 5% of a skin-lightening agent.
  • Suitable skin lightening or whitening agents include those known in the art, including hydroquinone, azelaic acid and other related dicarboxylic acids, and salts and derivatives thereof, retinoids, kojic acid, arbutin, nicotinic acid and nicotinic acid precursors, salts and derivatives, ascorbic acid and salts and derivatives thereof (e.g., magnesium ascorbyl phosphate or sodium ascorbyl phosphate), and herbal extracts (e.g., mulberry extract, placental extract).
  • the foam composition includes a combination of at least one skin-whitening agent and at least one additional active agent selected from retinoids, keratolytically active agents and anti-inflammatory agents.
  • the composition includes a combination of at least one skin-whitening agent and at least one keratolytically active agent selected from a alpha-hydroxy acids, beta hydroxy acids, and retinoids.
  • the foam composition includes a combination of a skin-whitening agent and an inorganic sunscreen agent.
  • inorganic sunscreen agents e.g. titanium dioxide and zinc oxide
  • the whitening agent, in combination with the inorganic sunscreen agent in the foam carrier can be easily and uniformly distributed on the skin surface, thereby affording an even instant whitening effect, unlike creams that are difficult to spread evenly on skin areas.
  • Agents that affect the pattern of hair growth can be suitably incorporated in the foam composition.
  • Male pattern baldness (MPB) the commonest cause of balding, is induced by the activity of the male hormone dihydrotestosterone (DHT), which is converted from the hormone testosterone by the enzymes 5-alpha reductase.
  • DHT dihydrotestosterone
  • Current treatments of MPB include minoxidil and agents, which inhibit 5-alpha reductase, such as finasteride, spironolactone, azelaic acid and azelaic acid derivatives and salts. Such agents, as well as other agents known in the art, can be incorporated in the foam composition.
  • Polyunsaturated fatty acids i.e., such which include any of the essential fatty acids (EFA's), such as linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are also known to contribute to hair growth.
  • EFA's essential fatty acids
  • GLA gamma-linoleic acid
  • EPA eicosapentaenoic acid
  • DHA docosahexaenoic acid
  • a hair growth foam composition in which the hydrophobic solvent comprises in full or in part, an oil, rich in such unsaturated fatty acids.
  • Figure forming agents such as used in the treatment of cellulite and in slimming products can be suitably incorporated in the foam composition.
  • a non-limiting exemplary list of active agents known in the treatment of cellulite and in the induction of a slimming effect include:
  • Cosmetic and pharmaceutical ingredients which are known in the art of pharmacology and cosmetology to treat dermatitis, minor skin irritations, sunburn, heat burn, radiation burn, and inhibit inflammation can be beneficially incorporated in the foam composition.
  • Examples of such active agents include chamomile extract ( matricaria recutitia ), cucumber distillate ( cucumis sativus ), lavender water ( lavendula angustifolia ), rose water ( rosa damascena ), witch hazel ( hamamelis virginiana ), allantoin, bisabolol, rosehip oil, calendula oil, azulaene, menthol and camphor.
  • the active agent can be selected from the group of sulfur-containing amino acids, thiol compounds, alpha hydroxy acids, lactic acid and lactic acid derivatives and salts, glycolic acid, glycolic acid derivatives and glycolic acid salts, beta-hydroxy acids, salicylic acid and salicylic acid salts and derivatives, phytic acid, lipoic acid, lysophosphatidic acid, skin peel agents, phenol, resorcinol, vitamin B3 compounds, niacinamide, nicotinic acid and nicotinic acid salts and esters, tocopheryl nicotinate, nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide, retinoids, retinol, retinal, retinoic acid, retinyl acetate, retinyl palmitate and retinyl ascorbate, caffeine, theophilline
  • the foam carrier or foam composition is essentially free of short chain aliphatic alcohols (i.e., methyl, ethyl, isopropyl and butyl alcohol), unlike the composition disclosed in U.S. Pat. Nos. 6,126,920 and 6,358,541, which contains an aliphatic alcohol, preferably in amounts of 40-90% aliphatic alcohol.
  • alcohol free refers to compositions that contain no more than 7.5% by weight of any aliphatic alcohol, having one to six carbon atoms in their carbon backbone, or no more than 7.5% by weight of any mixture of such aliphatic alcohols.
  • the pharmaceutical or cosmetic foam carrier optionally includes a variety of pharmaceutical or cosmetic ingredients, which are added in order to fine-tune the consistency of the formulation, protect the formulation components from degradation and oxidation and bestow their cosmetic acceptability.
  • Such an excipient is preferably selected from the group consisting of: a diglyceride, a triglyceride, a stabilizing agent, an antioxidant, glycerol, a flavoring, a colorant, an odorant agent and any other formulation component known in the art of pharmaceutical and cosmetic formulary.
  • a pharmaceutical or cosmetic composition manufactured using the foam carrier according to the present invention is very easy to use. When applied onto the afflicted body surface of humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
  • a pharmaceutical or cosmetic composition manufactured using the foam carrier according to one or more embodiments of the present invention is very easy to use. When applied onto the afflicted body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
  • the foam composition or carrier includes water, hydrophobic solvents, surfactant, gelling agent and propellant, thereby creating a stable emulsion having an acceptable shelf-life of at least one year, or at least two years at ambient temperature.
  • a feature of a product for cosmetic or medical use is long term stability.
  • Propellants which are a mixture of low molecular weight hydrocarbons, tend to impair the stability of emulsions. It has been observed, however, that foam compositions including amphiphilic copolymers as gelling agents are surprisingly stable. Following accelerated stability studies, they demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
  • compositions containing semi-solid hydrophobic solvents e.g., white petrolatum, as the main ingredients of the oil phase of the emulsion, exhibit high viscosity and poor flowability and are inappropriate candidates for a foamable composition.
  • Foam quality can be graded as follows:
  • Grade E excellent: very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery.
  • Grade G (good): rich and creamy in appearance, very small bubble size, “dulls” more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery.
  • Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity.
  • Grade F very little creaminess noticeable, larger bubble structure than a “fairly good” foam, upon spreading on the skin it becomes thin in appearance and watery.
  • Grade P no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance.
  • Grade VP dry foam, large very dull bubbles, difficult to spread on the skin.
  • Topically administrable foams are typically of quality grade E or G, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
  • a further aspect of the foam is breakability.
  • the breakable foam is thermally stable, yet breaks under sheer force. Sheer-force breakability of the foam is clearly advantageous over thermally-induced breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
  • foams Another property of the foam is specific gravity, as measured upon release from the aerosol can. Typically, foams have specific gravity of between about 0.01 g/mL and about 0.1 g/mL.
  • the composition of the present invention can be contained in and dispensed from a container capable of withstanding the pressure of the propellant gas and having an appropriate valve/nozzle for dispensing the composition as foam under pressure.
  • a customary liquefied propellant can be added, in the amount of about 3-18% of the total composition.
  • Liquefied propellants are gases that exist as liquids under pressure, including high purity hydrocarbons such as propane, isobutane and n-butane, dimethyl ether and chlorofluorocarbons (CFCs).
  • a specific embodiment according to the present invention comprises placing the composition of the present invention on a patch, regulating residence of an active ingredient in the skin tape or the skin-contact compartment of a transdermal delivery apparatus and applying such object onto the skin, in order to attain effective superficial treatment or enhanced penetration of the drug into the skin or through the skin.
  • drugs which are currently administered systemically or that require transdermal delivery, in the preferred therapeutic system of the present invention.
  • examples for such drugs are nicotine, testosterone and other male hormones and male hormone precursors, estrogen and other female hormones and hormone precursors, growth hormone, insulin, caffeine, steroidal and non-steroidal antiinflammatory agents and thyroid hormone substitutes.
  • Example 1 The general process, as typically exemplified in Example 1 can be applied in order to produce the composition of the present invention.
  • the pharmaceutical carrier according to the present invention can also be used to prepare cosmetics for beauty purpose by adding into skin care agents and perfume.
  • the foam composition of the present invention is useful in the therapy of a variety of disorders, such as classified, in a non-limiting exemplary manner, according to the following groups:
  • Dermatitis including contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis of the hands and feet, generalized exfoliative dermatitis, stasis dermatitis; lichen simplex chronicus; diaper rash; bacterial infections including cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, staphylococcal scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, erythrasma; fungal infections including dermatophyte infections, yeast infections; parasitic infections including scabies, pediculosis, creeping eruption; viral infections; disorders of hair follicles and sebaceous glands including acne, rosacea, perioral dermatitis, hypertrichosis (hirsut
  • the foam composition is useful in the therapy of non-dermatological disorders, which respond to topical/transdermal delivery of an active agent.
  • non-dermatological disorders include localized pain in general, as well as joint pain, muscle pain, back pain, rheumatic pain, arthritis, ostheoarthritis and acute soft tissue injuries and sports injuries.
  • Other disorders of this class include conditions, which respond to hormone therapy, such as hormone replacement therapy, transdermal nicotine administration, and other respective disorders, known in the art of drug delivery.
  • the foam compositions are further useful for the treatment and prevention of disorders and diseases of other body cavities including the rectum, vagina, penile urethra and ear canal.
  • the foam compositions are useful in treating a patient having any one of a variety of gynecological disorders, such as classified, in a non-limiting exemplary manner, according to the following groups: pelvic pain, including premenstrual syndrome (PMS), kar inconvenience (severe midcycle pain due to ovulation), dysmenorrhea (pain related to the menstrual cycle), endometriosis, ectopic pregnancy, ovarian cysts and masses, acute pelvic inflammatory disease, pelvic congestion syndrome and vulvodynia; vulvovaginal infections, including bacterial vaginosis, candidal vaginitis, trichomonas vaginalis , herpes simplex genital ulcers and warts, pelvic inflammatory disease (PID), cervicitis, acute and chronic salpingitis; endometriosis; gynecological neoplasms, including endometrial Cancer, ovarian cancer, cervical cancer, vulvar cancer,
  • Rectal applications include, for example, anal abscess/fistula, anal cancer, anal warts, Crohn's disease, haemorrhoids, anal and perianal pruritus, soreness, and excoriation, perianal thrush, anal fissures, fecal incontinence, constipation, polyps of the colon and rectum.
  • the foam compositions are further useful for intra-vaginal and rectal treatment of sexually-transmitted and non-sexually-transmitted infectious disease (STDs).
  • STDs sexually-transmitted and non-sexually-transmitted infectious disease
  • the invention provides a method of treatment of a disorder of the skin, mucosal membrane, ear channel, vaginal, rectal and penile urethra disorders, comprising topical application of the foam composition, whereby one or more active agents, in a therapeutically effective concentration to the afflicted area.
  • the invention provides a method of treatment of a non-dermatological disorder, which responds to topical delivery of an active agent, comprising topical application of the foam composition of the present invention, whereby one or more active agents, in a therapeutically effective concentration to the skin.
  • treatment cover any treatment of a disease or disorder, and includes, for example:
  • the method for preparing of a pharmaceutical foam carrier generally comprised following steps.
  • Step 1 Aqueous Phase: Gelling agent and surface-active agent are dissolved in water, with agitation. The solution is warmed to 50-70° C. Water soluble cosmetic or pharmaceutical active Ingredients* and optional water soluble ingredients are added with agitation to the Aqueous Phase mixture.
  • Step 2 Hydrophobic Phase: The hydrophobic solvent is heated to same temperature. Oil soluble cosmetic or pharmaceutical active agents* and optional oil soluble formulation ingredients are added with agitation to the Hydrophobic Phase mixture.
  • Step 3 The warm Hydrophobic Phase is gradually poured into the warm Aqueous Phase, with agitation, followed by Ultraturax homogenization. The mixture is allowed to cool down to ambient temperature.
  • Step 4 The mixture, at ambient temperature, is added to an aerosol container, the container is sealed and appropriate amount of propellant (about 10% of the composition mass) is compressed into the container.
  • foam compositions were prepared as described above and tested for foam quality
  • Component % w/w Capric/caprylic triglycerides 25.00 Glyceryl monostearate 0.50 Stearyl alcohol 1.00 Xanthan gum 0.30 Methocel K100M 0.30 TWEEN 80 1.00 MYRJ 52P 3.00 Urea 10.00 Cocamidopropyl betaine 0.50 Hydrophilic Drug 0.1-2.0 Phenonip 0.30 Butane/propane 6.00 Water to 100 Foam Quality E Density 0.034
  • Component % w/w Capric/caprylic triglycerides 25.00 Glyceryl monostearate 0.50 Stearyl alcohol 1.00 Xanthan gum 0.30 Methocel K100M 0.30 TWEEN 80 1.00 MYRJ 52P 3.00 Urea 10.00 Cocamidopropyl betaine 0.50 Lipophilic Drug 2.0 Phenonip 0.30 Butane/propane 8.00 Water to 100 Foam Quality E Density 0.020
  • Component % w/w Capric/caprylic triglycerides 18.00 Glyceryl monostearate 0.50 Pemulene TR1 0.50 Methocel K100M 0.30 Xanthan gum 0.30 Hydrophilic Drug 1.0 Lactic acid 6.0 Phenonip 0.30 Butane/propane 8.00 Water to 100 Foam Quality E Density 0.030
  • Component % w/w Capric/caprylic triglycerides 18.00 Glyceryl monostearate 0.50 Pemulene TR1 0.50 Methocel K100M 0.30 Xanthan gum 0.30 Hydrophobic Drug 1.0 Lactic acid 6.0 Phenonip 0.30 Butane/propane 6.00 Water to 100 Foam Quality E Density 0.038
  • Component % w/w Capric/caprylic triglycerides 25.00 Glyceryl monostearate 0.50 Stearyl alcohol 1.00 Xanthan gum 0.30 Methocel K100M 0.30 TWEEN 80 1.00 MYRJ 52P 3.00 Glycolic acid 4.00 Cocamidopropylbetaine 0.50 Hydrophylic Drug 2.0 Phenonip 0.30 Butane/propane 6.00 Water to 100 Foam Quality E Density 0.044
  • Component % w/w Capric/caprylic triglycerides 25.00 Glyceryl monostearate 0.50 Stearyl alcohol 1.00 Xanthan gum 0.30 Methocel K100M 0.30 TWEEN 80 1.00 MYRJ 52P 3.00 Glycolic acid 4.00 Cocamidopropylbetaine 0.50 Hydrohobic Drug 2.0 Phenonip 0.30 Butane/propane 12.00 Water to 100 Foam Quality E Density 0.020

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)

Abstract

The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 14/258,700, filed on Apr. 22, 2014, which is a continuation application of U.S. patent application Ser. No. 13/784,085, filed on Mar. 4, 2013, which is a continuation application of U.S. patent application Ser. No. 12/752,718, filed on Apr. 1, 2010, which is a divisional application under 35 U.S.C. §121 of co-pending U.S. patent application Ser. No. 10/922,358 (now U.S. Pat. No. 7,700,076), filed on Aug. 20, 2004, which claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 60/497,648, filed on Aug. 25, 2003, and is also (1) a continuation-in-part of International Application No. PCT/IB2003/005527, filed on Oct. 24, 2003, which claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 60/429,546, filed on Nov. 29, 2002, and claims benefit to IL 152486, filed on Oct. 25, 2002 and (2) a continuation-in-part of U.S. patent application Ser. No. 10/911,367, filed on Aug. 4, 2004, which claims the benefit under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 60/492,385, filed on Aug. 4, 2003. The contents of all of the patent applications referenced in this paragraph are hereby incorporated in their entirety by reference.
    • FIELD OF THE INVENTION
  • The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a surface-active agent and a gelling agent. The foam carrier further comprises active agents and excipients providing beneficial therapeutic properties.
    • BACKGROUND OF THE INVENTION
  • Foam products are used for topical applications of drugs and cosmetics. Aerosol products and particularly foams are complicated physical-chemical structures that do not form under arbitrary circumstances. In particular, a special balance between the foam-forming components is important. Slight shifts in the composition may already result in a collapse of the foam; thus, a formulation of per se active substances may not be capable of being formulated as a foam without further provisions.
  • The inventors of the present invention have developed a series of novel emulsion-based foam formulations. See, for example, commonly assigned, co-pending application WO 2004/037225.
  • U.S. Pat. No. 6,423,323 describes a foam skin cream, which optionally contains urea and lactic acid. The skin cream formulation is limited to a very specific list of ingredients that are not contemplated in the present invention.
  • U.S. Pat. No. 4,145,411 describes shaving foam compositions with low levels of mineral oil (0.25-1% by weight) and urea (0.001-0.006% by weight). A shaving foam is, by definition, not breakable and thus cannot readily facilitate topical administration of an active ingredient and especially is not well-suited for topical administration of compositions geared towards skin penetration.
    • SUMMARY OF THE INVENTION
  • In one aspect of the present invention, an alcohol-free cosmetic or pharmaceutical foamable composition containing at least one active component, selected from the group of: (1) urea, in a concentration of at least 2%; (2) a hydroxy acid in a concentration of at least 1%; and (3) a therapeutic enhancer is provided, which upon admixing with a liquefied gas propellant in an aerosol container releases a breakable foam that is suitable for topical administration. The alcohol-free foam composition is suitable for inclusion of both water-soluble and oil-soluble active agents. As used herein, a foamable composition includes formulations that are capable of forming a foam when dispensed from an aerosol container.
  • The cosmetic or pharmaceutical foamable composition according to one or more embodiments of the present invention includes water, a hydrophobic solvent, a surface-active agent and a gelling agent and at least one active component selected from the group of (1) urea in a concentration of at least 2%; (2) a hydroxy acid in a concentration of at least 1%; and (3) a therapeutic enhancer in a concentration of at least 2%; and a liquefied gas propellant in the amount of about 3-18% by weight of the total composition.
  • Such a composition creates an oil-in-water emulsion that is stable in its pre-dispensed state. Upon release from the aerosol container, the composition forms a breakable foam product, which is suitable for topical or mucosal administration.
  • In one or more embodiments of the present invention, the hydrophobic solvent is included in the foamable composition at a concentration of 5% to about 10% (Class A), or 10% to about 20% (Class B), or about 20% to about 50% (Class C). The surface-active agent concentration is about 0.1% to about 5%; the concentration of the gelling agent is 0.01% to about 5% by weight and the liquefied gas propellant is included at a concentration of about 3% to about 18% of the total composition. Water and optional ingredients are added to complete the total mass to 100%. Yet, in other embodiments, as specified herein, foamable composition, the hydrophobic solvent content can be between 0% and 5%.
  • In one or more embodiments, each of the above compositions further optionally comprises a foam adjuvant in the concentration range of 0.1% to 5%.
  • The foamable composition does not contain short chain aliphatic alcohols, making it non-irritant and non-drying.
  • In one or more embodiments, a foamable composition is provided that includes a foamable composition as described herein and further includes at least one active agent at a therapeutically effective concentration. The foam carrier is suitable for inclusion of both water-soluble and oil-soluble active agents, as well as suspended active agents. Such a composition is suitable for topical treatment of human and animal skin and mucosal disorders or diseases. Alternatively, the composition is suitable for cosmetic treatment, for example, for cleansing, beautifying, promoting attractiveness or altering the appearance without affecting the body structure or function.
  • In addition, cosmetic and medical disorders are identified that are best treated using the alcohol-free foam carrier and the alcohol-free cosmetic or pharmaceutical composition, and the advantages of such carrier and products are demonstrated.
  • The foam carrier or composition according to one or more embodiments of the present invention provides various advantages over current foam compositions.
      • 1. The foam is lightweight and thus, economical.
      • 2. The foam contains a hydrophobic solvent, in desirable concentration, which provides a refatting and skin soothing effect.
      • 3. The foam can include water-soluble, oil-soluble active and suspended agents.
      • 4. The foam is easily spreadable, allowing treatment of large areas such as the arms, back, legs and the breast.
      • 5. Due to flow properties of the foam, the foam spreads effectively into folds and wrinkles, thereby providing uniform distribution and absorption of the active agent without the need of extensive rubbing.
  • As used herein, all component percentages are reported as percent by weight of the total composition.
  • As used herein, the term “about” when used to refer to weight % in a composition means±10% of the reported weight %. As used herein, the term “about” when used to refer to measured characteristics of the composition means±20% of the reported value.
    • DETAILED DESCRIPTION OF THE INVENTION Hydrophobic Solvent
  • The foamable composition includes a hydrophobic solvent. The hydrophobic solvent includes a material having solubility in distilled water at ambient temperature of less than about 1 gm per 100 mL, or less than about 0.5 gm per 100 mL, or less than about 0.1 gm per 100 mL. The hydrophobic solvent is a liquid at ambient (room) temperature, e.g., about 20-30° C.
  • The total content of hydrophobic solvent may vary from 5% to 50% (w/w). However, different ranges (herein “composition Classes A-C”) have been designated, in order to facilitate a choice of an appropriate class, according to the anticipated cosmetic or pharmaceutical need. As a rule of thumb, higher hydrophobic solvent concentrations are more appropriate for the treatment of dry skin, and/or for the treatment of a disease, which is more responsive to drugs, delivered in an oily vehicle and regulating the residence of an active ingredient in the target area. Another consideration relates to the usability and tolerability of the product, whereby very high concentration of the hydrophobic solvent (from about 25% of the composition) would leave an oily feeling subsequent to application, which is undesirable in the product. Thus, when using a foamable composition, the hydrophobic solvent concentration is selected in view of the target treated population and the specific needs of the intended treated population.
  • In one embodiment, the hydrophobic solvent is mineral oil. Mineral oil (Chemical Abstracts Service Registry number 8012-95-1) is a mixture of aliphatic, naphthalenic, and aromatic liquid hydrocarbons that derive from petroleum. They are typically liquid, their viscosity is in the range of between about 35 CST and about 100 CST (at 40° C.), and their pour point (the lowest temperature at which an oil can be handled without excessive amounts of wax crystals forming so preventing flow) is below 0° C. By contrast, white petrolatum, also termed “Vaseline”, is disadvantageous, due to the waxy nature of petrolatum. It is known to leave waxy and sticky feeling after application and occasionally stain cloths. Thus, white petrolatum is not a preferred hydrophobic solvent according to the present invention.
  • Yet other hydrophobic solvents include, but are not limited to, liquid oils from vegetable, marine or animal sources. Preferably, the unsaturated oil is selected from the group consisting of an olive oil, a corn oil, a soybean oil, a canola oil, a cottonseed oil, a coconut oil, a sesame oil, a sunflower oil, a borage seed oil, an syzigium aromaticum oil, a hempseed oil, a herring oil, a cod-liver oil, a salmon oil, a flaxseed oil, a wheat germ oil, an evening primrose oil and any mixtures thereof, at any proportion.
  • A particular class of oils includes polyunsaturated oils, containing omega-3 and omega-6 fatty acids. Examples of such polyunsaturated fatty acids are linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Thus, in a particular embodiment of the present invention the unsaturated oil contains at least 6% of an oil selected from omega-3 oil, omega-6 oil, and mixtures thereof.
  • Another class of oils is essential oils, which are considered “therapeutic oils” containing active biologically occurring molecules, which, upon topical application, exert a therapeutic effect. Examples of such oils are rosehip oil, which contain retinoids and is known to reduce acne and post-acne scars, tea tree oil, which possesses antibacterial, antifungal and antiviral properties. Other examples of essential oils are basil, camphor, cardamom, carrot, citronella, clary sage, clove, cypress, frankincense, ginger, grapefruit, hyssop, jasmine, lavender, lemon, mandarin, marjoram, myrrh, neroli, nutmeg, petitgrain, sage, tangerine, vanilla, verbena, as well as any other therapeutically beneficial oil, know in the art of herbal medication.
  • Another class of solvents includes, but is not limited to, liquid hydrophobic plant-derived oils, which are known to possess therapeutic benefits when applied topically.
  • A further class of hydrophobic solvents is known as the group of “emollients”. Without derogating the generality of this definition, examples of suitable emollients for use include isostearic acid derivatives, isopropyl palmitate, lanolin oil, diisopropyl dimerate, maleated soybean oil, octyl palmitate, isopropyl isostearate, cetyl lactate, cetyl ricinoleate, tocopheryl acetate, acetylated lanolin alcohol, cetyl acetate, phenyl trimethicone, glyceryl oleate, tocopheryl linoleate, wheat germ glycerides, arachidyl propionate, myristyl lactate, decyl oleate, propylene glycol ricinoleate, isopropyl lanolate, pentaerythrityl tetrastearate, neopentylglycol dicaprylate/dicaprate, hydrogenated coco-glycerides, isononyl isononanoate, isotridecyl isononanoate, myristal myristate, triisocetyl citrate, octyl dodecanol, sucrose esters of fatty acids, octyl hydroxystearate and mixtures thereof. Other examples of other suitable emollients can also be found in the Cosmetic Bench Reference, pp. 1.19-1.22 (1996).
  • In a particular embodiment, the hydrophobic solvent comprises a mixture of mineral oil and an emollient in a ratio between 2:8 and 8:2 on a weight basis.
  • Silicone oils are known for their skin protective properties and may be used as a hydrophobic solvent. The silicone oil is either a volatile silicon oil or a non-volatile silicone oil, wherein water-soluble silicones, such as dimethicone copolyol are not included in the definition of silicone oils (as hydrophobic solvents).
  • In a particular embodiment, the hydrophobic solvent includes at least 2% silicone oil.
  • One or more hydrophobic solvents in any combination can be used.
    • Surface-Active Agents
  • The foamable composition includes a surface-active agent. Surface-active agents (surfactants) include any agent that alters the surface properties of the oil and water components in the composition to aid in the formation of an emulsion. A surfactant's hydrophilic/lipophilic balance (HLB) describes the emulsifier's affinity toward water or oil. The HLB scale ranges from 1 (totally lipophilic) to 20 (totally hydrophilic), with 10 representing an equal balance of both characteristics. Lipophilic emulsifiers tend to form water-in-oil (w/o) emulsions; hydrophilic surfactants tend to form oil-in-water (o/w) emulsions. The HLB of a blend of two emulsifiers equals the weight fraction of emulsifier A times its HLB value plus the weight fraction of emulsifier B times its HLB value (weighted average).
  • Any surface-active agent, selected from anionic, cationic, non-ionic, zwitterionic, amphoteric and ampholytic surfactants, or combinations thereof may be used as surface-active agent. According to one or more embodiments of the present invention, the surface-active agent has a hydrophilic lipophilic balance (HLB) between about 9 and about 14, which is the required HLB (the HLB required to stabilize an O/W emulsion of a given oil) of most oils and hydrophobic solvents. Thus, in one or more embodiments, the composition is a single surface active agent having an HLB value between about 9 and 14, and in one or more embodiments, the foam composition contains more than one surface active agent and the weighted average of their HLB values is between about 9 and about 14.
  • Non-limiting examples of surfactants include polysorbates, such as polyoxyethylene (20) sorbitan monostearate (Tween 60) and polyoxyethylene (20) sorbitan monooleate (Tween 80); Polyoxyethylene (POE) fatty acid esters, such as Myrj 45, Myrj 49 and Myrj 59; poly(oxyethylene) alkylyl ethers, such as poly(oxyethylene) cetyl ether, poly(oxyethylene) palmityl ether, polyethylene oxide hexadecyl ether, polyethylene glycol cetyl ether, brij 38, brij 52, brij 56 and brij W1; sucrose esters, partial esters of sorbitol and sorbitol anhydrides, such as sorbitan monolaurate and sorbitan monolaurate-mono or diglycerides, isoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, sodium lauryl sulfate, triethanolamine lauryl sulfate and betaines.
  • In some embodiments, the surface-active agent is a non-ionic surfactant. Exemplary non-ionic surfactants include mono-, di- and tri-esters of sucrose with food fatty acids (sucrose esters), prepared from sucrose and methyl and ethyl esters of food fatty acids or by extraction from sucroglycerides. Further examples are sucrose esters with high monoester content, which have higher HLB values.
  • A combination of a non-ionic surfactant and an ionic surfactant (such as sodium lauryl sulphate) may be used. In one example, a non-ionic surfactant and an ionic surfactant are present in the foam carrier or composition at a ratio of between 1:1 and 20:1 or between 4:1 and 10:1.
  • Unlike prior art foamable compositions, low total amounts of surfactant are employed to obtain a stable foam. Surprisingly, lower surfactant levels are required to obtain a stable foamable composition, which is preferred in order to reduce skin irritations. Total surfactant level is in the range of about 0.1% to 5% by weight of the foamable composition, and can be less than 2% by weight or even less than 1% by weight. Thus, according to one or more embodiments, the ratio between the surface active agent and the hydrophobic solvent is between about 1:8 and about 1:16 or between about 1:16 and about 1:32.
    • Foam Adjuvants
  • Foam adjuvants may optionally be included in the foam composition and include fatty alcohols having 15 or more carbons in their carbon chain, such as cetyl alcohol and stearyl alcohol (or mixtures thereof). Other examples of fatty alcohols are arachidyl alcohol (C20), behenyl alcohol (C22), 1-triacontanol (C30), as well as alcohols with longer carbon chains (up to C50). The concentration of the fatty alcohol, required to support the foam system is inversely related to the length of its carbon chains. Fatty alcohols derived from beeswax including a mixture of alcohols, a majority of which has at least 20 carbon atoms in their carbon chain, are especially well suited as foam adjuvants.
  • Another class of foam adjuvants includes fatty acids having 16 or more carbons in their carbon chain, such as hexadecanoic acid (C16) stearic acid (C18), arachidic acid (C20), behenic acid (C22), octacosanoic acid (C28), as well as fatty acids with longer carbon chains (up to C50), or mixtures thereof.
  • Optionally, the carbon atom chain of the fatty alcohol or the fatty acid may have at least one double bond. A further class of foam adjuvant includes a long chain fatty alcohol or fatty acid, wherein the carbon atom chain is branched. In a further class of foam adjuvants, the carbon chain of the fatty acid is substituted with a hydroxyl group, such as 12-hydroxy stearic acid.
  • The foam adjuvant may include a mixture of fatty alcohols, fatty acids and hydroxy fatty acids and derivatives thereof in any proportion, providing that the total amount is 0.1% to 5% (w/w) of the carrier mass. The total amount can be 0.4%-2.5% (w/w) of the carrier mass.
  • Long chain saturated and mono unsaturated fatty alcohols, e.g., stearyl alcohol, erycyl alcohol, arachidyl alcohol and docosanol have been reported to possess antiviral, anti infective, anti-proliferative and anti-inflammatory properties (U.S. Pat. No. 4,874,794). Longer chain fatty alcohols, e.g., tetracosanol, hexacosanol, heptacosanol, octacosanol, triacontanol, etc. are also known for their metabolism modifying properties and tissue energizing properties. Long chain fatty acids have also been reported to possess anti-infective characteristics. Thus, the pharmaceutical or cosmetic composition containing therapeutic foam adjuvant provides an extra therapeutic benefit in comparison with currently used vehicles, which are inert and non-active.
    • Gelling Agents
  • Gelling agents include, but are not limited to, naturally-occurring polymeric materials such as, locust bean gum, sodium alginate, sodium caseinate, egg albumin, gelatin agar, carrageenin gum sodium alginate, xanthan gum, quince seed extract, tragacanth gum, starch, chemically modified starches and the like, semi-synthetic polymeric materials such as cellulose ethers (e.g. hydroxyethyl cellulose, methyl cellulose, carboxymethyl cellulose, hydroxy propylmethyl cellulose), micro-crystalline cellulose and compositions (Avicel types) manufactured by FMC, polyvinylpyrrolidone, polyvinylalcohol, guar gum, hydroxypropyl guar gum, soluble starch, cationic celluloses, cationic guars and the like and synthetic polymeric materials such as carboxyvinyl polymers, polyvinylpyrrolidone, polyvinyl alcohol polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl acetate polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers and the like. Optionally, mixtures of the above compounds are contemplated.
  • Also useful herein are gelling agents such as the acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold, for example, by the B.F. Goodrich Company under the trademark of Carbopol Registered™ resins. These resins consist essentially of a colloidally water-soluble polyalkenyl polyether crosslinked polymer of acrylic acid crosslinked with from 0.75% to 2% of a crosslinking agent such as polyallyl sucrose or polyallyl pentaerythritol. Examples include Pemulene TR1 and TR2, Carbopol 934, Carbopol 940, Carbopol 950, Carbopol 980, Carbopol 951 and Carbopol 981. Carbopol 934 is a water-soluble polymer of acrylic acid crosslinked with about 1% of a polyallyl ether of sucrose having an average of about 5.8 allyl groups for each sucrose molecule.
  • In one aspect of the invention, the gelling agent is selected from the class of amphiphilic copolymers. Amphiphilic copolymers include polymers having hydrophobic groups and hydrophilic groups or regions. These materials are referred to alternatively as “polymeric surfactants” because the hydrophilic and hydrophobic regions of the polymers serve to interact with and stabilize hydrophilic and lipophilic components, respectively, of a composition. The copolymer may be a random copolymer, a block copolymer of a graft or comb copolymer. Exemplary amphiphilic copolymers include di-, tri- or multi-block copolymer or graft copolymer of a biodegradable polymer.
  • The Amphiphilic copolymer may be an acrylate copolymer, in which hydrophobic moieties are chemically linked to hydrophilic polymer or hydrophilic moieties are attached to hydrophobic polymers to produce amphiphilic surface active and surface stabilizing agent. By way of example, suitable amphiphilic copolymers include cross linked copolymers of acrylic acid and a hydrophobic comonomer, such as Pemulen TR-1 and Pemulen TR-2, ETD 2020 and Carbopol 1382 (all, Acrylates/C10-30 alkyl acrylate crosspolymer), Natrosol CS Plus 330 and 430 and Polysurf 67 (all, cetyl hydroxyethyl cellulose), Aculyn 22 (acrylates/steareth-20 methacrylate copolymer), Aculyn 25 (acrylates/laureth-25 methacrylate copolymer), Aculyn 28 (acrylates/beheneth-25 methacrylate copolymer), Aculyn 46 (PEG-150/stearyl alcohol/SMDI copolymer), Stabylen 30 (acrylates/vinyl isodecanoate), Structure 2001 (acrylates/steareth-20 itaconate copolymer), Structure 3001 (acrylates/ceteth-20 itaconate copolymer) and Structure Plus (acrylates/aminoacrylates/C10-30 alkyl PEG 20 itaconate copolymer), where PEG is polyethylene glycol, PPG is polypropylene glycol.
  • Other exemplary amphiphilic copolymers include silicone polymers such as amphiphilic silicone polyols or copolyol, for example cetyl dimethicone copolyol and dimethicone copolyol PPG-3 oleyl ether, acetylated starch derivatives, amphiphilic modified starches, and amphiphilic block copolymers of ethylene oxide, propylene oxide and/or propylene glycol (also known as “poloxamer”).
  • One or more gelling agents in any combination can be used.
  • The gelling agent is present in the foam composition in an amount of about 0.1% to 5.0%. In one or more embodiments, the gelling agent included in the foamable composition can be less than 1% of the foamable composition.
    • Active Component
  • According to one or more embodiments, urea is included in the foam composition as an active component.
  • Urea has been long recognized as a cosmetic ingredient in formulations acting as a humectant and moisturizer. There have been reports of keratolytic activity attributed to urea with the ability at high concentrations to solubilize and denature protein. High concentrations of urea are also known to have a mild, antimicrobial effect. Urea further possesses skin exfoliating properties, which are useful in the control of passage of active agents through the dermal barrier.
  • Urea preparations, especially those containing high urea concentration are provided in gels, creams, lotions and pastes, but not in foam. Foam is preferable in many cases where urea is needed for therapy. For example, xerosis, which is a common indication for high concentration urea preparations, is disseminated over large skin areas, and thus, the foam of the present invention, having low specific gravity and excellent spreading and absorption properties is advantageous.
  • In one embodiment, urea is contained in the foam composition in an amount from about 1% to about 50% of the total composition. Preferably compositions contain from about 10% to about 20%, and from about 20% to about 50%, depending on the intended use.
  • Because of its keratolytic effect, urea can serve as means to induce dermal penetration of a variety of drugs or cosmetic active agents. Furthermore, in many dermatological disorders, having urea, with its beneficial properties as mentioned above and a drug or cosmetic active agent provides a synergistic therapeutic effect. This is also the case when urea, which is known for its antibacterial and antifungal effects, is combined with another anti-infective agent.
  • Thus, in one or more embodiments of the present invention, the foamable composition includes urea and at least one pharmaceutical or cosmetic active agent, as defined hereinbelow. The penetration of the active agent is enhanced due to the urea present in the foam composition.
  • Hence, a foam according to the present invention includes a foamable composition containing urea in a therapeutically—effective concentration. In one embodiment, the foamable composition forms an emulsion of oil and water including a hydrophobic solvent at a level described herein as Class A, Class B, or Class C.
  • According to one or more embodiments, a hydroxy acid is included in the foam composition as an active component.
  • Hydroxy acids are useful in increasing the clarity of the skin surface, increasing cellular turnover, and increasing skin radiance and smoothness. They further possess skin exfoliating properties, which are useful in the control of passage of active agents through the dermal barrier.
  • Suitable hydroxy acids include alpha- or beta-hydroxy acids, poly-hydroxy acids, or any combinations of any of the foregoing. The hydroxy acid can be an alpha-hydroxy acid. Non-limiting examples of alpha hydroxy acids include, but are not limited to, glycolic acid, lactic acid, malic acid, citric acid, alpha-hydroxyethanoic acid, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic acidglycolic acid, tartaric acid, pyuric acid, citric acid, as well as their corresponding salts and pharmaceutically-acceptable derivatives; or any combination of any of the foregoing.
  • Ascorbic acid has skin permeation and collagen synthesis activity. Beta-hydroxy acids include, but are not limited to, salicylic acid, beta hydroxybutanoic acid, tropic acid and trethocanic acid.
  • Because of its keratolytic effect, hydroxy acids can serve as means to induce dermal penetration of a variety of drugs or cosmetic active agents. Furthermore, in many dermatological disorders, having urea, with its beneficial properties as mentioned above and a drug or cosmetic active agent provides a synergistic therapeutic effect.
  • Thus, in one or more embodiments of the present invention, the foamable composition comprises a hydroxy acid and at least one pharmaceutical or cosmetic active agent, as defined hereinbelow.
  • In one embodiment, the hydroxy acid is contained in the foamable composition in an amount from about 1% to about 30% of the total composition. The compositions can contain from about 1% to about 10% and from about 10% to about 30%, depending on their designated use.
  • According to one or more embodiments, a therapeutic enhancer is included in the foam composition as an active component. In the context of the present invention, a therapeutic enhancer is a material that facilitates an enhanced delivery of an active agent into a target site of treatment, thus enabling an improved therapeutic effect. Suitable therapeutic enhancers include polyhydric alcohols having at least two hydroxy groups, or at least three hydroxy groups, or a derivative of a polyhydric alcohol.
  • Non-limiting examples are propylene glycol, butylene glycols, glycerol, pentaerythritol, sorbitol, mannitol, oligosaccharides, dimethyl isosorbide, monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), polyethylene glycol 200-600, transcutol (diethylene glycol monoethyl ether) and glycofurol (tetrahydrofurfuryl alcohol PEG ether). The therapeutic enhancer can further comprise at least cyclodextrins a related compounds. Cyclodextrins are structurally related cyclic oligomaltoses, which form a new group of pharmaceutical excipients. These are torus-shaped molecules with a hydrophilic outer surface and a lipophilic central cavity. Cyclodextrins are capable of forming water-soluble inclusion complexes with a wide variety of lipophilic water-insoluble drugs by taking up a whole drug molecule, or some part of it, into the cavity. The cyclodextrin molecules are relatively large (molecular weight ranging from almost 1000 to over 1500), with a hydrated outer surface, and under normal conditions, cyclodextrin molecules will only permeate the skin barrier with considerable difficulty. It is generally believed that the cyclodextrin molecules act as true carriers by keeping lipophilic drug molecules in solution and deliver them to the skin surface where they partition from the cyclodextrin cavity into the skin.
  • In one embodiment, the therapeutic enhancer is contained in the foamable composition in an amount from about 2% to about 30% of the total composition. The compositions can contain from about 2% to about 10% and from about 10% to about 30%, depending on their designated use.
    • Active Agents
  • The foam composition is useful and advantageous for the treatment of skin disorders and for skin care and cosmetic care. The addition of an oil having refatting, protective and moisture-retaining properties in a spreadable foam form can substitute for currently available dermatological and cosmetic creams, lotions, gels, etc.
  • In one or more embodiments of the present invention, the foam composition includes an active agent directed to the treatment of a medical disorder or a cosmetic disorder. The active agent can be categorized by the benefit it provides or by its postulated mode of action. The active agents can in some instances provide more than one benefit or operate via more than one mode of action. Therefore, classifications are made for the sake of convenience and are not intended to limit the active to that particular application or applications listed. Furthermore, foam compositions, with or without further active ingredients, are suitable for the application as “cosmeceutical” preparations.
    • Antibacterial Agents
  • One class of drugs comprises antibacterial agents. The term “antibacterial” as used herein shall include, but is not limited to, any substance being destructive to or inhibiting the growth of bacteria or any substance having the capacity to inhibit the growth of or to destroy bacteria and other microorganisms, and are used in the treatment of infectious diseases. It is well known that bacterial infections are involved in a variety of superficial disorders of the skin, eye, mucosal membrane, oral cavity, vagina and rectum. The antibacterial drug can be active against gram positive and gram-negative bacteria, protozoa, aerobic bacteria and unaerobic ones.
  • The antibacterial drug is selected from the group consisting of chloramphenicol, tetracyclines, synthetic and semi-synthetic penicillins, beta-lactams, quinolones, fluoroquinolnes, macrolide antibiotics, metronidazole and metronidazole derivatives and analogs, dicarboxylic acids, such as azelaic acid, silicylates, peptide antibiotics, cyclosporines and any combination thereof at a therapeutically effective concentration. Another group of antibacterial agents is non-specific and includes strong oxidants and free radical liberating compounds, such as hydrogen peroxide, bleaching agents (e.g., sodium, calcium or magnesium hypochlorite and the like) iodine, chlorohexidine and benzoyl peroxide.
  • Exemplary foamable compositions are particularly useful and beneficial in the prevention and treatment of secondary infections, accompanying skin-structure damage, such as in cuts, wounds, burns and ulcers. In all such cases, the present formulation is easy to use, being in foam state when applied and becoming liquid upon rubbing onto the skin.
  • While being useful in the prevention and treatment of infections, the antibacterial foam is also applicable for decontaminating areas, afflicted with bacterial warfare organisms, such as anthrax and smallpox.
    • Anti-Fungal Agents
  • Fungal infections are another object of treatment using the foamable composition. Superficial fungal infection of the skin is one of the commonest skin diseases seen in general practice. Dermatophytosis is probably the most common superficial fungal infection of the skin. Dermatophytosis is caused by a group of fungi capable of metabolizing the keratin of human epidermis, nails or hair. There are three genera of dermatophytes causing dermatophytosis, i.e., microsporum, trichophyton and epidermophyton.
  • Candidiasis is an infection caused by the yeast like fungus candida albicans or occasionally other species of candida. Clinical syndromes of candidiasis include: (a) oral candidiasis (oral thrush); (b) candidiasis of the skin and genital mucous membrane; (c) candida paronychia, which inflicts the nail; and (d) genital and vaginal candida, which inflict genitalia and the vagina.
  • The pharmaceutical composition can include an antifungal drug that is effective against dermatophytes and candida. The antifungal drug is selected from the group consisting of azoles, diazoles, triazoles, miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B, potassium iodide, flucytosine (5FC) and any combination thereof at a therapeutically effective concentration.
  • The foam composition according to one or more embodiments of the present invention is useful, for example, for the treatment of tinea corporis, tinea pedis, tinea rubrum, tinea unguium, tinea cruris, tinea barbae and tinea versicolor, as well as yeast Infections, such as candidiasis, and candidal vaginitis.
    • Anti-Viral Agents
  • Any known antiviral drugs, in a therapeutically effective concentration, can be incorporated into the foam composition. Exemplary compositions are particularly beneficial in the case of viral infections. Cold sores are caused by the herpes simplex Type 1 virus and are sometimes referred to as facial herpes. Mollusca are small viral growths that appear singly or in groups on the face, trunk, lower abdomen, pelvis, inner thighs, or penis. Shingles (herpes zoster) usually occurs only once in a lifetime, appears as a rash (clusters of blisters with a red base). Shingles is caused by the same virus that is responsible for chickenpox. Warts are a common, benign skin tumor caused by viral infection.
    • Anti-Inflammatory and Antiallergic Agents
  • The active agent can be an anti-inflammatory or antiallergic agent. Exemplary anti-inflammatory or antiallergic agents include corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), anti-histamines, immunosuppressants and any combination thereof at a therapeutically effective concentration.
  • The anti-inflammatory active agent is a corticosteroid. The corticosteroid can be selected from the group consisting of clobetasol proprionate, halobetasol proprionate, betamethasone diproprionate, betamethasone valerate, fluocinolone acetonide, halcinonide, betamethasone valerate, fluocinolone acetonide, hydrocortisone valerate, triamcinolone acetonide, hydrocortisone and any combination thereof at a therapeutically effective concentration. Since corticosteroid drugs are typically hydrophobic, suitable foam carriers include high levels of a hydrophobic solvent. The hydrophobic solvent facilitates topical distribution and enhances the rate of penetration of any of the corticosteroid drugs.
  • The composition may include active agents for the treatment of psoriasis. Corticosteroid ointments, greasy preparations containing little or no water, are commonly used for treating psoriasis. Their main disadvantage is in a sticky feeling subsisting for extended periods subsequent to treatment being completed thereby creating a latent inconvenience and possible discomfort to the treatment recipient. In contrast, the foam composition according to one or more embodiments of the present invention containing high levels of an oil (hydrophobic solvent) spreads very easily throughout the afflicted area and absorbs into the skin without leaving any unpleasant sensation or look. Examples of other inflammatory disorders that are treatable by a foamable composition including a steroid as an active agent are atopic dermatitis, seborrhea, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis (gravitational eczema; varicose eczema), exfoliative dermatitis (erythroderma), lichen simplex chronicus, pityriasis rosea and pemphigus.
  • Topical antihistaminic preparations currently available include 1% and 2% diphenhydramine (Benadryl® and Caladryl®), 5% doxepin (Zonalon®) cream, phrilamine maleate, chlorpheniramine and tripelennamine, phenothiazines, promethazine hydrochloride (Phenergan®) and dimethindene maleate. These drugs, as well as additional antihistamines, can also be used.
  • Polyunsaturated fatty acids containing omega-3 and omega-6 fatty acids (e.g., linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) also are beneficial in the treatment of psoriasis and other skin inflammation conditions and may be included in the foamable composition.
  • Nonsteroidal anti-inflammatory agents (NSAIDs) are useful against skin and systemic bio-abnormalities and can be added to the foam composition. The variety of compounds encompassed by NSAIDs is well-known to those skilled in the art. Specific non-steroidal anti-inflammatory agents useful in the composition include, but are not limited to oxicams, such as piroxicam, isoxicam, tenoxicam, sudoxicam; salicylates, such as salicylic acid, ethyl salicylate, methyl salycilate, aspirin, disalcid, benorylate, trilisate, safapryn, solprin, diflunisal, and fendosal; acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, and ketorolac; fenamates, such as mefenamic, meclofenamic, flufenamic, niflumic, and tolfenamic acids; propionic acid derivatives, such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indopropfen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic; and pyrazoles, such as phenylbutazone, oxyphenbutazone, feprazone, azapropazone, and trimethazone.
  • Any other steroidal and nonsteroidal compounds having the capacity to prevent, alleviate the symptoms of, treat or cure inflammation processes, may be generally included as anti-inflammatory agents.
  • The pharmaceutical composition may include an anti-inflammatory and/or an antiallergic agent that reduces the occurrence of pro-inflammatory cytokines or inhibits the effect of pro-inflammatory cytokines.
  • Mixtures of any anti-inflammatory agents can be used in the composition, as well as the dermatologically acceptable salts, esters, amides, prodrugs and derivatives of these agents.
  • Topical application of a foam, comprising a safe and effective dose of an NSAID can be useful in the prevention and/or alleviation of the symptoms of rheumatoid arthritis, osteoarthritis and pain. Topical NSAIDs, incorporated in the foam composition can be also used in the treatment of dermatological disorders such as acne, rosacea, hair growth disorders, actinic keratosis and certain skin cancer conditions.
    • Local Anesthetics
  • The foam compositions may include an effective amount of a topical anesthetic. The topical anesthetic can be selected from the group consisting of benzocaine, lidocaine, bupivacaine, chlorprocaine, dibucaine, etidocaine, mepivacaine, tetracaine, dyclonine, hexylcaine, procaine, cocaine, ketamine, pramoxine, phenol, any pharmaceutically acceptable salts thereof and mixtures of such anesthetic agents. Any mixture of synergistically beneficial anesthetic agents is contemplated
    • Keratolytically Active Agents
  • A keratolytic agent may be included as an active agent of a foamable composition. The term “keratolytically active agent” as used herein includes a compound that loosens and removes the stratum corneum of the skin, or alters the structure of the keratin layers of skin. Keratolytically active agents are used in the treatment of dermatological disorders that involve dry skin, hyperkeratinization (such as psoriasis), skin itching (such as xerosis), acne and rosacea.
  • Suitable keratolytically active agents include phenol and substituted phenolic compounds. Such compounds are known to dissolve and loosen the intracellular matrix of the hyperkeratinized tissue. As such, they are used in the treatment of dermatological disorders. Dihydroxybenzene and derivatives thereof have been recognized as potent keratolytic agents. Resorcinol (m-dihydroxybenzene) and derivatives thereof are used in anti-acne preparations. In addition to hydroquinone (p-dihydroxybenzene) having anti-pigmentation properties, hydroquinone is also known to be keratolytic. These compounds also exhibit antiseptic properties. Cresols also possess bactericidal and keratolytic properties.
  • Vitamin A and vitamin A derivatives, also termed herein “retinoids”, such as retinoic acid, isoretinoic acid, retinol and retinal are another class of keratolytically active agents.
  • Another group of keratolytically active agents include alpha-hydroxy acids, such as lactic acid and glycolic acid and their respective salts and derivatives; and beta-hydroxy acids, such as salicylic acid (o-hydroxybenzoic acid) and salicylic acid salts and pharmaceutically acceptable derivatives.
    • Another Class of Keratolytically Active Agents Includes Urea and Urea Derivatives. Retinoids
  • Another group of active agents includes retinol, retinal, all trans retinoic acid and derivatives, isomers and analogs thereof, collectively termed “retinoids”. Etretinate, actiretin, isotretinoin, adapalene and tazarotene are further examples of said retinoid isomers and analogs. Foamable compositions containing retinoids as the active drug can be used for the treatment of acne, seborrhea, various dermatoses, inflammation of the skin, mucosal membranes, vagina and the rectum, psoriasis, actinic keratosis and skin cancers, by application onto the affected area.
    • Insecticide and Insect Repellents Agents
  • Insects such as mosquitoes, biting flies, mites, gnats, fleas, chiggers, punkies, sand flies, lice and ticks can be annoying and sometimes pose a serious risk to human and animal health. In certain areas of the United States, mosquitoes can transmit diseases like equine and St. Louis encephalitis. Biting flies can inflict a painful bite that can persist for days, swell, and become infected. Ticks can transmit serious diseases like Lyme disease and Rocky Mountain spotted fever.
  • Insect repellents may be added to the foamable composition to protect people and animals from flying or biting insects, spiders, ticks and mites.
  • Examples of insect repellants include, but are not limited to, DEET (N, N-diethyl-m-toluamide), dimethyl phthalate, piperonyl butoxide and permethrin. Insect repelling terpenoids, have been reported by Hwang, et al, J. Chem. Ecol., 11, 1297 (1985); and Ruledge, J. Am. Mosquito Control Assoc. 4, 414 (1988).
  • A particular group of insect repellents includes the terpenoid compounds, described in U.S. Pat. No. 5,411,992, including:
  • (1) Terpenoid-alcohol or terpene-ols are terpenoids which have at least one hydroxyl group. Examples of terpene-ols include: C10H16O compounds, perillyl alcohol, carveol, myrtenol, and cis-verbenol; C10H18O compounds, myrtanol, iso-pinocampheol, dihydrocarveol, isopulegol, terpineol, terpinen-4-ol, nerol, geraniol, and linalool, and C10H20O compounds, menthol, beta-citronellol, and dihydro-myrcenol.
  • (2) Terpenoid-esters are terpenoids, which have at least one ester group which is the product of the bonding of the hydroxyl group of a terpene-ol with an aliphatic carboxylic acid that can contain functional groups such as the hydroxyl or amine on the aliphatic chain. Examples of suitable aliphatic carboxylic acids include acetic acid, propionic acid, lactic acid, and various amino acids. Examples of terpenoid-esters include: carvyl acetate, carvyl propionate, and menthyl lactate.
  • (3) Essential oils which contain terpenoids and perfumes which contain terpenoids. Non-limiting examples of essential oils having a high content of terpene-ols and esters include bergamot (62% terpenoids); sage (>50% terpenoids); styrax (>50% terpenoids); peppermint (>50% terpenoids); and pine Siberian (75% terpenoids %). Terpenes, aldehydes and ketones vary in their usefulness but as a general group have potential as insect-repellent.
  • The foamable composition is particularly suitable for the effective uniform spreading of an insect repellent agent onto large areas of the skin of humans and animals. The hydrophobic solvent present in the foam composition helps retain the insect repellent on the skin surface for an extended period of time.
  • The foamable composition is suitable for delivery of insect-killing agents (insecticides) to an afflicted external surface area of humans and animals. Thus, the pharmaceutical or cosmetic composition includes an insecticide selected from the group consisting of permethrin, hexachlorobenzene, carbamate, naturally occurring pyrethroids, permethrin, allethrin, malathion, piperonyl butoxide and any combination thereof at a therapeutically effective concentration. The application of the composition is very convenient and it spreads easily, even over hairy areas. The hydrophobic solvent present in the foam composition helps retain the insecticide on the treated area for an extended period of time. Furthermore, the presence of a hydrophobic solvent in the foam eases mechanical removal of lice and nits with a comb.
    • Anti-Cancer Drugs
  • Anti-cancer drugs can also be used as the drug of choice for the treatment of skin malignant tumors such as basal cell carcinoma, squamous sell carcinoma, melanoma and Kaposi's sarcoma, as well as the pre-cancerous condition actinic keratosis. In certain cases, topical cytotoxic and antiproliferative drugs are used to treat or prevent such cancers, including 5-fluorouracil, also called 5-FU. 5-FU, as well as any other anti-cancer agents, know in the art of cancer medicine, can be incorporated in the foam at therapeutically effective levels. An exemplary family of anticancer drugs, suitable for usage in the foam of the present formulation comprises antiestrogens, such as tamoxifen.
    • Photodynamic Therapy Agents
  • The foam composition is also useful to deliver photo-sensitizing agents. A photosensitizer can be selected from the group consisting of poephyrins, modified porphyrins, psoralen, 8-methoxypsoralen, 5-methoxypsoralen, psoralen derivatives, chlorins, bacteriochlorins, phthalocyanines, naphthalocyanines, pheophorbides, purpurins, m-THPC, mono-L-aspartyl chlorin e6, bacteriochlorins, phthalocyanines, benzoporphyrin derivatives and photosensitizer precursors, such as aminolevulinic acid (ALA).
    • Active Agents for Burns, Wounds, Cuts and Ulcers
  • The treatment of burns, wounds, cuts and ulcers using a foamable composition is particularly advantageous. The foam can include both anti-infective agents (against bacteria, fungi and/or viruses), antiinflammatory agents (steroidal and/or NSAIDs) and pain relieving components. Upon application, the foam spreads easily, covering the surface of the affected area, and without causing pain.
    • Skin Care Active Agents
  • The foam composition is useful and advantageous for skin care and cosmetic care. The combination of oil and water having moisture-retaining properties in a spreadable foam form can be used to substitute currently used cosmetic skin care creams, lotions, gels, etc. The cosmetic foam compositions are suitable for the further application as “cosmeceutical” preparation (cosmetic products with therapeutic benefit), to treat “cosmetic” skin disorders, such as aging skin, wrinkles, hyperpigmentation (melasma, chloasma, freckles, etc.), scaly skin and other skin undesirable properties.
  • The CTFA Cosmetic Ingredient Handbook describes a wide variety of nonlimiting cosmetic and pharmaceutical ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention. Examples of these ingredient classes include: abrasives, absorbents, aesthetic components such as fragrances, pigments, colorings/colorants, essential oils, astringents, etc. (e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate), anti-acne agents, anti-caking agents, antifoaming agents, antimicrobial agents (e.g., iodopropyl butylcarbamate), antioxidants, binders, biological additives, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film formers or materials, e.g., polymers, for aiding the film-forming properties and substantivity of the composition (e.g., copolymer of eicosene and vinyl pyrrolidone), opacifying agents, pH adjusters, propellants, reducing agents, sequestrants, skin bleaching and lightening agents (e.g., hydroquinone, kojic acid, ascorbic acid, magnesium ascorbyl phosphate, ascorbyl glucosamine), skin-conditioning agents (e.g., humectants, including miscellaneous and humectants facilitating regulating the residence of an active agent in the skin), skin soothing and/or healing agents (e.g., panthenol and derivatives (e.g., ethyl panthenol), aloe vera, pantothenic acid and pantothenic acid derivatives, allantoin, bisabolol, and dipotassium glycyrrhizinate), skin treating agents, thickeners, and vitamins and derivatives thereof.
    • Anti-Acne Active Agents
  • An anti-acne agent can be included in the foamable composition. The anti-acne agent can be selected from the group consisting of resorcinol, sulfur, salicylic acid and salicylates, alpha-hydroxy acids, nonsteroidal anti-inflammatory agents, benzoyl peroxide, retinoic acid, isoretinoic acid and other retinoid compounds, adapalene, tazarotene, azelaic acid and azelaic acid derivatives, antibiotic agents, such as erythromycin and clyndamycin, zinc salts and complexes, and combinations thereof, in a therapeutically effective concentration.
    • Anti-Wrinkle Active Agents/Anti-Atrophy Active Agents and Agents to Treat Dry and Scaly Skin (Xerosis and Ichthyosis)
  • The foamable composition may also include an effective amount of an anti-wrinkle active and/or at least one anti-atrophy active. Exemplary anti-wrinkle/anti-atrophy active agents suitable for use in the foamable compositions include sulfur-containing D and L amino acids and their derivatives and salts, particularly the N-acetyl derivatives; thiols; hydroxy acids (e.g., alpha-hydroxy acids such as lactic acid and glycolic acid and their derivatives and salts; or beta-hydroxy acids such as salicylic acid and salicylic acid salts and derivatives), urea, hyaluronic acid, phytic acid, lipoic acid; lysophosphatidic acid, skin peel agents (e.g., phenol, resorcinol and the like), vitamin B3 compounds (e.g., niacinamide, nicotinic acid and nicotinic acid salts and esters, including non-vasodilating esters of nicotinic acid (such as tocopheryl nicotinate), nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide), vitamin B5 and retinoids (e.g., retinol, retinal, retinoic acid, retinyl acetate, retinyl palmitate, retinyl ascorbate). In the case of dry, scaly skin (xerosis) and ichthyosis such agents can alleviate the symptoms by temporary relief of itching associated with these conditions.
    • Anti-Oxidants/Radical Scavengers
  • An effective amount of an anti-oxidant/radical scavenger can be added to the foamable compositions, for example, in an amount from about 0.1% to about 10% (w/w), or from about 1% to about 5% (w/w).
  • Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and ascorbic acid salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl sorbate), tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the tradename Trolox.®), gallic acid and gallic acid alkyl esters, especially propyl gallate, uric acid and uric acid salts and alkyl esters, sorbic acid and sorbic acid salts, lipoic acid, amines (e.g., N,N-diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), dihydroxy fumaric acid and dihydroxy fumaric acid salts, lycine pidolate, arginine pilolate, nordihydroguaiaretic acid, bioflavonoids, curcumin, lysine, methionine, proline, superoxide dismutase, silymarin, tea extracts, grape skin/seed extracts, melanin, and rosemary extracts can be used.
  • The foam is suitable for delivering skin protecting and revitalizing anti-oxidants/radical scavengers. Polyunsaturated fatty acids containing omega-3 and omega-6 fatty acids (e.g., linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) are beneficial in the treatment of psoriasis and other skin inflammation conditions. Likewise, emollients and silicone oils exert moisture-retaining and skin protective effects on the skin. Thus, a skin protective foam is provided, wherein the hydrophobic solvent comprises in full or in part, a solvent, selected from the group of emollients, silicone oil and oils, rich in unsaturated fatty acids, thus, affording a synergistic therapeutic effect of the anti-oxidants/radical scavenger agent and the vehicle components.
    • Self-Tanning Active Agents
  • The foam composition is particularly suitable for the uniform delivery of a tanning active agent onto large areas of the skin. The compositions contain from about 0.1% to about 20%, or from about 2% to about 7%, or even from about 3% to about 6% of dihydroxyacetone or any other compound know in the art as an artificial tanning active agent.
    • Skin Lightening and Whitening Agents
  • The foam composition may be formulated to provide a composition for the uniform delivery of a skin lightening agent. When used, the composition contains from about 0.1% to about 10%, or from about 0.2% to about 5% of a skin-lightening agent. Suitable skin lightening or whitening agents include those known in the art, including hydroquinone, azelaic acid and other related dicarboxylic acids, and salts and derivatives thereof, retinoids, kojic acid, arbutin, nicotinic acid and nicotinic acid precursors, salts and derivatives, ascorbic acid and salts and derivatives thereof (e.g., magnesium ascorbyl phosphate or sodium ascorbyl phosphate), and herbal extracts (e.g., mulberry extract, placental extract).
  • In one or more embodiments of the present invention, the foam composition includes a combination of at least one skin-whitening agent and at least one additional active agent selected from retinoids, keratolytically active agents and anti-inflammatory agents.
  • In one or more embodiments, the composition includes a combination of at least one skin-whitening agent and at least one keratolytically active agent selected from a alpha-hydroxy acids, beta hydroxy acids, and retinoids.
  • In one or more embodiments of the present invention, the foam composition includes a combination of a skin-whitening agent and an inorganic sunscreen agent. When inorganic sunscreen agents, e.g. titanium dioxide and zinc oxide, are rubbed onto the skin, they leave a white coating, which provides an instant (although transient) whitening effect, which is highly desirable by the consumer, who wishes to see instant change in his/her appearance. The whitening agent, in combination with the inorganic sunscreen agent in the foam carrier can be easily and uniformly distributed on the skin surface, thereby affording an even instant whitening effect, unlike creams that are difficult to spread evenly on skin areas.
    • Agents for Hair Growth Disorders
  • [Agents that affect the pattern of hair growth can be suitably incorporated in the foam composition. Male pattern baldness (MPB), the commonest cause of balding, is induced by the activity of the male hormone dihydrotestosterone (DHT), which is converted from the hormone testosterone by the enzymes 5-alpha reductase. Current treatments of MPB include minoxidil and agents, which inhibit 5-alpha reductase, such as finasteride, spironolactone, azelaic acid and azelaic acid derivatives and salts. Such agents, as well as other agents known in the art, can be incorporated in the foam composition.
  • Polyunsaturated fatty acids, i.e., such which include any of the essential fatty acids (EFA's), such as linoleic and linolenic acid, gamma-linoleic acid (GLA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are also known to contribute to hair growth. Thus, a hair growth foam composition is provided, in which the hydrophobic solvent comprises in full or in part, an oil, rich in such unsaturated fatty acids.
    • Figure-Forming Agents; Agents to Treat Cellulite/Slimming
  • Figure forming agents such as used in the treatment of cellulite and in slimming products can be suitably incorporated in the foam composition. A non-limiting exemplary list of active agents known in the treatment of cellulite and in the induction of a slimming effect include:
      • Herbal extracts: baldderwack extract, butcher's, broom, cayenne, dandelion, red clover, ginkgo biloba, horse chestnut, witch hazel and borage oil
      • Omega 3 and omega 6 oils
      • Caffeic acid and salts and derivatives thereof
      • Xanthine agents, such as theophiline and pentoxyphilline
      • Nicotinic acid and salts and derivatives thereof
    Agents to Treat Sunburn, Heat Burn, Radiation Burn, Rash and Itch
  • Cosmetic and pharmaceutical ingredients which are known in the art of pharmacology and cosmetology to treat dermatitis, minor skin irritations, sunburn, heat burn, radiation burn, and inhibit inflammation can be beneficially incorporated in the foam composition.
  • Examples of such active agents include chamomile extract (matricaria recutitia), cucumber distillate (cucumis sativus), lavender water (lavendula angustifolia), rose water (rosa damascena), witch hazel (hamamelis virginiana), allantoin, bisabolol, rosehip oil, calendula oil, azulaene, menthol and camphor.
    • Other Skin Care Active Agents
  • The active agent can be selected from the group of sulfur-containing amino acids, thiol compounds, alpha hydroxy acids, lactic acid and lactic acid derivatives and salts, glycolic acid, glycolic acid derivatives and glycolic acid salts, beta-hydroxy acids, salicylic acid and salicylic acid salts and derivatives, phytic acid, lipoic acid, lysophosphatidic acid, skin peel agents, phenol, resorcinol, vitamin B3 compounds, niacinamide, nicotinic acid and nicotinic acid salts and esters, tocopheryl nicotinate, nicotinyl amino acids, nicotinyl alcohol esters of carboxylic acids, nicotinic acid N-oxide and niacinamide N-oxide, retinoids, retinol, retinal, retinoic acid, retinyl acetate, retinyl palmitate and retinyl ascorbate, caffeine, theophilline, pentoxyphilline, dihydroxy acetone kojic acid, arbutin, nicotinic acid and nicotinic acid precursors, nicotinic acid salts, nicotinic acid derivatives, ascorbic acid, ascorbic acid salts and ascorbic acid derivatives
    • “Alcohol Free”
  • The foam carrier or foam composition is essentially free of short chain aliphatic alcohols (i.e., methyl, ethyl, isopropyl and butyl alcohol), unlike the composition disclosed in U.S. Pat. Nos. 6,126,920 and 6,358,541, which contains an aliphatic alcohol, preferably in amounts of 40-90% aliphatic alcohol. For the purpose of the present application, the term “alcohol free” refers to compositions that contain no more than 7.5% by weight of any aliphatic alcohol, having one to six carbon atoms in their carbon backbone, or no more than 7.5% by weight of any mixture of such aliphatic alcohols.
    • Optional Ingredients
  • The pharmaceutical or cosmetic foam carrier optionally includes a variety of pharmaceutical or cosmetic ingredients, which are added in order to fine-tune the consistency of the formulation, protect the formulation components from degradation and oxidation and bestow their cosmetic acceptability. Such an excipient is preferably selected from the group consisting of: a diglyceride, a triglyceride, a stabilizing agent, an antioxidant, glycerol, a flavoring, a colorant, an odorant agent and any other formulation component known in the art of pharmaceutical and cosmetic formulary. A pharmaceutical or cosmetic composition manufactured using the foam carrier according to the present invention is very easy to use. When applied onto the afflicted body surface of humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
    • Composition and Foam Physical Characteristics
  • A pharmaceutical or cosmetic composition manufactured using the foam carrier according to one or more embodiments of the present invention is very easy to use. When applied onto the afflicted body surface of mammals, i.e., humans or animals, it is in a foam state, allowing free application without spillage. Upon further application of a mechanical force, e.g., by rubbing the composition onto the body surface, it freely spreads on the surface and is rapidly absorbed.
  • The foam composition or carrier includes water, hydrophobic solvents, surfactant, gelling agent and propellant, thereby creating a stable emulsion having an acceptable shelf-life of at least one year, or at least two years at ambient temperature. A feature of a product for cosmetic or medical use is long term stability. Propellants, which are a mixture of low molecular weight hydrocarbons, tend to impair the stability of emulsions. It has been observed, however, that foam compositions including amphiphilic copolymers as gelling agents are surprisingly stable. Following accelerated stability studies, they demonstrate desirable texture; they form fine bubble structures that do not break immediately upon contact with a surface, spread easily on the treated area and absorb quickly.
  • The composition should also be free flowing, to allow it to flow through the aperture of the container, e.g., and aerosol container, and create an acceptable foam. Compositions containing semi-solid hydrophobic solvents, e.g., white petrolatum, as the main ingredients of the oil phase of the emulsion, exhibit high viscosity and poor flowability and are inappropriate candidates for a foamable composition.
  • Foam quality can be graded as follows:
  • Grade E (excellent): very rich and creamy in appearance, does not show any bubble structure or shows a very fine (small) bubble structure; does not rapidly become dull; upon spreading on the skin, the foam retains the creaminess property and does not appear watery.
  • Grade G (good): rich and creamy in appearance, very small bubble size, “dulls” more rapidly than an excellent foam, retains creaminess upon spreading on the skin, and does not become watery.
  • Grade FG (fairly good): a moderate amount of creaminess noticeable, bubble structure is noticeable; upon spreading on the skin the product dulls rapidly and becomes somewhat lower in apparent viscosity.
  • Grade F (fair): very little creaminess noticeable, larger bubble structure than a “fairly good” foam, upon spreading on the skin it becomes thin in appearance and watery.
  • Grade P (poor): no creaminess noticeable, large bubble structure, and when spread on the skin it becomes very thin and watery in appearance.
  • Grade VP (very poor): dry foam, large very dull bubbles, difficult to spread on the skin.
  • Topically administrable foams are typically of quality grade E or G, when released from the aerosol container. Smaller bubbles are indicative of more stable foam, which does not collapse spontaneously immediately upon discharge from the container. The finer foam structure looks and feels smoother, thus increasing its usability and appeal.
  • A further aspect of the foam is breakability. The breakable foam is thermally stable, yet breaks under sheer force. Sheer-force breakability of the foam is clearly advantageous over thermally-induced breakability. Thermally sensitive foams immediately collapse upon exposure to skin temperature and, therefore, cannot be applied on the hand and afterwards delivered to the afflicted area.
  • Another property of the foam is specific gravity, as measured upon release from the aerosol can. Typically, foams have specific gravity of between about 0.01 g/mL and about 0.1 g/mL.
    • Further Technical Parameters
  • The composition of the present invention can be contained in and dispensed from a container capable of withstanding the pressure of the propellant gas and having an appropriate valve/nozzle for dispensing the composition as foam under pressure. A customary liquefied propellant can be added, in the amount of about 3-18% of the total composition. Liquefied propellants are gases that exist as liquids under pressure, including high purity hydrocarbons such as propane, isobutane and n-butane, dimethyl ether and chlorofluorocarbons (CFCs).
  • A specific embodiment according to the present invention comprises placing the composition of the present invention on a patch, regulating residence of an active ingredient in the skin tape or the skin-contact compartment of a transdermal delivery apparatus and applying such object onto the skin, in order to attain effective superficial treatment or enhanced penetration of the drug into the skin or through the skin.
  • Utilizing such strategy, one can apply drugs, which are currently administered systemically or that require transdermal delivery, in the preferred therapeutic system of the present invention. Examples for such drugs are nicotine, testosterone and other male hormones and male hormone precursors, estrogen and other female hormones and hormone precursors, growth hormone, insulin, caffeine, steroidal and non-steroidal antiinflammatory agents and thyroid hormone substitutes.
  • The general process, as typically exemplified in Example 1 can be applied in order to produce the composition of the present invention.
  • The pharmaceutical carrier according to the present invention can also be used to prepare cosmetics for beauty purpose by adding into skin care agents and perfume.
    • Fields of Pharmaceutical Applications
  • By including an appropriate active component and optionally an appropriate at least one active agent, the foam composition of the present invention is useful in the therapy of a variety of disorders, such as classified, in a non-limiting exemplary manner, according to the following groups:
  • Dermatitis including contact dermatitis, atopic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis of the hands and feet, generalized exfoliative dermatitis, stasis dermatitis; lichen simplex chronicus; diaper rash; bacterial infections including cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, staphylococcal scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, erythrasma; fungal infections including dermatophyte infections, yeast infections; parasitic infections including scabies, pediculosis, creeping eruption; viral infections; disorders of hair follicles and sebaceous glands including acne, rosacea, perioral dermatitis, hypertrichosis (hirsutism), alopecia, including male pattern baldness, alopecia areata, alopecia universalis and alopecia totalis; pseudofolliculitis barbae, keratinous cyst; scaling papular diseases including psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris; benign tumors including moles, dysplastic nevi, skin tags, lipomas, angiomas, pyogenic granuloma, seborrheic keratoses, dermatofibroma, keratoacanthoma, keloid; malignant tumors including basal cell carcinoma, squamous cell carcinoma, malignant melanoma, paget's disease of the nipples, Kaposi's sarcoma; reactions to sunlight including sunburn, chronic effects of sunlight, photosensitivity; bullous diseases including pemphigus, bullous pemphigoid, dermatitis herpetiformis, linear immunoglobulin A disease; pigmentation disorders including hypopigmentation such as vitiligo, albinism and postinflammatory hypopigmentation and hyperpigmentation such as melasma (chloasma), drug-induced hyperpigmentation, postinflammatory hyperpigmentation; disorders of cornification including ichthyosis, keratosis pilaris, calluses and corns, actinic keratosis; pressure sores; disorders of sweating; inflammatory reactions including drug eruptions, toxic epidermal necrolysis; erythema multiforme, erythema nodosum, granuloma annulare.
  • The foam composition is useful in the therapy of non-dermatological disorders, which respond to topical/transdermal delivery of an active agent. By way of example, such disorders include localized pain in general, as well as joint pain, muscle pain, back pain, rheumatic pain, arthritis, ostheoarthritis and acute soft tissue injuries and sports injuries. Other disorders of this class include conditions, which respond to hormone therapy, such as hormone replacement therapy, transdermal nicotine administration, and other respective disorders, known in the art of drug delivery.
  • The foam compositions are further useful for the treatment and prevention of disorders and diseases of other body cavities including the rectum, vagina, penile urethra and ear canal.
  • Thus, the foam compositions are useful in treating a patient having any one of a variety of gynecological disorders, such as classified, in a non-limiting exemplary manner, according to the following groups: pelvic pain, including premenstrual syndrome (PMS), mittelschmerz (severe midcycle pain due to ovulation), dysmenorrhea (pain related to the menstrual cycle), endometriosis, ectopic pregnancy, ovarian cysts and masses, acute pelvic inflammatory disease, pelvic congestion syndrome and vulvodynia; vulvovaginal infections, including bacterial vaginosis, candidal vaginitis, trichomonas vaginalis, herpes simplex genital ulcers and warts, pelvic inflammatory disease (PID), cervicitis, acute and chronic salpingitis; endometriosis; gynecological neoplasms, including endometrial Cancer, ovarian cancer, cervical cancer, vulvar cancer, vaginal cancer, fallopian tube cancer and gestational trophoblastic disease; benign tumors; sexually transmitted diseases; sexual dysfunction disorders that respond to pharmacological therapy, including sexual arousal disorder, female orgasmic disorder, dyspareunia and vaginismus; and various gynecological disorders that respond to hormonal therapy.
  • Rectal applications include, for example, anal abscess/fistula, anal cancer, anal warts, Crohn's disease, haemorrhoids, anal and perianal pruritus, soreness, and excoriation, perianal thrush, anal fissures, fecal incontinence, constipation, polyps of the colon and rectum.
  • The foam compositions are further useful for intra-vaginal and rectal treatment of sexually-transmitted and non-sexually-transmitted infectious disease (STDs).
  • In one or more embodiments, the invention provides a method of treatment of a disorder of the skin, mucosal membrane, ear channel, vaginal, rectal and penile urethra disorders, comprising topical application of the foam composition, whereby one or more active agents, in a therapeutically effective concentration to the afflicted area.
  • In a further embodiment, the invention provides a method of treatment of a non-dermatological disorder, which responds to topical delivery of an active agent, comprising topical application of the foam composition of the present invention, whereby one or more active agents, in a therapeutically effective concentration to the skin.
    • Treatment/Therapy
  • The terms “therapy” and “treatment” as used herein interchangeably, cover any treatment of a disease or disorder, and includes, for example:
      • (i) Curing the disease or disorder;
      • (ii) preventing the disease or disorder from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it;
      • (iii) inhibiting the disease or disorder;
      • (iv) relieving the disease or disorder;
      • (v) causing regression of the disease;
      • (vi) providing a beneficial immunological effect;
      • (vii) improving the quality of life of a subject afflicted by a disease or disorder; and, in the case of cosmetic treatment
      • (viii) cleansing, beautifying, promoting attractiveness, or altering the appearance without affecting the body's structure or functions
    EXAMPLES
  • In the following, we are going to describe some examples and experiments in detail. This invention is not limited to these examples and experiments. Many variations will suggest themselves are within the full intended scope of the appended claims.
    • Example 1 Production of Pharmaceutical or Cosmetic Foam Carrier and Composition—General Method
  • The method for preparing of a pharmaceutical foam carrier generally comprised following steps.
  • Step 1—Aqueous Phase: Gelling agent and surface-active agent are dissolved in water, with agitation. The solution is warmed to 50-70° C. Water soluble cosmetic or pharmaceutical active Ingredients* and optional water soluble ingredients are added with agitation to the Aqueous Phase mixture.
  • Step 2—Hydrophobic Phase: The hydrophobic solvent is heated to same temperature. Oil soluble cosmetic or pharmaceutical active agents* and optional oil soluble formulation ingredients are added with agitation to the Hydrophobic Phase mixture.
  • Step 3—The warm Hydrophobic Phase is gradually poured into the warm Aqueous Phase, with agitation, followed by Ultraturax homogenization. The mixture is allowed to cool down to ambient temperature.
  • Step 4—The mixture, at ambient temperature, is added to an aerosol container, the container is sealed and appropriate amount of propellant (about 10% of the composition mass) is compressed into the container.
  • * In case of heat sensitive active ingredients, add the active ingredient with agitation to the mixture, after Step 3.
  • In the following examples, foam compositions were prepared as described above and tested for foam quality
    • Example 2 Diclofenac Foam Composition with Transcutol
  • Component % w/w
    Mineral oil (hydrophobic solvent) 6.00
    Isopropyl myristate (hydrophobic solvent) 6.00
    Stearyl alcohol (foam adjuvant) 1.00
    Xanthan gum (gelling agent) 0.30
    Methocel K100M (gelling agent) 0.30
    TWEEN 80 (surfactant) 1.00
    MYRJ 49p (surfactant) 3.00
    Cocamidopropyl betaine (surfactant) 0.50
    Transcutol p (therapeutic enhancer) 20.00
    Glyceryl monostearate (co-emulsifier) 0.50
    Diclofenac sodium (active agent) 1.00
    Phenonip (preservative) 0.30
    Butane/propane (propellant) 8.00
    Water to 100.0
    Foam Quality E
    Density 0.028
    • Example 3 Local Anesthetic Lidocaine Foam Compositions with Either Urea, Lactic Acid or a Therapeutic Enhancer
  • Component % w/w
    Mineral oil 6.00 6.00 6.00 6.00 12.00
    Isopropyl myristate 6.00 6.00 6.00 6.00 12.00
    Glyceryl monostearate 0.50 0.50 0.50 0.50 1.00
    Stearyl alcohol 1.00 1.00 1.00 1.00 1.00
    Xanthan gum 0.30 0.30 0.30 0.30 0.30
    Methocel K100M 0.30 0.30 0.30 0.30 0.30
    TWEEN 60 1.00
    TWEEN 80 1.00 1.00 1.00 2.00
    MYRJ 49p 3.00 3.00 3.00 3.00 4.00
    Lactic acid 10.00 5.00
    Glycofurol 1.00 10.00
    Urea 10.00
    Cocamidopropyl betaine — 0.50 — 0.50 —
    Lidocaine base 4.00 4.00 4.00 4.00 4.00
    Phenonip 0.30 0.30 0.30 0.30 0.30
    Butane/propane 8 8 6 10 10
    Water to 100 to 100 to 100 to 100 to 100
    Foam Quality E E E E E
    Density 0.028 0.038 0.044 0.028 0.028
    Mineral oil 6.00 6.00 6.00 22.00 6.00
    Isopropyl myristate 6.00 6.00 6.00 22.00 6.00
    Glyceryl monostearate 0.50 0.50 0.50 1.00 0.50
    Stearyl alcohol 1.00 1.00 1.00 1.00 1.00
    Xanthan gum 0.30 0.30 0.30 0.40 0.30
    Methocel K100M 0.30 0.30 0.30 0.40 0.30
    TWEEN 80 1.00 1.00 2.00 1.00
    MYRJ 49p 1.00 3.00 3.00 4.00 3.00
    Propylene glycol 3.00
    Transcutol p 10.00 1.00 2.00 10.00
    Cocamidopropyl betaine 0.50 0.50 0.50 0.50 0.50
    Lidocaine base 4.00 4.00 4.00 4.00 4.00
    Phenonip 0.30 0.30 0.30 0.30 0.30
    Butane/propane 8 8 6 8 10
    Water to 100 to 100 to 100 to 100 to 100
    Foam Quality E E E E E
    Density 0.032 0.035 0.048 0.075 0.025
    • Example 4 Foam Compositions with Urea
  • Component % w/w
    Mineral oil 6.00 6.00 6.00 6.00
    Isopropyl myristate 6.00 6.00 6.00 6.00
    Glyceryl monostearate 0.50 0.50 0.50 0.50
    Stearyl alcohol 0.20 0.20 0.20 1.00
    Urea 10.00 10.00 10.00 10.00
    Xanthan gum 0.30 0.30 0.30 0.30
    Methocel K100M 0.30 0.30 0.30 0.30
    Myrj 52 3.00
    TWEEN 80 1.00
    Myrj 49p 3.00
    TWEEN 60 1.00 1.00 1.00
    Cocamidopropyl betaine 0.50 0.50 0.50
    Phenonip 0.30 0.30 0.30 0.30
    Butane/propane 8.00 8.00 8.00 6.00
    Water to 100 to 100 to 100 to 100
    Foam Quality E E E E
    Density n/a 0.023 n/a 0.044
    Mineral oil 6.00 6.00
    Isopropyl myristate 6.00 6.00
    Glyceryl monostearate 0.50 0.50
    Stearyl alcohol 1.00 1.00
    Urea 40.00 40.00 20.00 20.00
    Xanthan gum 0.30 0.30 0.30 0.30
    Methocel K100M 0.30 0.30 0.30 0.30
    Myrj 52 3.00 3.00 3.00 3.00
    TWEEN 80 1.00 1.00 1.00 1.00
    Cocamidopropyl betaine 0.50 0.50 0.50
    Phenonip 0.30 0.30 0.30 0.30
    Butane/propane 8.00 6.00 8.00 8.00
    Water to 100 to 100 to 100 to 100
    Foam Quality E E E E
    Density 0.022 0.029 0.032 0.024
  • Component % w/w
    Capric/caprylic triglycerides 12.00
    Glyceryl monostearate 0.50
    Tween 80 3.0
    Pemulene TR1 0.50
    Hydrophilic Drug 1.0
    Urea 10.0
    Phenonip 0.30
    Butane/propane 8.00
    Water to 100
    Foam Quality E
    Density 0.030
  • Component % w/w
    Capric/caprylic triglycerides 12.00
    Glyceryl monostearate 0.50
    Tween 80 3.0
    Pemulene TR1 0.50
    Hydrophobic Drug 1.0
    Urea 10.0
    Phenonip 0.30
    Butane/propane 8.00
    Water to 100
    Foam Quality E
    Density 0.030
  • Component % w/w
    Capric/caprylic triglycerides 25.00
    Glyceryl monostearate 0.50
    Stearyl alcohol 1.00
    Xanthan gum 0.30
    Methocel K100M 0.30
    TWEEN 80 1.00
    MYRJ 52P 3.00
    Urea 10.00
    Cocamidopropyl betaine 0.50
    Hydrophilic Drug 0.1-2.0
    Phenonip 0.30
    Butane/propane 6.00
    Water to 100
    Foam Quality E
    Density 0.034
  • Component % w/w
    Capric/caprylic triglycerides 25.00
    Glyceryl monostearate 0.50
    Stearyl alcohol 1.00
    Xanthan gum 0.30
    Methocel K100M 0.30
    TWEEN 80 1.00
    MYRJ 52P 3.00
    Urea 10.00
    Cocamidopropyl betaine 0.50
    Lipophilic Drug 2.0
    Phenonip 0.30
    Butane/propane 8.00
    Water to 100
    Foam Quality E
    Density 0.020
  • Component % w/w
    Capric/caprylic triglycerides 12.00
    Glyceryl monostearate 0.50
    Pemulene TR1 0.50
    Methocel K100M 0.30
    Xanthan gum 0.30
    Urea 10.00
    Ketoconazole 1.0
    Phenonip 0.30
    Butane/propane 8.00
    Water to 100
    Foam Quality E
    Density 0.020
    • Example 5 Further Foam Composition with Either Transcutol or Glycofurol
  • Component % w/w
    Isopropyl myristate 30.00
    Glyceryl monostearate 0.50
    Xanthan gum 0.30
    Methocel K100M 0.30
    TWEEN 80 1.00
    MYRJ 49p 3.00
    Cocamidopropyl betaine 0.50
    Transcutol p 20.00
    Hyrdophylic drug 1.0
    Phenonip 0.30
    Butane/propane 8.00
    Water to 100
    Foam Quality E
    Density 0.028
  • Component % w/w
    Isopropyl myristate 30.00
    Glyceryl monostearate 0.50
    Xanthan gum 0.30
    Methocel K100M 0.30
    TWEEN 80 1.00
    MYRJ 49p 3.00
    Cocamidopropyl betaine 0.50
    Transcutol p 20.00
    Hyrdophobic drug 1.0
    Phenonip 0.30
    Water to 100
    Butane/propane 8.00
    Foam Quality E
    Density 0.030
  • Component % w/w
    Capric/caprylic triglycerides 12.00
    Glyceryl monostearate 0.50
    Pemulene TR1 0.50
    Methocel K100M 0.30
    Xanthan gum 0.30
    Transcutol 10.00
    Ketoconazole 1.0
    Phenonip 0.30
    Water to 100
    Butane/propane 8.00
    Foam Quality E
    Density 0.038
  • Component % w/w
    Capric/caprylic triglycerides 12.00
    Glyceryl monostearate 0.50
    Pemulene TR1 0.50
    Methocel K100M 0.30
    Xanthan gum 0.30
    Glycofurol 10.00
    Ketoconazole 1.0
    Phenonip 0.30
    Water to 100
    Butane/propane 8.00
    Foam Quality E
    Density 0.034
    • Example 6 Foam Compositions with Hydroxy Acids
  • Component % w/w
    Capric/caprylic triglycerides 18.00
    Glyceryl monostearate 0.50
    Pemulene TR1 0.50
    Methocel K100M 0.30
    Xanthan gum 0.30
    Hydrophilic Drug 1.0
    Lactic acid 6.0
    Phenonip 0.30
    Butane/propane 8.00
    Water to 100
    Foam Quality E
    Density 0.030
  • Component % w/w
    Capric/caprylic triglycerides 18.00
    Glyceryl monostearate 0.50
    Pemulene TR1 0.50
    Methocel K100M 0.30
    Xanthan gum 0.30
    Hydrophobic Drug 1.0
    Lactic acid 6.0
    Phenonip 0.30
    Butane/propane 6.00
    Water to 100
    Foam Quality E
    Density 0.038
  • Component % w/w
    Capric/caprylic triglycerides 25.00
    Glyceryl monostearate 0.50
    Stearyl alcohol 1.00
    Xanthan gum 0.30
    Methocel K100M 0.30
    TWEEN 80 1.00
    MYRJ 52P 3.00
    Glycolic acid 4.00
    Cocamidopropylbetaine 0.50
    Hydrophylic Drug 2.0
    Phenonip 0.30
    Butane/propane 6.00
    Water to 100
    Foam Quality E
    Density 0.044
  • Component % w/w
    Capric/caprylic triglycerides 25.00
    Glyceryl monostearate 0.50
    Stearyl alcohol 1.00
    Xanthan gum 0.30
    Methocel K100M 0.30
    TWEEN 80 1.00
    MYRJ 52P 3.00
    Glycolic acid 4.00
    Cocamidopropylbetaine 0.50
    Hydrohobic Drug 2.0
    Phenonip 0.30
    Butane/propane 12.00
    Water to 100
    Foam Quality E
    Density 0.020
  • Although various embodiments that incorporate the teachings of the present invention have been shown and described in detail herein, those skilled in the art can readily devise many other varied embodiments that incorporate these teachings.

Claims (36)

1. (canceled)
2. A composition comprising a carrier and a propellant, the carrier comprising:
i) a surface-active agent;
ii) about 2% to about 75% by weight of the carrier of a liquid non-volatile hydrophobic solvent;
iii) a gelling agent;
iv) an active component selected from the group consisting of a urea, a hydroxy acid, a hydroxy acid salt, and a mixture of any two or more thereof; and
v) water,
wherein a breakable foam forms upon dispensing the composition.
3. The composition of claim 2, comprising a hydroxy acid and a hydroxy acid salt.
4. The composition of claim 2, wherein the surface-active agent is present at about 0.1% to about 8% by weight of the carrier.
5. The composition of claim 2, wherein the surfactant comprises a glycerol ester, a polyoxyethylene alkyl ether, or a mixture thereof.
6. The composition of claim 5, wherein the surfactant is selected from the group consisting of glyceryl monostearate, steareth-2, steareth-21, and mixtures of any two or more thereof.
7. The composition of claim 2, wherein the hydrophobic solvent is selected from the group consisting of a vegetable oil, a marine oil, a mineral oil, an emollient, a silicone oil, a plant-derived therapeutic oil, and mixtures of any two or more thereof.
8. The composition of claim 7, wherein the hydrophobic solvent comprises caprylic/capric triglycerides and or octyldodecanol.
9. The composition of claim 2, further comprising a volatile silicone oil.
10. The composition of claim 2, wherein the hydrophobic solvent is about 5% to about 50% by weight of the carrier.
11. The composition of claim 2, wherein the carrier further comprises a foam adjuvant at about 0.1% to about 5% by weight of the carrier.
12. The composition of claim 2, wherein the gelling agent is present in an amount of about 0.01% to about 5.0% by weight of the carrier.
13. The composition of claim 12, wherein the gelling agent is selected from the group consisting of a locust bean gum, sodium alginate, sodium caseinate, egg albumin, a gelatin agar, a carrageenin gum, a xanthan gum, a quince seed extract, a tragacanth gum, a guar gum, a starch, a chemically modified starch, cellulose ethers, a microcrystalline cellulose, a hydroxyethyl cellulose, a methyl cellulose, a carboxymethyl cellulose, a hydroxy propylmethyl cellulose, a hydroxypropyl guar gum, a soluble starch, cationic celluloses, cationic guars, carboxyvinyl polymers, a polyvinylpyrrolidone, a polyvinyl alcohol, polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl acetate polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers, acrylic acid/ethyl acrylate copolymers, crosslinked copolymers of acrylic acid and C10-C30 alkyl acrylates (a pemulen), a carbopol, and mixtures of any two or more thereof.
14. The composition of claim 2, wherein the carrier further comprising a therapeutic enhancer selected from the group consisting of a polyhydric alcohol, propylene glycol, butylene glycol, glycerol, pentaerythritol, sorbitol, mannitol, an oligosaccharide, dimethyl isosorbide, a monooleate of ethoxylated glycerides (with 8 to 10 ethylene oxide units), a polyethylene glycol 200-600, transcutol (diethylene glycol monoethyl ether), glycofurol (tetrahydrofurfuryl alcohol PEG ether), a cyclodextrin, and mixtures of any two or more thereof.
15. The composition of claim 2, wherein the carrier further comprises a humectant, a moisturizer, a preservative, a pH adjusting agent, or a mixture of any two or more thereof.
16. The composition of claim 2, wherein the liquefied or compressed gas propellant is at a concentration of about 3% to about 18% by weight of the carrier.
17. The composition of claim 2, wherein the carrier further comprises a polar solvent.
18. The composition of claim 2, wherein the active component comprises a urea, a hydroxy acid, and a hydroxy acid salt.
19. The composition of claim 18, wherein the carrier further comprises a foam adjuvant and a gelling agent.
20. The composition of claim 18, wherein the carrier further comprises a polar solvent and or a therapeutic enhancer.
21. The composition of claim 18, wherein the carrier further comprises a humectant, a moisturizer, a preservative, a pH adjusting agent, or a mixture of any two or more thereof.
22. A composition comprising a carrier and a propellant, the carrier comprising:
i) a surface active agent comprising a non-ionic surface-active agent;
ii) about 2% to about 75% by weight of the carrier of a liquid non-volatile hydrophobic solvent;
iii) a gelling agent;
iv) an active component selected from the group consisting of a urea, a hydroxy acid, a hydroxy acid salt, and a mixture of any two or more thereof; and
v) water,
wherein at least 50% of the surface active agent comprises a non-ionic surface active agent if an ionic surface active agent is present; and
wherein a breakable foam forms upon dispensing the composition.
23. The composition of claim 22, wherein the active agent comprises a urea, and wherein the urea is present at about 1% to about 50% by weight of the carrier.
24. The composition of claim 22, wherein the active agent comprises a hydroxy acid, and wherein the hydroxy acid is present at about 1% to about 30% by weight of the carrier.
25. The composition of claim 22, wherein the active agent comprises a hydroxy acid salt, and wherein the hydroxy acid salt is present at about 1% to about 30% by weight of the carrier.
26. The composition of claim 22, wherein the ionic surface-active agent is selected from the group consisting of a cationic surface-active agent, an amphoteric surface-active agent, an anionic surface-active agent, a zwitterionic-surface active agent, and mixtures of any two or more thereof.
27. The composition of claim 22, wherein the carrier further comprises a foam adjuvant, a polar solvent, a therapeutic enhancer, a humectant, a moisturizer, a preservative, a pH adjusting agent, or a mixture of any two or more thereof.
28. The composition of claim 27, wherein the foam adjuvant comprises a fatty alcohol having 15 or more carbons in its carbon chain.
29. The composition of claim 28, wherein the fatty alcohol comprises cetyl alcohol or stearyl alcohol or a mixture thereof.
30. The composition of claim 27, wherein the combined amount of surface-active agent, gelling agent and foam adjuvant is less than about 8% by weight of the carrier or less than about 5% by weight of the carrier.
31. The composition of claim 22, wherein if an ionic surface active agent is present then the ratio of non-ionic surface active agent to ionic surface active agent is greater than 6:1.
32. The composition of claim 27, wherein the hydrophobic solvent comprises a vegetable oil and or an emollient, wherein the foam adjuvant comprises a fatty alcohol and or a fatty acid, wherein the gelling agent comprises a polymeric agent, and wherein the non-ionic surface active agent comprises a glycerol ester, a polyoxyethylene alkyl ether, or a mixture of two or more thereof.
33. The composition of claim 32, wherein the hydrophobic solvent comprises caprylic/capric triglycerides, octyldodecanol, or mixtures thereof; the foam adjuvant comprises cetyl alcohol, stearyl alcohol, or mixtures thereof; the gelling agent comprises a gum, a cellulose ether, or a mixture thereof; and the non-ionic surface active agent comprises glyceryl monostearate, steareth-2, steareth-21, and mixtures of any two or more thereof.
34. The composition of claim 22, wherein the carrier comprises:
a) from about 12% to about 44% hydrophobic solvent by weight of the carrier;
b) from about 0% to about 40% urea by weight of the carrier, or when hydroxy acid is 0%, from about 6% to about 40% urea by weight of the carrier;
c) from about 0% to about 10% hydroxy acid by weight of the carrier, or when urea is 0%, from about 4% to about 10% hydroxyl acid by weight of the carrier;
d) from about 0.5% to about 1.1% gelling agent by weight of the carrier;
e) from about 0.5% to about 7.5% surfactant by weight of the carrier;
f) from about 0% to about 1% foam adjuvant by weight of the carrier;
g) from about 0% to about 20% therapeutic enhancer by weight of the carrier; and
wherein the non-ionic surface active agent has a HLB or an average HLB of about 3.8 to about 15.
35. A method of skin or mucosal surface application and or treatment comprising spreading or collapsing a foam of claim 22 at or about a target site of a subject having a skin or mucosal disorder.
36. The method of claim 35, wherein the disorder is selected from the group consisting of dry skin, scaly skin, xerosis, ichthyosis, dermatitis, eczema, psoriasis, keratoses, calluses, and hyperkeratotic skin.
US14/528,038 2002-10-25 2014-10-30 Penetrating pharmaceutical foam Abandoned US20150157586A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/528,038 US20150157586A1 (en) 2002-10-25 2014-10-30 Penetrating pharmaceutical foam

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
IL152486 2002-10-25
IL15248602A IL152486A0 (en) 2002-10-25 2002-10-25 Alcohol-free cosmetic and pharmaceutical foam carrier
US42954602P 2002-11-29 2002-11-29
US49238503P 2003-08-04 2003-08-04
US49764803P 2003-08-25 2003-08-25
PCT/IB2003/005527 WO2004037225A2 (en) 2002-10-25 2003-10-24 Cosmetic and pharmaceutical foam
US10/911,367 US20050069566A1 (en) 2003-08-04 2004-08-04 Foam carrier containing amphiphilic copolymeric gelling agent
US10/922,358 US7700076B2 (en) 2002-10-25 2004-08-20 Penetrating pharmaceutical foam
US12/752,718 US8435498B2 (en) 2002-10-25 2010-04-01 Penetrating pharmaceutical foam
US13/784,085 US8741265B2 (en) 2002-10-25 2013-03-04 Penetrating pharmaceutical foam
US14/258,700 US9492412B2 (en) 2002-10-25 2014-04-22 Penetrating pharmaceutical foam
US14/528,038 US20150157586A1 (en) 2002-10-25 2014-10-30 Penetrating pharmaceutical foam

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/258,700 Continuation US9492412B2 (en) 2002-10-25 2014-04-22 Penetrating pharmaceutical foam

Publications (1)

Publication Number Publication Date
US20150157586A1 true US20150157586A1 (en) 2015-06-11

Family

ID=46302609

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/922,358 Active 2027-09-18 US7700076B2 (en) 2002-10-25 2004-08-20 Penetrating pharmaceutical foam
US12/752,718 Expired - Lifetime US8435498B2 (en) 2002-10-25 2010-04-01 Penetrating pharmaceutical foam
US13/784,085 Expired - Lifetime US8741265B2 (en) 2002-10-25 2013-03-04 Penetrating pharmaceutical foam
US14/258,700 Expired - Lifetime US9492412B2 (en) 2002-10-25 2014-04-22 Penetrating pharmaceutical foam
US14/528,038 Abandoned US20150157586A1 (en) 2002-10-25 2014-10-30 Penetrating pharmaceutical foam
US15/349,768 Abandoned US20170119665A1 (en) 2002-10-25 2016-11-11 Penetrating pharmaceutical foam

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US10/922,358 Active 2027-09-18 US7700076B2 (en) 2002-10-25 2004-08-20 Penetrating pharmaceutical foam
US12/752,718 Expired - Lifetime US8435498B2 (en) 2002-10-25 2010-04-01 Penetrating pharmaceutical foam
US13/784,085 Expired - Lifetime US8741265B2 (en) 2002-10-25 2013-03-04 Penetrating pharmaceutical foam
US14/258,700 Expired - Lifetime US9492412B2 (en) 2002-10-25 2014-04-22 Penetrating pharmaceutical foam

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/349,768 Abandoned US20170119665A1 (en) 2002-10-25 2016-11-11 Penetrating pharmaceutical foam

Country Status (1)

Country Link
US (6) US7700076B2 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
WO2018086790A1 (en) * 2016-11-11 2018-05-17 Beiersdorf Ag Cleaning foam containing hydroxypropyl methylcellulose and xanthan gum
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263580B2 (en) * 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20060233721A1 (en) * 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8119150B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US20120156144A1 (en) * 2002-10-25 2012-06-21 Foamix Foamable Compositions, Kits and Methods for Hyperhidrosis
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20080031907A1 (en) * 2002-10-25 2008-02-07 Foamix Ltd. Cosmetic and pharmaceutical foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
NZ541526A (en) * 2003-01-24 2008-03-28 Stiefel Res Australia Pty Ltd Clindamycin phosphate foam
NL1022597C2 (en) * 2003-02-05 2004-08-06 Photobiochem N V Use of a photosensitizer compound for the preparation of a pharmaceutical preparation, a method for preparing a pharmaceutical preparation and a method for treating a mammal.
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
US8940321B2 (en) * 2003-12-12 2015-01-27 Otic Pharma Ltd. Compositions for treatment of ear disorders and methods of use thereof
CA2555121A1 (en) * 2004-02-04 2005-08-25 Foamix Ltd. Cosmetic and pharmaceutical foam with solid matter
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060177399A1 (en) * 2004-11-16 2006-08-10 Herve Jourdan Pressurized device for hair fiber styling and use of the same for hair fiber styling and/or hair
CA2610662A1 (en) * 2005-05-09 2007-05-18 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
JP2008540534A (en) * 2005-05-09 2008-11-20 ドラッグテック コーポレイション Modified release pharmaceutical composition
ES2407407T3 (en) 2005-06-01 2013-06-12 Glaxosmithkline Intellectual Property Development Limited Vitamin formulation
WO2007085902A2 (en) * 2005-07-19 2007-08-02 Foamix Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US8153162B2 (en) 2005-09-27 2012-04-10 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
JP2009522360A (en) * 2006-01-05 2009-06-11 ドラッグテック コーポレイション Composition and method of use thereof
EA200870155A1 (en) * 2006-01-05 2009-02-27 Драгтек Корпорейшн SYSTEM OF DELIVERY MEDICINE
BRPI0709674A2 (en) 2006-03-31 2011-12-06 Stiefel Res Australia Pty Ltd sparkling suspension gel
CN101529870B (en) * 2006-11-14 2013-05-15 诺基亚公司 Swivel hinge mechanism and related device comprising a plurality of housing parts
FR2910321B1 (en) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc CREAM GEL COMPRISING AT LEAST ONE RETINOID AND BENZOLE PEROXIDE
FR2910320B1 (en) 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc EMULSION COMPRISING AT LEAST ONE RETINOID AND BENZOLE PEROXIDE
US8101664B2 (en) * 2007-01-19 2012-01-24 Quinnova Pharmaceuticals, Inc. Urea foam
PL1986473T3 (en) * 2007-04-03 2017-07-31 Tsinghua University Organic electroluminescent device
US20080255103A1 (en) * 2007-04-12 2008-10-16 Ballay Pharmaceuticals, Inc. Antihistamine and anti-nausea pharmaceutical compositions for topical application
ES2382110T3 (en) * 2007-05-10 2012-06-05 Neubourg Skin Care Gmbh & Co. Kg Surfactant-free foam formulations
PL2187736T3 (en) 2007-08-16 2016-01-29 Univ Chicago Plant pathogen resistance
US20090068117A1 (en) * 2007-09-04 2009-03-12 Quinnova Pharmaceuticals, Inc. Stay-on selenium foam
AR068409A1 (en) * 2007-09-14 2009-11-18 Drugtech Corp PHARMACEUTICAL, TRANSDERMIC COMPOSITIONS WITHOUT ALCOHOL
US20090136430A1 (en) * 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
WO2009141541A2 (en) * 2008-04-22 2009-11-26 Centre National De La Recherche Scientifique Novel compositions which inhibit melanogenesis and uses thereof
US20110092493A1 (en) * 2008-09-24 2011-04-21 Clark Levi Dose-controlled transdermal promethazine compositions and methods of use
US8637577B2 (en) 2009-01-22 2014-01-28 Absorption Pharmaceuticals, LLC Desensitizing drug product
CA2752070C (en) * 2009-02-12 2017-11-28 Precision Dermatology, Inc. Foamable benzoyl peroxide compositions for topical administration
PT2400951T (en) 2009-02-25 2018-11-26 Mayne Pharma Llc Topical foam composition
WO2011038446A1 (en) * 2009-09-30 2011-04-07 Stiefel Research Australia Pty Ltd Cosmetic foam
US8957095B2 (en) 2009-10-26 2015-02-17 Sephoris Pharmaceuticals, Llc Treatment of sunburn using analgesics and antihistamines
US8174881B2 (en) 2009-11-24 2012-05-08 Micron Technology, Inc. Techniques for reducing disturbance in a semiconductor device
PL2335675T3 (en) * 2009-12-10 2015-08-31 Neubourg Skin Care Gmbh & Co Kg Emulsifier-free, polymer stabilised foam formulas
BR112012019827A2 (en) * 2010-02-09 2016-05-17 Galderma Res & Dev use of a combination of adapalene and benzoyl peroxide
EP2544662B1 (en) 2010-03-10 2020-05-20 Nuvo Pharmaceuticals Inc. Foamable formulation
WO2011156803A2 (en) * 2010-06-11 2011-12-15 Transdel Pharmaceuticals, Inc. Anti-cellulite composition and method of treating cellulite
FR2969492B1 (en) * 2010-12-23 2013-07-05 Galderma Res & Dev DERMATOLOGICAL FOAMS OBTAINED FROM GEL OR SUSPENSION CONTAINING ADAPALENE
WO2012170905A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
US8709501B1 (en) * 2011-07-22 2014-04-29 Beverly Jansen Method for treating wounds for mammals, wound healer compound, and method of manufacturing thereof
EP2748308A4 (en) 2011-08-26 2015-04-29 Tissuetech Inc Methods of sterilizing fetal support tissues
WO2013115759A1 (en) * 2012-02-01 2013-08-08 Horvat Branimir L Topical medications for controlling epidermal symptoms
CN104321053A (en) 2012-03-30 2015-01-28 桑茨利奥&孔帕尼股份有限公司 Omega-3 fatty acid ester compositions
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US8877185B2 (en) 2012-05-10 2014-11-04 Stan S. Sastry Managing and treating keloids
JP6189962B2 (en) 2012-10-09 2017-08-30 ザ プロクター アンド ギャンブル カンパニー How to identify synergistic cosmetic ingredient combinations
WO2014059008A1 (en) 2012-10-09 2014-04-17 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
RU2496478C1 (en) * 2012-10-19 2013-10-27 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Gel formulation for wounds and burns of various aethiologies enabling epithelisation
PT106679B (en) 2012-11-27 2015-03-25 Hovione Farmaciencia Sa TOPICAL FORMULATIONS OF TETRACYCLINES, THEIR PREPARATION AND USES
US8936814B2 (en) * 2012-11-30 2015-01-20 Zuri A. Murrell Skin cream
CN105025881A (en) 2012-12-26 2015-11-04 奥蒂科制药有限公司 Foamable otic pharmaceutical compositions
WO2014164200A1 (en) 2013-03-13 2014-10-09 Avon Products, Inc Tyrosinase inhibitors
US9364405B2 (en) * 2013-03-13 2016-06-14 Avon Products, Inc. Tyrosinase inhibitors
US9408796B2 (en) 2013-03-13 2016-08-09 Avon Products, Inc Cosmetic compositions for improving the appearance of skin
EP2967056B1 (en) 2013-03-15 2018-02-21 Suncor Energy Inc. Herbicidal compositions
US10111956B2 (en) 2013-06-03 2018-10-30 Tolmar, Inc. Corticosteroid compositions
JP2015000871A (en) * 2013-06-18 2015-01-05 ロレアル Foam aerosol cosmetic composition
FR3009956B1 (en) * 2013-08-29 2018-05-11 L'oreal MOISTURIZING COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION; MOISTURIZING CARE PROCESS
MX2016004257A (en) 2013-10-03 2016-08-17 Imprimis Pharmaceuticals Inc Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricatiing thereof.
US20160235708A1 (en) * 2013-10-04 2016-08-18 Sanjay Banerji Topical pigmentory composition
US10335390B2 (en) 2014-09-05 2019-07-02 Symbiomix Therapeutics, Llc Secnidazole for use in the treatment of bacterial vaginosis
CN107205971A (en) 2014-11-18 2017-09-26 罗格斯，新泽西州立大学 New mitochondrial uncoupler for treating metabolic disease and cancer
KR101525532B1 (en) * 2015-01-15 2015-06-11 (주)씨아이티 Cosmetic impregnated foam manufacturing apparatus and a manufacturing method
WO2017042049A1 (en) * 2015-09-07 2017-03-16 Medskin Solutions Dr. Suwelack Ag Composition for topical application comprising dimethyl isosorbide, a polyol, and a phenolic or polyphenolic antioxidant
HUE054917T2 (en) 2016-03-01 2021-10-28 The Fynder Group Inc Filamentous fungal biomats, methods of their production and methods of their use
WO2017201313A1 (en) 2016-05-18 2017-11-23 Shengkan Jin Novel mitochondrial uncouplers for treatment of metabolic diseases and cancer
EP3175838A1 (en) * 2017-03-16 2017-06-07 Evonik Degussa GmbH Foamed, oil-in-water emulsion containing formulations containing at least one co-surfactant
WO2018222223A1 (en) * 2017-05-30 2018-12-06 Herbal Cleanze, Inc. Herbal cleanser
WO2019006217A1 (en) 2017-06-28 2019-01-03 Collidion, Inc. Compositions, methods and uses for cleaning, disinfecting and/or sterilizing
SG10201911092WA (en) 2017-08-30 2020-01-30 Sustainable Bioproducts Inc Edible composition with filamentous fungi and bioreactor system for the cultivation thereof
CN111801122B (en) 2018-01-14 2023-06-02 科利迪恩公司 Compositions, kits, methods and uses for cleaning, sanitizing, disinfecting and/or treating
AR118204A1 (en) 2019-02-27 2021-09-22 The Fynder Group Inc FOOD MATERIALS INCLUDING FILAMENTAL FUNGI PARTICLES, AND MEMBRANE BIOREACTOR DESIGN
EP3986186A4 (en) 2019-06-18 2023-05-17 The Fynder Group, Inc. Fungal textile materials and leather analogs
CN111920755B (en) * 2020-09-11 2021-09-07 山东本真化妆品有限公司 Foamable oral care compositions free of surfactants
EP4112041A1 (en) * 2021-06-30 2023-01-04 GSK Consumer Healthcare SARL Micellar solution comprising diclofenac
US11549066B1 (en) 2021-08-10 2023-01-10 Cameron International Corporation Citrate polyester additives for crude oil, mixtures of said additives and crude oil, and methods for producing said mixtures
WO2024072942A2 (en) 2022-09-29 2024-04-04 Adora Animal Health Corporation Skin penetrating formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679324A (en) * 1994-07-08 1997-10-21 The Procter & Gamble Co. Aerosol foamable fragrance composition
US20020182234A1 (en) * 2000-12-19 2002-12-05 Beiersdorf Aktiengesellschaft Self-foaming or foam-like preparations
US6902737B2 (en) * 2001-01-18 2005-06-07 L'oreal Translucent nanoemulsion, production method, and uses thereof in the cosmetic, dermatological and/or ophthalmological fields

Family Cites Families (1137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1159250A (en) 1914-05-01 1915-11-02 Frank Moulton Vaginal irrigator.
US1666684A (en) 1926-01-15 1928-04-17 Carstens Mfg Co H Vaginal douche
US1924972A (en) 1929-04-15 1933-08-29 Carl J Beckert Stabilized egg product
US2085733A (en) 1935-07-15 1937-07-06 John C Bird Shaving cream
US2390921A (en) 1943-03-23 1945-12-11 Ethel Hudson Clark Applicator for facial creams
US2524590A (en) 1946-04-22 1950-10-03 Carsten F Boe Emulsion containing a liquefied propellant gas under pressure and method of spraying same
US2586287A (en) * 1948-12-11 1952-02-19 Colagte Palmolive Peet Company Aluminum sulfamate antiperspirant preparation
US2617754A (en) 1949-08-29 1952-11-11 Procter & Gamble Cosmetic cream
DE933486C (en) 1949-10-02 1955-09-29 Ibm Deutschland Electromechanical computing device with counter value setting device
US3062715A (en) 1953-11-18 1962-11-06 George S Pfaus Vaginal tablet
US2767712A (en) 1954-03-01 1956-10-23 Neil S Waterman Medicinal applicator
GB808104A (en) 1955-01-04 1959-01-28 Udylite Res Corp Electrodeposition of copper from aqueous alkaline cyanide solutions
GB808105A (en) 1956-06-15 1959-01-28 Ici Ltd New pharmaceutical compositions
US3092555A (en) 1958-04-21 1963-06-04 Roy H Horn Relatively collapsible aerosol foam compositions
US3144386A (en) 1958-05-09 1964-08-11 Merck & Co Inc Mastitis aerosol foam
US2968628A (en) * 1958-10-17 1961-01-17 Shulton Inc Propellant composition
US3178352A (en) 1959-02-27 1965-04-13 Erickson Roy Shaving method and composition therefor
US3141821A (en) 1959-03-17 1964-07-21 Lehn & Fink Products Corp Synergistic combination of alkyl sulfonates, alkylaryl sulfonates and topical antibacterial agents for local antisepsis
US3004894A (en) 1959-04-07 1961-10-17 Upjohn Co Therapeutic composition comprising tetracycline and a dioxolane
GB922930A (en) 1959-09-21 1963-04-03 Sunnen Joseph Spermicidal composition and method of making same
US3142420A (en) 1959-11-09 1964-07-28 Neotechnic Eng Ltd Metering dispenser for aerosol with fluid pressure operated piston
US3092255A (en) 1960-02-05 1963-06-04 Robert F Hohman Sorting apparatus
US3067784A (en) 1960-04-14 1962-12-11 Esta Medical Lab Inc Adapter connecting aerosol container valve stem to dispenser for filling said dispenser
NL270627A (en) 1960-10-26
US3154075A (en) 1960-11-02 1964-10-27 Norwich Pharma Co Vaginal applicator
GB998490A (en) 1961-06-03 1965-07-14 Albert Fritz Albach A foam projector
DE1926796U (en) 1961-10-12 1965-11-11 Heidolph Elektro K G FAN.
NL285082A (en) 1962-02-28
US3261695A (en) 1962-12-24 1966-07-19 Gen Foods Corp Process for preparing dehydrated foods
US3330730A (en) 1962-08-03 1967-07-11 Colgate Palmolive Co Pressurized emulsion quick breaking foam compositions
US3252859A (en) 1962-10-24 1966-05-24 Masti Kure Company Inc Colloidal silica-oil composition and method of using same
US3244589A (en) 1962-10-26 1966-04-05 Sunnen Alkyl phenoxy polyethoxy ether spermicidal aerosol
US3298919A (en) * 1962-12-26 1967-01-17 Dow Corning Shaving cream containing polysiloxanes
US3383280A (en) 1963-01-09 1968-05-14 Miles Lab Dermatological abradant stick-type applicator
FR1355607A (en) 1963-01-22 1964-03-20 Improvements to cannula probes and their applications
US3149543A (en) * 1963-03-04 1964-09-22 Ingersoll Rand Co Non-lubricated piston
GB1026831A (en) 1963-05-31 1966-04-20 Mediline Ag Preparations for use in feminine hygiene
US3824303A (en) 1963-07-24 1974-07-16 Yardley Of London Inc Collapsible foam pre-electric shave lotion containing diester lubricants
GB1081949A (en) 1963-08-12 1967-09-06 Avon Prod Inc Improvements in cosmetic mask
US3333333A (en) 1963-08-14 1967-08-01 Rca Corp Method of making magnetic material with pattern of embedded non-magnetic material
US3236457A (en) * 1963-08-21 1966-02-22 John R Kennedy Composite spray container assembly
US3263867A (en) 1963-12-26 1966-08-02 Valve Corp Of America Metering button-type aerosol actuator
US3395214A (en) 1964-01-09 1968-07-30 Scholl Mfg Co Inc Antiperspirant composition providing a readily collapsible sprayable foam
US3278093A (en) 1964-01-13 1966-10-11 Valve Corp Of America Metering and non-metering aerosol actuator button
GB1052724A (en) * 1964-04-27
US3303970A (en) * 1964-07-14 1967-02-14 Jerome Marrow Device for simultaneously dispensing from plural sources
US3395215A (en) 1964-10-15 1968-07-30 Colgate Palmolive Co Pressurized lotion composition
US3384541A (en) 1964-10-28 1968-05-21 William G. Clark Spermicidal vaginal pharmaceutical concentrate for producing nonaqueous foam with aerosol propellants
US3263869A (en) 1964-11-03 1966-08-02 Calmar Inc Liquid dispenser with overcap
US3342845A (en) 1964-11-05 1967-09-19 Upjohn Co Terphenyl triisocyanates
US3419658A (en) 1965-01-25 1968-12-31 Du Pont Nonaqueous aerosol foams containing mineral oil
US3346451A (en) 1965-01-27 1967-10-10 S E Massengill Company Concentrated liquid lactic acid douche preparation containing aromatics
US3301444A (en) 1965-08-12 1967-01-31 Oel Inc Aerosol metering valve
US3456052A (en) 1965-09-28 1969-07-15 Garrett Lab Inc Aerosol composition containing butoxymonoether of a polyoxyalkylene glycol
GB1121358A (en) 1965-10-21 1968-07-24 Bristol Myers Co Aerosol manufacture
US3849569A (en) 1965-12-02 1974-11-19 Glaxo Lab Ltd Composition containing procaine penicillin
BE692228A (en) 1966-01-10 1967-07-05
US3401849A (en) 1966-05-24 1968-09-17 Robert L. Weber Low force metering valve
US3886084A (en) 1966-09-29 1975-05-27 Champion Int Corp Microencapsulation system
US3377004A (en) 1966-10-03 1968-04-09 Gen Mills Inc Metered dispensing container
GB1201918A (en) 1966-12-21 1970-08-12 Bespak Industries Ltd Improvements in or relating to valves for pressurised dispensers
US3527559A (en) 1967-01-05 1970-09-08 Standard Pharmacal Corp Dense aqueous aerosol foam depilatory compositions containing a mixture of alkaline metal and alkali metal thioglycolates and a fatty alcohol-alkylene oxide wax emulsifying agent
US3366494A (en) 1967-02-15 1968-01-30 Du Pont Pressurized aerosol food emulsions
US3561262A (en) * 1967-10-26 1971-02-09 Magnaflux Corp Water soluble developer
US3540448A (en) 1968-01-17 1970-11-17 Joseph Sunnen Rechargeable applicator for dispensing substances in a foam condition
US3563098A (en) * 1968-06-28 1971-02-16 Rex Chainbelt Inc Automatic quick release mechanism
US3559890A (en) * 1968-09-03 1971-02-02 William R Brooks Foam dispenser
US3878118A (en) 1968-09-06 1975-04-15 Wilkinson Sword Ltd Self-heating chemical compositions
US3667461A (en) 1968-11-05 1972-06-06 Paul A Zamarra Disposable syringe
CA975500A (en) * 1969-02-06 1975-09-30 Joseph G. Spitzer Structures such as applicator pads for cleaning and other purposes, propellant compositions for forming the same, and process
US3866800A (en) * 1969-02-12 1975-02-18 Alberto Culver Co Non-pressurized package containing self-heating products
US3966090A (en) 1969-02-17 1976-06-29 Dart Industries Inc. Package for dispensing an antiseptic composition
US4001391A (en) * 1969-04-18 1977-01-04 Plough, Inc. Means for depositing aerosol sprays in buttery form
US3819524A (en) 1969-06-17 1974-06-25 Colgate Palmolive Co Cosmetic composition for thermal dispensing
US3577518A (en) 1969-07-18 1971-05-04 Nat Patent Dev Corp Hydrophilic hairspray and hair setting preparations
US3787566A (en) * 1969-07-29 1974-01-22 Holliston Labor Inc Disinfecting aerosol compositions
BE759520A (en) 1969-11-28 1971-04-30 Aspro Nicholas Ltd ASPIRIN COMPOSITIONS
GB1353381A (en) 1971-02-04 1974-05-15 Wilkinson Sword Ltd Substituted p-menthanes and compositions containing them
GB1351761A (en) 1971-02-04 1974-05-01 Wilkinson Sword Ltd Substituted p-menthane carboxamides and compositions containing them
GB1351762A (en) 1971-02-14 1974-05-01 Wilkinson Sword Ltd Tobacco and tobacco-containing manufactures
CA958338A (en) 1971-03-08 1974-11-26 Chung T. Shin Antiperspirant powder aerosol compositions containing aluminum chloride and water soluble aluminum compounds and methods of preparation
US3770648A (en) 1971-07-12 1973-11-06 Bristol Myers Co Anhydrous aerosol foam
US3912667A (en) 1971-09-13 1975-10-14 Spitzer Joseph G Structures such as applicator pads for cleaning and other purposes, propellant compositions for forming the same and process
BE788788A (en) 1971-09-13 1973-03-13 Treuhandvereinigung Ag PRODUCT FOR PRESERVING, PROMOTING AND RESTORING HAIR AND METHOD OF MANUFACTURING THIS PRODUCT
SE358308B (en) 1971-11-26 1973-07-30 Pharmacia Ab
US3997467A (en) 1971-11-26 1976-12-14 Pharmacia Aktiebolag Foam forming composition
CH554911A (en) 1971-12-30 1974-10-15 Ciba Geigy Ag USE OUTSIDE THE TEXTILE INDUSTRY OF NEW 4,4'-DIVINYLDIPHENYL COMPOUNDS AS OPTICAL LIGHTENING AGENTS FOR ORGANIC MATERIALS.
JPS4892282U (en) 1972-02-05 1973-11-06
US3963833A (en) 1972-06-02 1976-06-15 Colgate-Palmolive Company Antiperspirant composition and method containing a dihydro-benzofuran and an astringent metal salt
US3841525A (en) 1972-06-14 1974-10-15 N Siegel Aerosol spray device with cam activator
US3849580A (en) 1972-09-05 1974-11-19 American Home Prod Aerosol dispensing system for anhydrous edible fat compositions
US3751562A (en) 1972-09-22 1973-08-07 Princeton Biomedix Medicated gelled oils
US3970584A (en) 1973-02-14 1976-07-20 S. C. Johnson & Son, Inc. Aerosol package containing a foam-forming emulsion and propellent system
US4439416A (en) 1973-03-23 1984-03-27 Colgate-Palmolive Company Self-heating shaving composition
GB1423179A (en) 1973-05-16 1976-01-28 Wilkinson Sword Ltd Pressurised shaving foam dispensers
YU36328B (en) 1973-07-18 1983-06-30 Elastin Werk Ag Method of manufacturing red foils for packing sausages
US4110426A (en) 1973-07-24 1978-08-29 Colgate-Palmolive Company Method of treating skin and hair with a self-heated cosmetic
US3865275A (en) * 1973-07-30 1975-02-11 Raymond Lee Organization Inc Apparatus for operating an aerosol can
US3929985A (en) 1974-01-18 1975-12-30 Richardson Merrell Inc Anhydrous candicidin foam compositions
DE2501548A1 (en) 1974-01-25 1975-07-31 Procter & Gamble ORAL TREATMENT PRODUCTS
GB1457671A (en) 1974-01-31 1976-12-08 Wilkinson Sword Ltd Flavour
US3923970A (en) 1974-03-29 1975-12-02 Carter Wallace Stable aerosol shaving foams containing mineral oil
US3962150A (en) 1974-04-10 1976-06-08 Richardson-Merrell Inc. Foam producing cleansing compositions
US3953591A (en) 1974-04-29 1976-04-27 The Procter & Gamble Company Fatty acid, polysiloxane and water-soluble polymer containing skin conditioning emulsion
US3966632A (en) 1974-06-06 1976-06-29 G. D. Searle & Co. Vegetable oil emulsion
US4145411A (en) * 1974-09-05 1979-03-20 Colgate-Palmolive Company Pressurized foaming shaving composition
JPS5729213B2 (en) 1974-11-12 1982-06-21
US4052513A (en) 1974-12-13 1977-10-04 Plough, Inc. Stable topical anesthetic compositions
US3952916A (en) 1975-01-06 1976-04-27 Warner-Lambert Company Automatic dispenser for periodically actuating an aerosol container
US4019657A (en) 1975-03-03 1977-04-26 Spitzer Joseph G Aerosol containers for foaming and delivering aerosols
US3970219A (en) 1975-03-03 1976-07-20 Spitzer Joseph G Aerosol containers for foaming and delivering aerosols and process
US4018396A (en) 1975-05-05 1977-04-19 Bechtel International Corporation Embedded housing for ore crusher
US3993224A (en) 1975-09-08 1976-11-23 Aerosol Investments, Ltd. Spout for two-component resin dispenser
DE2608226A1 (en) 1976-02-28 1977-09-08 Haarmann & Reimer Gmbh AGENTS WITH PHYSIOLOGICAL COOLING EFFECT
US4102995A (en) 1976-05-13 1978-07-25 Westwood Pharmaceuticals Inc. Tar gel formulation
US4124149A (en) 1976-07-19 1978-11-07 Spitzer Joseph G Aerosol container with position-sensitive shut-off valve
CA1089368A (en) 1976-08-02 1980-11-11 Daniel C. Geary Polyethoxylated fatty alcohol in antiperspirant sticks
IL52045A (en) 1976-08-25 1979-12-30 Mundipharma Ag Sprayable germicidal foam compositions
US4310510A (en) * 1976-12-27 1982-01-12 Sherman Kenneth N Self administrable anti-fertility composition
US4252787A (en) * 1976-12-27 1981-02-24 Cambridge Research And Development Group Anti-fertility composition and method
US4083974A (en) 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
JPS5744429Y2 (en) 1977-04-14 1982-10-01
US4386104A (en) 1977-04-19 1983-05-31 Nazzaro Porro Marcella Process for the treatment of acne
IT1114950B (en) * 1977-12-30 1986-02-03 Porro Marcella COMPOSITIONS FOR ACNE TREATMENT AND THERAPY
GB2004746B (en) 1977-10-03 1982-03-10 Scherico Ltd Stable hopical anaesthetic compositions
JPS5639815Y2 (en) 1977-11-25 1981-09-17
SE7713618L (en) * 1977-12-01 1979-06-02 Astra Laekemedel Ab LOCAL ANESTHETIC MIXTURE
US4160827A (en) 1978-02-06 1979-07-10 The Upjohn Company Metronidazole phosphate and salts
US4229432A (en) 1978-04-19 1980-10-21 Bristol-Myers Company Antiperspirant stick composition
US4603812A (en) 1978-06-27 1986-08-05 The Dow Chemical Company Foam-generating pump sprayer
US4178373A (en) 1978-08-21 1979-12-11 William H. Rorer, Inc. Coal tar gel composition
US4214000A (en) 1978-10-30 1980-07-22 Johnson & Johnson Zinc salt of all-trans-retinoic acid for the treatment of acne
JPS5569682U (en) 1978-11-08 1980-05-13
US4213979A (en) 1978-12-18 1980-07-22 Plough, Inc. Stable sprayable hydrocortisone product
US4954487A (en) 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4439441A (en) 1979-01-11 1984-03-27 Syntex (U.S.A.) Inc. Contraceptive compositions and methods employing 1-substituted imidazole derivatives
US4226344A (en) 1979-02-06 1980-10-07 Booth, Inc. Constant flow valve actuator
CH639913A5 (en) 1979-03-16 1983-12-15 Aerosol Service Ag Container for receiving and delivering a liquid substance
US4230701A (en) 1979-03-21 1980-10-28 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4335120A (en) 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4278206A (en) 1979-04-13 1981-07-14 Ae Development Corporation Non-pressurized dispensing system
US4241048A (en) 1979-05-01 1980-12-23 Bristol-Myers Company Suspension composition of benzocaine
JPS55153712A (en) 1979-05-18 1980-11-29 Kao Corp Insulin pharmaceutical preparation and its production
US4268499A (en) * 1979-06-07 1981-05-19 Dow Corning Corporation Antiperspirant emulsion compositions
US4241149A (en) 1979-07-20 1980-12-23 Temple University Canal clathrate complex solid electrolyte cell
DE2931469A1 (en) 1979-08-02 1981-02-26 Bayer Ag SURFACE SEALED MOLDED BODIES MADE OF CELLED POLYURETHANE ELASTOMERS AND METHOD FOR THE PRODUCTION THEREOF
US4271149A (en) * 1979-09-21 1981-06-02 West Agro-Chemical, Inc. Germicidal iodine compositions with enhanced iodine stability
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
EP0032309A3 (en) 1980-01-10 1981-08-05 Imperial Chemical Industries Plc Production of catalyst component, catalyst and use thereof
US4309995A (en) * 1980-01-28 1982-01-12 Sacco Susan M Vaginal irrigation apparatus
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
SE8004580L (en) 1980-06-19 1981-12-20 Draco Ab PHARMACEUTICAL PREPARATION
US4338211A (en) 1980-06-30 1982-07-06 The Procter & Gamble Company Liquid surfactant skin cleanser with lather boosters
US4508705A (en) 1980-07-02 1985-04-02 Lever Brothers Company Skin treatment composition
US4323582A (en) 1980-07-21 1982-04-06 Siegel Norman H Method of treating animals and humans for internal and external parasites
JPS601113Y2 (en) 1980-07-22 1985-01-12 三菱電機株式会社 Round lighting equipment packaging
US4329990A (en) 1980-08-07 1982-05-18 Sneider Vincent R Expanding swab applicator
US4325939A (en) 1980-09-22 1982-04-20 Richardson-Vicks Inc. Zinc derivatives and their use in dental compositions
US4305936A (en) 1980-10-09 1981-12-15 Dermik Laboratories Topical corticosteroid formulations
US4292250A (en) 1980-11-17 1981-09-29 Wisconsin Alumni Research Foundation Vitamin D derivatives
EP0052404B1 (en) 1980-11-19 1987-05-27 THE PROCTER &amp; GAMBLE COMPANY Non-yellowing topical pharmaceutical composition
EP0065513B1 (en) 1980-11-27 1985-09-18 CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. Antimycotic synergistic pharmaceutical compositions and process for the preparation thereof
DE3147726A1 (en) 1980-12-03 1982-06-24 Leo Pharmaceutical Products Ltd. A/S (Loevens kemiske Fabrik Produktionsaktieselskab), 2750 Ballerup ANTIBIOTIC COMPLEXES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS THAT CONTAIN THESE COMPOUNDS
US4352808A (en) 1980-12-12 1982-10-05 Schering Corporation 3-Aralkyloxy-2,3-dihydro-2-(imidazolylmethyl)benzo(b)thiophenes and related derivatives, their use as antimicrobials and pharmaceutical formulations useful therefore
US4323694A (en) 1981-04-13 1982-04-06 Finetex, Inc. Benzoic acid esters
US4522948A (en) 1981-04-24 1985-06-11 Syntex (U.S.A.) Inc. Spermicidal substituted 1-(cycloalkyl)alkylimidazoles
US4393066A (en) 1981-06-05 1983-07-12 Garrett David M Method for treatment of herpetic lesions
US4607101A (en) 1981-08-27 1986-08-19 Jaye-Boern Laboratories, Inc. Method of treating acne vulgaris with a composition containing carbamide peroxide
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
US4469674A (en) 1981-09-03 1984-09-04 Richardson-Vicks Inc. Stable oral compositions containing zinc and fluoride compounds
US4440320A (en) 1981-11-30 1984-04-03 Wernicke Steven A Foam dispensing apparatus
LU83876A1 (en) * 1982-01-15 1983-09-02 Oreal COSMETIC COMPOSITION FOR TREATMENT OF KERATINIC FIBERS AND METHOD FOR TREATING THE SAME
LU83949A1 (en) 1982-02-16 1983-09-02 Oreal COMPOSITION FOR THE TREATMENT OF KERATINIC MATERIALS CONTAINING AT LEAST ONE CATIONIC POLYMER AND AT LEAST ONE ANIONIC LATEX
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US4529605A (en) 1983-01-12 1985-07-16 Una E. Lynch Bathing oil composition
US4661340A (en) 1983-06-06 1987-04-28 Interkemia Vegyipari Gazdasagi Tarsasag Quail egg based stabilized foam compositions for cosmetic purposes
GB8315787D0 (en) * 1983-06-08 1983-07-13 Briggs J H Coolant spray
US4552872A (en) 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
GB8402748D0 (en) 1984-02-02 1984-03-07 Dunlop Ltd Intravaginal device
US4985459A (en) * 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4912124A (en) 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
NZ207341A (en) 1984-03-01 1988-02-29 Harvey Alex Ind Ltd Device containing chemical impregnants for insertion into a body cavity of an animal
US4628063A (en) 1984-03-08 1986-12-09 Dana P. Brigham Antiviral pharmaceutical preparations and methods for their use
US4574052A (en) 1984-05-31 1986-03-04 Richardson-Vicks Inc. Crackling aerosol foam
GB8416638D0 (en) 1984-06-29 1984-08-01 Beecham Group Plc Topical treatment and composition
DE3564973D1 (en) 1984-08-06 1988-10-20 Ciba Geigy Ag Process for paper sizing with anionic hydrophobic sizing agents and cationic retention agents
US4595526A (en) 1984-09-28 1986-06-17 Colgate-Palmolive Company High foaming nonionic surfacant based liquid detergent
SE443914B (en) 1984-10-01 1986-03-17 Torkel Ingemar Fischer MEANS OF A SENSITIVITY TEST
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
CA1261276A (en) 1984-11-09 1989-09-26 Mark B. Grote Shampoo compositions
US4701320A (en) 1984-11-29 1987-10-20 Lederle (Japan), Ltd. Composition stably containing minocycline for treating periodontal diseases
US4627973A (en) 1984-12-14 1986-12-09 Charles Of The Ritz Group Ltd. Skin mousse
AU5078885A (en) 1984-12-20 1986-06-26 Warner-Lambert Company Non-irritant detergent
US4673569A (en) 1985-02-12 1987-06-16 Faberge Incorporated Mousse hair composition
US5002680A (en) * 1985-03-01 1991-03-26 The Procter & Gamble Company Mild skin cleansing aerosol mousse with skin feel and moisturization benefits
DE3670569D1 (en) 1985-03-01 1990-05-31 Procter & Gamble Mild cleaning foam.
US4639367A (en) 1985-03-18 1987-01-27 Product Resources International, Inc. Aerosol foam
US4752465A (en) * 1985-09-20 1988-06-21 Product Resources International, Inc. Aerosol foam
EP0215903A1 (en) 1985-03-18 1987-04-01 Product Resources International, Inc. Exothermic stable foam compositions
US5094853A (en) * 1985-04-26 1992-03-10 S. C. Johnson & Son, Inc. Method of preparing a water-soluble stable arthropodicidally-active foam matrix
US4965063A (en) 1985-05-24 1990-10-23 Irene Casey Cleaner and disinfectant with dye
DE3521713A1 (en) * 1985-06-18 1986-12-18 Henkel KGaA, 4000 Düsseldorf OIL-IN-WATER EMULSIONS WITH IMPROVED VISCOSITY BEHAVIOR
US4672078A (en) 1985-07-03 1987-06-09 Schering-Plough Corporation Urea stabilized with a lactone in various pharmaceutical and cosmetic preparations
GB8519426D0 (en) 1985-08-01 1985-09-04 Ici Plc Composition for personal care products
GB2179052B (en) 1985-08-14 1989-03-30 Procter & Gamble Nonfoaming cleansing mousse with skin conditioning benefits
US4806262A (en) * 1985-08-14 1989-02-21 The Procter & Gamble Company Nonlathering cleansing mousse with skin conditioning benefits
AU6175586A (en) 1985-09-11 1987-03-12 Chesebrough-Pond's Inc. Petroleum jelly, mild detergent anhydrous base compositions
FR2591331A1 (en) 1985-12-10 1987-06-12 Drevet Jean Baptiste Device for dispensing metered portions of a product contained in a pressurised receptacle
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
GB8607570D0 (en) * 1986-03-26 1986-04-30 Euro Celtique Sa Vaginal pharmaceutical preparation
JPS62241701A (en) 1986-04-11 1987-10-22 Maeda Kogyo Kk Quick releasing device for hub for bicycle
CA1291036C (en) 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
DE3614515A1 (en) 1986-04-29 1987-11-05 Pfeiffer Erich Gmbh & Co Kg DISCHARGE DEVICE FOR MEDIA
FR2598392B1 (en) 1986-05-09 1988-08-26 Oreal PACKAGING FOR TWO PRESSURIZED CONTAINERS
PH25150A (en) 1986-06-05 1991-03-13 Ciba Geigy Ag Novel pharmaceutical preparation for topical application
US4770634A (en) 1986-06-11 1988-09-13 Pellico Michael A Method for treating teeth with foamable fluoride compositions
JPS62299423A (en) 1986-06-18 1987-12-26 Mazda Motor Corp Air-conditioner for vehicle
US4837019A (en) 1986-08-11 1989-06-06 Charles Of The Ritz Group Ltd. Skin treatment composition and method for treating burned skin
US4906453A (en) 1986-08-12 1990-03-06 Jumpeer Nails, Inc. Mousse product
DE3628531A1 (en) * 1986-08-22 1988-02-25 Merz & Co Gmbh & Co FOAMABLE CREAMS
WO1988001502A1 (en) 1986-09-05 1988-03-10 The Upjohn Company Sebum-dissolving nonaqueous minoxidil formulation
AU8025787A (en) 1986-09-12 1988-04-07 Upjohn Company, The Foams for delivery of minoxidil
LU86585A1 (en) 1986-09-15 1988-04-05 Oreal COMPOSITION IN THE FORM OF AN AEROSOL FOAM BASED ON A POLYMER DERIVED FROM QUATERNIZED CELLULOSE AND ANIONIC POLYMER
EP0270316A3 (en) 1986-12-04 1989-12-06 Pfizer Inc. Topical compositions comprising 1-substituted imidazoles and nsaids for treatment of acne
US4822613A (en) * 1986-12-15 1989-04-18 S. C. Johnson & Son, Inc. Water-soluble foamable insecticidally-active compositions
US4822614A (en) 1986-12-19 1989-04-18 S. C. Johnson & Son, Inc. Bioactive film-forming composition for control of crawling insects and the like
US5389677B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US4863900A (en) 1987-01-15 1989-09-05 The Research Foundation Of State University Of New York Method for reducing viral transmission with poly-L-histidine
JPS63119420U (en) 1987-01-30 1988-08-02
DE3704907A1 (en) 1987-02-17 1988-08-25 Bayer Ag TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS
US4828837A (en) 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
AU1388388A (en) 1987-04-01 1988-10-06 Dak-Laboratoriet A/S Benzoic acid derivatives and use thereof
LU86839A1 (en) 1987-04-10 1988-12-13 Oreal DETERGENT AND FOAMING COSMETIC COMPOSITION, DELAYING RE-LUBRICATION OF HAIR
EP0311657A4 (en) 1987-04-21 1991-09-18 Chattan Nominees Pty. Ltd. Vaginal douche
FR2615173B1 (en) 1987-05-13 1989-08-18 Valois DOSING VALVE FOR LIQUID LOADED WITH A LIQUID OR LIQUEFIED GAS PROPELLER, FOR USE IN THE REVERSE POSITION
US4867967A (en) 1987-06-04 1989-09-19 Crutcher Wilbert L Method for the treatment of pseudofolliculitis barbae
US4780309A (en) 1987-06-16 1988-10-25 Warner-Lambert Company Edible aerosol foam compositions and method of preparing same
US4849117A (en) 1987-06-17 1989-07-18 Sanitek Products, Inc. Concentrated composition for forming an aqueous foam
US4885282A (en) 1987-07-02 1989-12-05 Thornfeldt Carl R Treatment of hyperhidrosis, ichthyosis and wrinkling
US4898246A (en) * 1987-07-06 1990-02-06 Total Walther Feuerschutz Gmbh Quick release valve for sprinkler head
US5196405A (en) 1987-07-08 1993-03-23 Norman H. Oskman Compositions and methods of treating hemorrhoids and wounds
US4847068A (en) 1987-08-06 1989-07-11 Johnson & Johnson Consumer Products, Inc. Skin care compositions
US4913893A (en) * 1987-08-28 1990-04-03 Clairol Incorporated Aerosol hair setting composition containing an alginate
CA1273576A (en) 1987-09-16 1990-09-04 Patrick A. Beauchamp Topical treatment for diseased skin disorders
US4981677A (en) * 1987-09-23 1991-01-01 L'oreal Petrolatum-containing aerosol foam concentrate
US4784842A (en) 1987-09-25 1988-11-15 Jean London Therapeutic composition for treatment of cuts, burns and abrasions
US4772427A (en) 1987-12-01 1988-09-20 Colgate-Palmolive Co. Post-foaming gel shower product
US5143717A (en) 1987-12-30 1992-09-01 Code Blue Medical Corporation Burn foam and delivery system
EP0326196B1 (en) 1988-01-14 1992-03-25 Akzo N.V. Aqueous pharmaceutical preparation
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
JP2643217B2 (en) 1988-01-22 1997-08-20 エーザイ株式会社 Aqueous liquid of fat-soluble substance
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4897262A (en) 1988-03-22 1990-01-30 Playtex Jhirmack, Inc. Non-aerosol hair spray composition
DE3811081A1 (en) 1988-03-30 1989-10-12 Schering Ag USE OF TOPIC APPLICABLE PREPARATIONS FOR THE TREATMENT OF AGING SKIN
LU87187A1 (en) 1988-03-31 1989-10-26 Oreal COMBINATION OF PYRIMIDINE DERIVATIVES AND SALICYLIC ACID DERIVATIVES FOR INDUCING AND STIMULATING HAIR GROWTH AND REDUCING HAIR LOSS
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4873078A (en) 1988-04-22 1989-10-10 Plough, Inc. High-gloss, high-shine lipstick
GB8811409D0 (en) 1988-05-13 1988-06-15 Unilever Plc Cosmetic composition
US5378730A (en) * 1988-06-09 1995-01-03 Alza Corporation Permeation enhancer comprising ethanol and monoglycerides
US4827378A (en) 1988-06-15 1989-05-02 Rockwell International Corporation Jack coaxial connector EMI shielding apparatus
US5217707A (en) 1988-06-16 1993-06-08 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Pharmaceutical composition and process for the preparation thereof
US4902281A (en) * 1988-08-16 1990-02-20 Corus Medical Corporation Fibrinogen dispensing kit
US4950420A (en) 1988-08-31 1990-08-21 Nalco Chemical Company Antifoam/defoamer composition
US4855294A (en) 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
GB8821129D0 (en) 1988-09-09 1988-10-12 Unilever Plc Cosmetic composition
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5186857A (en) 1988-11-14 1993-02-16 Imaginative Research Associates, Inc. Self-foaming oil compositions and process for making and using same
GB8828013D0 (en) 1988-12-01 1989-01-05 Unilever Plc Topical composition
US4970067A (en) 1988-12-12 1990-11-13 Helene Curtis, Inc. Method and composition to condition hair and impart semi-permanent hair set retention properties
US5262407A (en) 1988-12-16 1993-11-16 L'oreal Use of salicylic derivatives for the treatment of skin aging
FR2640942A1 (en) 1988-12-23 1990-06-29 Suchard Sa Jacobs Container of the aerosol type for delivering, in the form of a foam, metered quantities of product, particularly of food product
EP0376104B2 (en) 1988-12-27 2003-08-20 Osaka Shipbuilding Co., Ltd. Aerosol composition
FR2641185B1 (en) 1988-12-29 1991-04-05 Oreal SHAVING COMPOSITION FOR THE SKIN BASED ON ACYLOXYALKYL FUNCTIONAL POLYORGANOSILOXANES AND METHOD FOR IMPLEMENTING SAME
LU87449A1 (en) 1989-02-09 1990-09-19 Oreal PROCESS FOR THE MANUFACTURE OF FOAMS FOR USE IN THE COSMETIC AND PHARMACEUTICAL AREAS AND FOAMS OBTAINED BY THIS PROCESS
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5019375A (en) 1989-03-14 1991-05-28 The Procter & Gamble Company Low residue antiperspirant creams
DE69030698T2 (en) 1989-03-17 1997-10-02 Taisho Pharmaceutical Co., Ltd., Tokio/Tokyo AEROSOL COMPOSITION FOR EXTERNAL USE
US5221696A (en) 1989-03-29 1993-06-22 Alcon Laboratories, Inc. Use of monoacyl phosphoglycerides to enhance the corneal penetration of ophthalmic drugs
ATE123937T1 (en) 1989-04-05 1995-07-15 Kao Corp COSMETIC DOUBLE EMULSION COMPOSITION.
US5071648A (en) 1989-04-06 1991-12-10 Merocel Corporation Polymeric broad-spectrum antimicrobial materials
US5204093A (en) * 1989-04-06 1993-04-20 Victor Steven A Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same
US5618798A (en) 1989-04-20 1997-04-08 Bar-Shalom; Daniel Use of sucralfate to treat baldness
GB8909559D0 (en) * 1989-04-26 1989-06-14 Smith Kline French Lab Pharmaceutical compositions
US4874794A (en) * 1989-04-28 1989-10-17 Lidak Biopharmaceuticals Inflammatory disease treatment
US5322683A (en) 1989-05-01 1994-06-21 Leonard Mackles Anhydrous aerosol foam
US5002540A (en) 1989-05-22 1991-03-26 Warren Kirschbaum Intravaginal device and method for delivering a medicament
GB8911853D0 (en) 1989-05-23 1989-07-12 Ici Plc Co2 blown integral skin foams
US5208031A (en) 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
MX21452A (en) 1989-07-07 1994-01-31 Ciba Geigy Ag PHARMACEUTICAL PREPARATIONS THAT ARE TOPICALLY ADMINISTERED.
US5560859A (en) 1989-07-26 1996-10-01 Pfizer Inc. Post foaming gel shaving composition
US4981367A (en) * 1989-07-28 1991-01-01 Stranco, Inc. Portable mixing apparatus
DE69020900T2 (en) * 1989-07-28 1995-12-14 Hisamitsu Pharmaceutical Co FOAM AEROSOL COMPOSITION.
JPH0383914A (en) 1989-08-18 1991-04-09 W R Grace & Co Drug carrier
JPH084364Y2 (en) * 1989-09-12 1996-02-07 株式会社東海理化電機製作所 Airbag safety device
US5219877A (en) 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
IL95952A0 (en) * 1989-10-19 1991-07-18 Sterling Drug Inc Aerosol composition for topical medicament
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US5508033A (en) 1989-12-06 1996-04-16 Societe D'engrais Composes Mineraux Et Amendments Utilization of algae extract for the preparation of pharmaceutical, cosmetic, food or agricultural compositions
US5295984A (en) 1989-12-07 1994-03-22 Ultrafem, Inc. Vaginal discharge collection device and intravaginal drug delivery system
EP0504301B1 (en) 1989-12-07 2004-03-31 Instead, Inc. Method of collecting vaginal discharge
WO1991008733A1 (en) 1989-12-20 1991-06-27 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
US4966779A (en) 1989-12-21 1990-10-30 Basf Corporation Stable, water miscible emulsion comprising a fat-soluble vitamin
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US4963351A (en) 1989-12-26 1990-10-16 Bhn Associates Shaving aid
US5100917A (en) 1989-12-29 1992-03-31 Merrell Dow Pharmaceuticals Inc. Novel a-nor-steroid-3-carboxylic acid derivatives
US5104645A (en) 1990-02-02 1992-04-14 The Proctor & Gamble Company Antidandruff shampoo compositions
SE9000485D0 (en) 1990-02-09 1990-02-09 Pharmacia Ab FOAMABLE COMPOSITION FOR PHARMACEUTICAL USE, USE THEREOF AND METHOD OF TREATMENT
US5164367A (en) 1990-03-26 1992-11-17 Procyte Corporation Method of using copper(ii) containing compounds to accelerate wound healing
US5130121A (en) * 1990-04-17 1992-07-14 Isp Investments Inc. Skin care compositions containing discrete microdroplets of an oil in water stabilized by in situ polymerization of water-soluble vinyl monomer
US5007556A (en) 1990-04-18 1991-04-16 Block Drug Company, Inc. Metering dispenser
US5156765A (en) * 1990-05-15 1992-10-20 Fox Valley Systems, Inc. Aerosol foam marking compositions
US5112359A (en) 1990-06-04 1992-05-12 Clairol, Inc. Hair colorants
JP3649341B2 (en) * 1990-06-15 2005-05-18 株式会社資生堂 COMPOSITE AND COMPOSITE COMPOSITION, EMULSION COMPOSITION, AND EMULSION COMPOSITION
US5034220A (en) * 1990-06-20 1991-07-23 Gaf Chemicals Corporation Non-aerosol shaving gel
US5336692A (en) 1990-06-28 1994-08-09 Medicis Pharmaceutical Corporation Ointment base and method of use
IT1243379B (en) 1990-07-27 1994-06-10 Giuliani Spa PHARMACEUTICAL COMPOSITION SUITABLE FOR RECTAL ADMINISTRATION OF ACTIVE PRINCIPLES WHICH EXPLICATE A MEDICATION ACTION AT THE LEVEL OF THE COLON, PREVALENTLY TOPICAL
US5108556A (en) 1990-09-14 1992-04-28 Minnesota Mining And Manufacturing Company Process for preparing tertiary perfluoroamines
US5091111A (en) * 1990-09-19 1992-02-25 S. C. Johnson & Son, Inc. Aqueous emulsion and aersol delivery system using same
US5114718A (en) 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
GB9021546D0 (en) 1990-10-04 1990-11-21 Beecham Group Plc Novel composition
FR2668927B1 (en) * 1990-11-09 1993-01-08 Oreal COSMETIC ANHYDROUS COMPOSITION IN AEROSOL FORM FOR THE FORMATION OF A FOAM.
DE9016291U1 (en) 1990-11-30 1991-03-28 Kali-Chemie Pharma Gmbh, 3000 Hannover Topically applicable diclofenac preparations
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
WO1992011839A1 (en) 1991-01-08 1992-07-23 Leonard Mackles Anhydrous aerosol
WO1992012717A2 (en) 1991-01-15 1992-08-06 A composition containing a tetracycline and use for inhibiting angiogenesis
US5227163A (en) * 1991-01-18 1993-07-13 Clilco, Ltd. Lice-repellant compositions
DE4102506C2 (en) 1991-01-29 1999-11-25 Pfeiffer Erich Gmbh & Co Kg Discharge device for media
WO1992013602A1 (en) 1991-02-05 1992-08-20 Buil Juergen Fire extinguishing and protection agent
US5650554A (en) * 1991-02-22 1997-07-22 Sembiosys Genetics Inc. Oil-body proteins as carriers of high-value peptides in plants
US6753167B2 (en) 1991-02-22 2004-06-22 Sembiosys Genetics Inc. Preparation of heterologous proteins on oil bodies
US5948682A (en) 1991-02-22 1999-09-07 Sembiosys Genetics Inc. Preparation of heterologous proteins on oil bodies
US5658956A (en) 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5648380A (en) 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5663208A (en) 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
IT1247138B (en) 1991-03-06 1994-12-12 Dompe Farmaceutici Spa HYDROPHILE PHARMACEUTICAL COMPOSITION CONTAINING KETOPROFENE LYSINE SALT FOR TOPICAL USE.
US5279819A (en) * 1991-03-18 1994-01-18 The Gillette Company Shaving compositions
JPH06509559A (en) * 1991-03-19 1994-10-27 セラピューティック　パッチ　リサーチ　エヌ．ブイ． Amino alcohol derivative compositions and methods as membrane permeation enhancers
US5389676A (en) * 1991-03-22 1995-02-14 E. B. Michaels Research Associates, Inc. Viscous surfactant emulsion compositions
AU658608B2 (en) 1991-03-25 1995-04-27 Astellas Pharma Europe B.V. Topical preparation containing a suspension of solid lipid particles
US5167950A (en) 1991-03-28 1992-12-01 S. C. Johnson & Son High alcohol content aerosol antimicrobial mousse
DE4110973A1 (en) 1991-04-05 1992-10-08 Haarmann & Reimer Gmbh MEDIUM WITH A PHYSIOLOGICAL COOLING EFFECT AND EFFECTIVE COMPOUNDS SUITABLE FOR THIS MEDIUM
HU209605B (en) * 1991-04-15 1994-09-28 Chinoin Gyogyszer Es Vegyeszet Process for production of wather-free transdermal preparation
IT1247529B (en) 1991-04-24 1994-12-17 Poli Ind Chimica Spa PHARMACEUTICAL COMPOSITIONS IN FOAM FORM FOR INTRAVAGINAL, SKIN AND ORAL ADMINISTRATION
US5204090A (en) 1991-05-30 1993-04-20 Bristol Myers Squibb Waterproof high-SPF sunscreen compositions
US5164357A (en) 1991-06-05 1992-11-17 Appleton Papers Inc. Thermally-responsive record material
FR2677544B1 (en) 1991-06-14 1993-09-24 Oreal COSMETIC COMPOSITION CONTAINING A MIXTURE OF NANOPIGMENTS OF METAL OXIDES AND MELANIC PIGMENTS.
DE4210165A1 (en) 1991-07-30 1993-02-04 Schering Ag TRANSDERMAL THERAPEUTIC SYSTEMS
GB9118028D0 (en) 1991-08-21 1991-10-09 Secr Defence Brit Improved transdrmal formulations
DE4127630A1 (en) 1991-08-21 1993-02-25 Bruno Jesswein TWO-COMPONENT PRESSURE CAN, IN PARTICULAR FOR 2K FOAM
US5643600A (en) 1991-09-17 1997-07-01 Micro-Pak, Inc. Lipid vesicles containing avocado oil unsaponifiables
DE69228373T2 (en) 1991-09-27 1999-06-17 Nof Corp COSMETIC AND EMULSION
GB2260079B (en) 1991-10-01 1995-08-09 American Cyanamid Co Pharmaceutical composition containing felbinac
US5230897A (en) 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
US5236707A (en) 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
EP0613369A1 (en) 1991-11-22 1994-09-07 Richardson-Vicks, Inc. Combined personal cleansing and moisturizing compositions
DE4140474C2 (en) 1991-12-09 1995-07-13 Schuelke & Mayr Gmbh Skincare additive
US5294365A (en) 1991-12-12 1994-03-15 Basf Corporation Hydroxypolyethers as low-foam surfactants
IT1253711B (en) * 1991-12-17 1995-08-23 Alfa Wassermann Spa VAGINAL PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMIN AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS
US5252246A (en) 1992-01-10 1993-10-12 Allergan, Inc. Nonirritating nonionic surfactant compositions
EP0552612A3 (en) 1992-01-22 1993-10-20 Hoffmann La Roche Methods for determining and isolating compounds which bind directly to nucleosolic proteins
US5318774A (en) 1992-02-28 1994-06-07 Richardson-Vicks Inc. Composition and method for imparting an artificial tan to human skin
UA41319C2 (en) * 1992-04-02 2001-09-17 Сембайозіс Дженетікс Інк. method for expression of DNA sequence being of interest in seedS cell, chimeric gene, expressing cassette, isolated regulatory section of transcription, a method for modification of metabolism specific for seeds, a method for obtaining new polypeptides by plant, isolated DNA, a method for expression of dna sequence being of interest by plant-host, a method for obtaining purified polypeptide being of interest, a method for obtaining polypeptide being of interest by oiL body
US5344051A (en) 1992-04-27 1994-09-06 Insta-Foam Products, Inc. Two-component foam dispensing apparatus
ZA932947B (en) 1992-04-28 1993-10-27 Schering Plough Healthcare Applicator for semisolid medications
US5409706A (en) 1992-05-04 1995-04-25 Imaginative Research Associates, Inc. Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin and emollients such as oils and esters
US5254334A (en) * 1992-05-04 1993-10-19 Imaginative Research Associates, Inc. Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin amd emollients such as oils and esters
ZA933133B (en) 1992-05-15 1994-10-05 Akzo Nv Application for introducing a cream-type substance into a woman's vagina
ATE158163T1 (en) 1992-05-18 1997-10-15 Procter & Gamble COMPOSITIONS WITH COOLING EFFECT
US5389305A (en) 1992-06-03 1995-02-14 Colgate Palmolive Co. High foaming nonionic surfactant base liquid detergent
US5346135A (en) 1992-06-16 1994-09-13 Vincent Edward C Spraying apparatus for blending liquids in a gaseous spray system
US5300286A (en) 1992-07-14 1994-04-05 Dow Corning Corporation Silicone emulsion for personal care application
CA2141192C (en) 1992-07-28 1999-02-02 Roberta C. Bloom Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
NO933239D0 (en) 1992-09-10 1993-09-10 Mcneil Ppc Inc Bioerodible device for administering active ingredients
EP0660720A4 (en) 1992-09-14 1996-12-27 Walter P Smith Skin-conditioning composition, its application and manufacture.
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5413775A (en) 1992-09-29 1995-05-09 Amerchol Corporation Hairsprays and acrylic polymer compositions for use therein
IT1255895B (en) * 1992-10-20 1995-11-17 Laura Chiodini PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN
EP0665733B1 (en) 1992-10-21 2003-05-07 Gynetech Laboratories, Inc. Vaginal sponge delivery system
DE59308338D1 (en) 1992-10-31 1998-05-07 Goldschmidt Ag Th Cosmetic or pharmaceutical preparations
DE4238860A1 (en) 1992-11-19 1994-05-26 Medicon Gmbh Skin protection products for the protection of human skin
US5308643A (en) * 1992-11-30 1994-05-03 Osipow Lloyd I Self-lather generating shaving compositions
JP3328344B2 (en) 1992-12-22 2002-09-24 タイホー工業株式会社 Method of controlling foaming state retention time of foaming type cleaning polishes
JPH06263630A (en) 1993-03-10 1994-09-20 Lion Corp Vitamin as-solubilizing eye drop
DE4309900C1 (en) * 1993-03-26 1994-06-30 Goldschmidt Ag Th Process for the preparation of amphoteric surfactants
JPH06279228A (en) 1993-03-30 1994-10-04 Kao Corp Foaming composition
US5326557A (en) * 1993-04-06 1994-07-05 Dow Corning Corporation Moisturizing compositions containing organosilicon compounds
US5807571A (en) 1993-05-06 1998-09-15 Lts Lohmann Therapie-Systeme Gmbh Transdermal therapeutic systems for administering indole serotonin agonists
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
CN1116900C (en) 1993-05-19 2003-08-06 久光制药株式会社 Solubilizing agent and external preparation containing the same
AU6825594A (en) 1993-05-21 1994-12-20 Henkel Corporation Mild shampoo composition
US5635469A (en) * 1993-06-10 1997-06-03 The Procter & Gamble Company Foaming cleansing products
US5447725A (en) 1993-06-11 1995-09-05 The Procter & Gamble Company Methods for aiding periodontal tissue regeneration
US5384308A (en) * 1993-06-14 1995-01-24 Henkin; R. I. Composition and method for enhancing wound healing
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5398846A (en) 1993-08-20 1995-03-21 S. C. Johnson & Son, Inc. Assembly for simultaneous dispensing of multiple fluids
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
FR2709666B1 (en) 1993-09-07 1995-10-13 Oreal Cosmetic or dermatological composition consisting of an oil-in-water emulsion based on oily globules provided with a lamellar liquid crystal coating.
JP2978043B2 (en) 1993-09-16 1999-11-15 高砂香料工業株式会社 (2S) -3-{(1R, 2S, 5R)-[5-methyl-2- (1-methylethyl) cyclohexyl] oxy} -1,2-propanediol, its production method and use
US5766632A (en) 1993-10-01 1998-06-16 Legere Pharmaceuticals, Ltd. Method of using lectins for contraception
FR2710854B1 (en) * 1993-10-08 1995-12-01 Oreal Oil-in-water emulsion usable for obtaining a cream.
US5578315A (en) 1993-12-01 1996-11-26 Rutgers, The State University Of New Jersey Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity
FR2713486B1 (en) 1993-12-14 1996-02-09 Scophysa New compositions for foams, in particular rectal foams, and foams thus obtained.
ATE199215T1 (en) 1993-12-23 2001-03-15 Procter & Gamble ANTIMICROBIAL COMPOSITIONS FOR WIPES
US5527822A (en) 1993-12-29 1996-06-18 Forest Laboratories, Inc. Method of treatment of traumatic brain injury
DE9422052U1 (en) 1994-01-04 1997-10-30 Adolf Würth GmbH & Co. KG, 74653 Künzelsau Filling device for filling a refillable dispensing container and refillable dispensing container
DE4405127A1 (en) 1994-02-18 1995-08-31 Henkel Kgaa Hair treatment products
US5514367A (en) 1994-02-28 1996-05-07 Estee Lauder, Inc. Skin tanning compositions and methods for their preparation and use
US5925669A (en) 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
IL109230A (en) 1994-04-05 1998-08-16 Agis Ind 1983 Ltd Anti-fungal composition containing bifonazole and fluocinonide
US5658749A (en) 1994-04-05 1997-08-19 Corning Clinical Laboratories, Inc. Method for processing mycobacteria
US5429815A (en) 1994-04-11 1995-07-04 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Stable single-phase self-foaming cleanser
FR2719467B1 (en) 1994-05-05 1996-05-31 Oreal Use of flavonoids to preserve and / or strengthen the mechanical properties of the hair and method of protecting hair using these compounds.
ES2079320B1 (en) * 1994-05-17 1996-10-16 Cusi Lab OPHTHALMIC DISSOLUTION BASED ON A DICLOFENACO AND TOBRAMYCIN AND ITS APPLICATIONS.
US5902574A (en) 1994-05-23 1999-05-11 The Gillette Company Shaving preparation for improved shaving comfort
US5545401A (en) * 1994-06-02 1996-08-13 Shanbrom; Edward Antiviral, spermicidal vaginal gel and foam containing low molecular weight povidone-iodine
FR2720635B1 (en) * 1994-06-03 1996-07-26 Oreal Sunscreen cosmetic compositions and uses.
US6221381B1 (en) 1994-06-28 2001-04-24 The University Of British Columbia Enhancing milk production by adding to feed a nonionic surfactant coated on a carrier
MA23592A1 (en) 1994-06-30 1995-12-31 Procter & Gamble COMPOSITIONS FOR BODY CARE CONTAINING THERMOPLASTIC ELASTOMERIC GRAFT COPOLYMERS
FR2722431B1 (en) 1994-07-12 1996-09-13 Lir France Sa DOUBLE DISPENSER FOR FLUID PRODUCTS
US5869529A (en) * 1994-07-20 1999-02-09 Agis Industries (1983) Ltd. Topical preparation for the prevention and treatment of lesions and sores associated with a herpes virus
JP3173330B2 (en) 1994-07-20 2001-06-04 トヨタ自動車株式会社 Slip control device for vehicle lock-up clutch
US5444092A (en) 1994-07-20 1995-08-22 Collins; Jerry Method and composition for treating psoriasis
GB9414699D0 (en) * 1994-07-21 1994-09-07 Slagel David Aqueous foamable composition
US5512555A (en) * 1994-07-21 1996-04-30 Merck & Co., Inc. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one
JP3241542B2 (en) 1994-07-29 2001-12-25 高砂香料工業株式会社 Method for purifying (-)-n-isopulegol and citrus-based fragrance composition containing (-)-n-isopulegol obtained by the method
DE4428096A1 (en) 1994-08-09 1996-02-15 Wella Ag Two-chamber container
US5656586A (en) 1994-08-19 1997-08-12 Rhone-Poulenc Inc. Amphoteric surfactants having multiple hydrophobic and hydrophilic groups
US5547989A (en) 1994-08-19 1996-08-20 Schering-Plough Healthcare Products, Inc. Compositions for treating corns and calluses
CN1159159A (en) * 1994-08-26 1997-09-10 普罗克特和甘保尔公司 Personal cleansing compositions
TW460296B (en) * 1994-09-01 2001-10-21 Janssen Pharmaceutica Nv Topical ketoconazole emulsion compositions without sodium sulfite
US5976555A (en) 1994-09-07 1999-11-02 Johnson & Johnson Consumer Products, Inc. Topical oil-in-water emulsions containing retinoids
JP3604177B2 (en) 1994-09-14 2004-12-22 日東電工株式会社 Transdermal formulation
US5500211A (en) 1994-09-22 1996-03-19 The Gillette Company Soap-free self-foaming shave gel composition
US5905092A (en) 1994-09-27 1999-05-18 Virotex Corporation Reel/Frame Topical antibiotic composition providing optimal moisture environment for rapid wound healing that reduces skin contraction
US5955414A (en) 1994-10-05 1999-09-21 S. C. Johnson & Son, Inc. Cleaning foam having fluorinated stain repellent and low flammability
US5540853A (en) 1994-10-20 1996-07-30 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
AU3855695A (en) 1994-11-08 1996-05-31 Mochida Pharmaceutical Co., Ltd. External preparation for skin protection
US5567420A (en) 1994-11-16 1996-10-22 Mceleney; John Lotion which is temporarily colored upon application
US5788664A (en) 1994-11-30 1998-08-04 Scalise; Gaspare Suppository applicator
GB9424562D0 (en) 1994-12-06 1995-01-25 Giltech Ltd Product
US5641480A (en) * 1994-12-08 1997-06-24 Lever Brothers Company, Division Of Conopco, Inc. Hair care compositions comprising heteroatom containing alkyl aldonamide compounds
US5529770A (en) 1994-12-09 1996-06-25 West Agro, Inc. Viscous liquid conditioning topical germicides
DE4444238A1 (en) 1994-12-13 1996-06-20 Beiersdorf Ag Cosmetic or dermatological drug combinations of cinnamic acid derivatives and flavone glycosides
FR2728166A1 (en) 1994-12-19 1996-06-21 Oreal TOPICAL COMPOSITION CONTAINING AN ANTAGONIST OF SUBSTANCE P
BR9510478A (en) 1994-12-21 1998-12-15 Cosmederm Technologies Formulations and methods for reducing skin irritation
WO1996019921A1 (en) 1994-12-23 1996-07-04 Commonwealth Scientific And Industrial Research Organisation Iodine biocidal material
DE4446891A1 (en) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stable aqueous budesonide solution
US5616136A (en) * 1995-01-09 1997-04-01 Med-Safe Systems, Inc. Quick release needle removal apparatus
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
FR2729855A1 (en) * 1995-01-26 1996-08-02 Oreal USE OF A CGRP ANTAGONIST IN A COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION AND COMPOSITION OBTAINED
US5523078A (en) 1995-02-03 1996-06-04 Michael E. Baylin Method of preparing and composition for treatment of hair and scalp
US5587149A (en) 1995-02-06 1996-12-24 R.P. Scherer Corporation Topical application emulsions
FR2730932B1 (en) 1995-02-27 1997-04-04 Oreal TRANSPARENT NANOEMULSION BASED ON FLUID NON-IONIC AMPHIPHILIC LIPIDS AND USE IN COSMETICS OR DERMOPHARMACY
FR2730930B1 (en) 1995-02-27 1997-04-04 Oreal USE OF NO-SYNTHASE INHIBITORS TO REDUCE THE IRRITANT SKIN EFFECT OF PRODUCTS USED IN THE COSMETIC OR PHARMACEUTICAL FIELD
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
US5558872A (en) 1995-03-07 1996-09-24 Healthpoint Medical Limited Partnership Gelled mineral oil skin protectant
US5618850A (en) 1995-03-09 1997-04-08 Focal, Inc. Hydroxy-acid cosmetics
US5783202A (en) * 1995-03-14 1998-07-21 Soltec Research Pty. Ltd. Pediculicidal mousse composition for killing head lice
EP0818195B1 (en) 1995-03-29 2003-11-26 Shionogi & Co., Ltd. Gelatin capsule with adjusted water activity
US5585104A (en) 1995-04-12 1996-12-17 The Procter & Gamble Company Cleansing emulsions
EP0738510A3 (en) * 1995-04-20 2005-12-21 L'oreal Use of a HMG-CoA reductase inhibitor as an anti-ageing agent and as an anti-acne agent. Composition comprising at least one HMG-CoA reductase inhibitor and at least one active substance with scaling properties.
FR2733417B1 (en) 1995-04-25 1997-06-06 Oreal FOAMING OIL-IN-WATER EMULSION BASED ON NON-IONIC SURFACTANTS, A FATTY PHASE AND A CATIONIC OR ANIONIC POLYMER CROSS-LINKED AND USE IN TOPICAL APPLICATION
GB9510856D0 (en) 1995-05-27 1995-07-19 Cussons Int Ltd Cleaning composition
UY24246A1 (en) 1995-06-06 1996-06-14 Neutrogena Corp TROPIC VEHICLES CONTAINING SOLUBILIZED AND STABILIZED AZELAIC ACID
AU715827B2 (en) * 1995-06-22 2000-02-10 Minnesota Mining And Manufacturing Company Stable hydroalcoholic compositions
JP3542665B2 (en) 1995-07-07 2004-07-14 株式会社資生堂 Anti-aging skin external preparation, collagen cross-linking inhibition skin external preparation and anti-ultraviolet skin external preparation
US5705472A (en) 1995-07-18 1998-01-06 Petroferm Inc. Neutral aqueous cleaning composition
FR2736824B1 (en) 1995-07-18 1997-10-10 Fabre Pierre Dermo Cosmetique MINOXIDIL HAIR COMPOSITION WITH LOW FAT SOLVENT CONTENT
DE29512760U1 (en) 1995-08-08 1995-11-16 Wella Ag, 64295 Darmstadt Pressurized gas container for dispensing foam
TW504387B (en) 1995-09-06 2002-10-01 Kao Corp Emulsified, water-in-oil type composition and skin cosmetic preparation
US5881493A (en) 1995-09-14 1999-03-16 D. B. Smith & Co. Inc. Methods for applying foam
CN1062129C (en) * 1995-09-14 2001-02-21 徐荣祥 Medicine matrix and its use
JPH0984855A (en) 1995-09-25 1997-03-31 Kyoto Yakuhin Kogyo Kk Aerosol preparation for administer medicine to rectum or vagina
US6221823B1 (en) 1995-10-25 2001-04-24 Reckitt Benckiser Inc. Germicidal, acidic hard surface cleaning compositions
ES2217334T3 (en) 1995-12-14 2004-11-01 Taisho Pharmaceutical Co. Ltd AEROSOL PREPARATION.
FR2742986B1 (en) * 1995-12-29 1998-01-30 Rhone Poulenc Chimie COSMETIC COMPOSITIONS FOR THE HAIR OR THE SKIN BASED ON SULPHONATED COPOLYESTERS WITH POLYORGANOSILOXANE MOTIFS
US5716611A (en) * 1996-01-02 1998-02-10 Euro-Celtique, S.A. Emollient antimicrobial formulations containing povidone iodine
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5843411A (en) 1997-02-06 1998-12-01 Topix Pharmaceuticals Inc. Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
US5759524A (en) * 1996-02-09 1998-06-02 The Procter & Gamble Company Photoprotective compositions
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5912007A (en) 1996-02-29 1999-06-15 Warner-Lambert Company Delivery system for the localized administration of medicaments to the upper respiratory tract and methods for preparing and using same
US6251369B1 (en) 1996-03-05 2001-06-26 Sultan Dental Products Dental fluoride foam
FR2745716B1 (en) 1996-03-07 1998-04-17 Oreal ULTRAFINE PRESSURIZABLE FOAMING OIL-IN-WATER EMULSIONS
WO1997039745A1 (en) 1996-04-19 1997-10-30 Sloan-Kettering Institute For Cancer Research Use of inhaled retinoids in the prevention of cancer
US5910382A (en) 1996-04-23 1999-06-08 Board Of Regents, University Of Texas Systems Cathode materials for secondary (rechargeable) lithium batteries
IT1283042B1 (en) 1996-05-21 1998-04-07 Condea Augusta Spa COSMETIC COMPOUNDS DEODORANT AND / OR ANTI-BREATHING
US5797955A (en) 1996-06-11 1998-08-25 Walters; David J. Pressure application unit for positioning vertebra
US5833961A (en) 1996-06-25 1998-11-10 Inolex Investment Corporation Polyester-based suncreen formulations
EP0932401A1 (en) 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
US5716621A (en) * 1996-07-03 1998-02-10 Pharmadyn, Inc. Nonocclusive drug delivery device and process for its manufacture
AU726543B2 (en) 1996-07-10 2000-11-09 S.C. Johnson & Son, Inc. Triclosan skin wash with enhanced efficacy
DE19631221C2 (en) 1996-08-02 1999-07-01 Beiersdorf Ag Foam-form sunscreen preparations containing water-soluble sunscreen filter substances and surface-active substances
US6042848A (en) 1996-08-15 2000-03-28 The Board Of Trustees Of Southern Illinois University Enhancement of antimicrobial peptide activity by metal ions
US5833963A (en) 1996-08-20 1998-11-10 Bristol-Myers Squibb Company Non-tacky and quick-drying aqueous-based antiperspirant compositions
US5837270A (en) 1996-08-26 1998-11-17 Burgess; Nelson Leon Topical anti-acne composition
EP0829259A1 (en) 1996-09-04 1998-03-18 Warner-Lambert Company Foam/gel with microbeads and/or fine particles
US6271295B1 (en) 1996-09-05 2001-08-07 General Electric Company Emulsions of silicones with non-aqueous hydroxylic solvents
US5952392A (en) * 1996-09-17 1999-09-14 Avanir Pharmaceuticals Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition
US7060253B1 (en) 1996-09-20 2006-06-13 Mundschenk David D Topical formulations and delivery systems
FR2754451B1 (en) 1996-10-14 1998-11-06 Oreal SELF-FOAMING CREAM
WO1998017282A1 (en) 1996-10-23 1998-04-30 Vertex Pharmaceuticals Incorporated Methods of using sucrose octasulfate to treat or prevent enveloped virus infection
US6093408A (en) 1996-10-25 2000-07-25 The Procter & Gamble Company Skin care compositions
IT1287114B1 (en) 1996-10-31 1998-08-04 Recordati Chem Pharm ANTI-HERPETIC PHARMACEUTICAL COMPOSITIONS FOR TOPICAL APPLICATORS, CONTAINING ACICLOVIR
WO1998019654A1 (en) 1996-11-04 1998-05-14 The Procter & Gamble Company Hair mousse composition comprising silicone emulsion
NZ335495A (en) 1996-11-12 2002-03-28 Dov Tamarkin alpha,omega-dicarboxylic acid esters and their use in treating dermatological disorders
FR2755854B1 (en) 1996-11-15 1998-12-24 Oreal NANOEMULSION BASED ON NON-IONIC AND CATIONIC AMPHIPHILIC LIPIDS AND USES
EP0889719B1 (en) * 1996-11-16 2003-04-02 Wella Aktiengesellschaft Agents for dying and decolorizing fibers
US5906992A (en) 1996-11-21 1999-05-25 Colgate Palmolive Company Foam cleaning compositions
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
US5951544A (en) 1996-12-04 1999-09-14 Laser Industries Ltd. Handpiece assembly for laser apparatus
US5759579A (en) 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
US5695551A (en) 1996-12-09 1997-12-09 Dow Corning Corporation Water repellent composition
US5856452A (en) * 1996-12-16 1999-01-05 Sembiosys Genetics Inc. Oil bodies and associated proteins as affinity matrices
US5672634A (en) * 1996-12-23 1997-09-30 Isp Investments Inc. Crosslinked PVP-I2 foam product
US6217707B1 (en) * 1996-12-31 2001-04-17 Kimberly-Clark Worldwide, Inc. Controlled coverage additive application
US5879469A (en) 1997-01-06 1999-03-09 Deeay Technologies Ltd. Dishwashing method and detergent composition therefor
US6582711B1 (en) 1997-01-09 2003-06-24 3M Innovative Properties Company Hydroalcoholic compositions thickened using polymers
SE520811C2 (en) 1997-01-17 2003-08-26 Ponsus Ab Skin protection preparations containing lipophilic and hydrophilic components, method of preparation and use thereof
IN186803B (en) * 1997-02-05 2001-11-10 Panacea Biotec Ltd
ES2133090B1 (en) 1997-02-21 2000-04-01 Uriach & Cia Sa J NEW APPLICATOR FOR THE ADMINISTRATION OF SEMI-SOLID MEDICATIONS.
WO1998034604A1 (en) 1997-02-11 1998-08-13 Bernard Salafsky ANTI-PARASITIC ACTION OF N,N-DIETHYL-m-TOLUAMIDE (DEET) AND FORMULATIONS THAT PROLONG ITS ACTIVITY IN THE SKIN
ATE277596T1 (en) 1997-02-24 2004-10-15 Sla Pharma Ag TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING A CHOLINERGIC ACT OR A CALCIUM CHANNEL BLOCKER
JP3050289B2 (en) 1997-02-26 2000-06-12 日本電気株式会社 Output impedance adjustment circuit of output buffer circuit
FR2760637B1 (en) 1997-03-11 1999-05-28 Fabre Pierre Dermo Cosmetique COAL TAR EXTRACT WITH REDUCED AROMATIC HYDROCARBON CONTENT, PROCESS FOR OBTAINING AND DERMO-COSMETIC PREPARATIONS
US5922331A (en) * 1997-03-26 1999-07-13 Chanel, Inc. Skin cream composition
US5951989A (en) 1997-04-07 1999-09-14 Heymann; Warren R. Method for the treatment of dry skin
USH2043H1 (en) 1997-05-23 2002-08-06 The Procter & Gamble Company Skin care compositions
US6599513B2 (en) 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
NZ501404A (en) 1997-05-27 2001-09-28 Sembiosys Genetics Inc Emulsion preparation comprising washed oil bodies of uniform size, shape and density
US6372234B1 (en) 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6183762B1 (en) * 1997-05-27 2001-02-06 Sembiosys Genetics Inc. Oil body based personal care products
US6217887B1 (en) 1997-06-04 2001-04-17 The Procter & Gamble Company Leave-on antimicrobial compositions which provide improved immediate germ reduction
EP0884045A1 (en) 1997-06-06 1998-12-16 Pfizer Products Inc. Self-tanning dihydroxyacetone formulations having improved stability and providing enhanced delivery
US20050276836A1 (en) 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
EP0993827A4 (en) 1997-06-13 2006-07-05 Taisho Pharmaceutical Co Ltd Aerosols
FR2765799B1 (en) 1997-07-08 1999-08-27 Oreal GLOSSY COMPOSITION CONTAINING AROMATIC OILS THICKENED BY A POLYSACCHARIDE ALKYLETHER
ES2170522T5 (en) * 1997-08-18 2011-11-14 NEUBOURG SKIN CARE GMBH &amp; CO. KG FOAMY SKIN CREAM.
SE9703226D0 (en) 1997-09-08 1997-09-08 Astra Ab New pharmaceutical composition
US5885581A (en) 1997-09-11 1999-03-23 Merz, Incorporated Composition and method for improvement of the appearance of scars
US6241971B1 (en) 1997-09-25 2001-06-05 The Procter & Gamble Company Hair styling compositions comprising mineral salt, lipophilic material, and low levels of surfactant
US5939376A (en) 1997-09-25 1999-08-17 Colgate Palmolive Company Liquid cleaning compositions containing an organic ester foam control agent
US6214318B1 (en) 1997-10-02 2001-04-10 Oms Holdings Llc Aerosol ointment compositions for topical use
US6075056A (en) 1997-10-03 2000-06-13 Penederm, Inc. Antifungal/steroid topical compositions
FR2769299B1 (en) 1997-10-03 1999-12-31 Oreal BI-PRODUCTS PACKAGING AND DISTRIBUTION SET
AUPO983897A0 (en) 1997-10-17 1997-11-06 Soltec Research Pty Ltd Topical antifungal composition
US5961957A (en) 1997-10-20 1999-10-05 Mcanalley; Bill H. Foam compositions
US5911981A (en) * 1997-10-24 1999-06-15 R.I.T.A. Corporation Surfactant blends for generating a stable wet foam
US5865347A (en) * 1997-10-27 1999-02-02 William T. Wilkinson Multi-chamber dispenser for flowable materials
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
JP3450680B2 (en) 1997-10-28 2003-09-29 高砂香料工業株式会社 Method for producing para-menthane-3,8-diol
WO1999021562A1 (en) * 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
DK1510213T3 (en) 1997-11-10 2009-03-23 Strakan Int Ltd Penetration-enhancing and irritation-reducing systems including testosterone
DE29720316U1 (en) 1997-11-17 1998-01-29 Raimund Andris Gmbh & Co Kg, 78052 Villingen-Schwenningen Two-chamber dispenser
US5849042A (en) 1997-11-19 1998-12-15 Bristol-Myers Squibb Hair dye compositions containing 2,3 dialkyl-4-aminophenol and a 2-alkyl-1-naphthol
US5871720A (en) * 1997-11-20 1999-02-16 Colgate-Palmolive Company Cosmetic compositions with DBS and functionalized silicones
EP1049486A4 (en) 1997-12-05 2006-01-04 Lilly Co Eli Glp-1 formulations
TWI225793B (en) 1997-12-25 2005-01-01 Ajinomoto Kk Cosmetic composition
JP3050289U (en) 1997-12-29 1998-06-30 丸隆株式会社 Pet animal room excretion tools
DE19802206A1 (en) 1998-01-22 1999-07-29 Beiersdorf Ag Stable cosmetic or dermatological composition with low viscosity
FR2774595A1 (en) 1998-02-06 1999-08-13 Rech D Innovation Et De Dev Ce EMULSION FOR TRANSDERMAL STEROID ADMINISTRATION
DE19805918A1 (en) * 1998-02-13 1999-08-19 Beiersdorf Ag Lipidreduced preparations
US6110966A (en) 1998-02-20 2000-08-29 Medi-Cell Laboratories, Inc. Triple action complex
DE19807774A1 (en) * 1998-02-24 1999-08-26 Beiersdorf Ag Use of flavone, flavanone or flavonoid compound for protection of ascorbic acid or ascorbyl compound against oxidation, especially in cosmetic and dermatological preparations,
JP3514105B2 (en) 1998-02-27 2004-03-31 ティアック株式会社 Recording medium recording / reproducing device
ES2245511T3 (en) 1998-03-04 2006-01-01 Teijin Limited VITAMIN LOANS D3 ACTIVE IN THE FORM OF EMULSION.
US6121210A (en) 1998-03-12 2000-09-19 Dap Products Inc. Foamable silicone oil compositions and methods of use thereof
US5990100A (en) 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
AUPP310798A0 (en) * 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
US5919830A (en) 1998-04-30 1999-07-06 Gopalkrishnan; Sridhar Stable non-aqueous blends for personal care compositions
US6649175B1 (en) 1998-05-04 2003-11-18 Schering-Plough Healthcare Products, Inc. Skin barrier composition
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
FR2779637B1 (en) 1998-06-15 2000-09-01 Oreal PHOTOPROTECTIVE COSMETIC COMPOSITIONS CONTAINING A METAL OXIDE NANOPIGMENT AND AN ACRYLIC TERPOLYMER AND USE OF SUCH COMPOSITIONS FOR PROTECTING KERATINIC MATERIALS FROM ULTRAVIOLET RADIATION
US6706290B1 (en) 1998-07-06 2004-03-16 Olvai E. Kajander Methods for eradication of nanobacteria
FR2780879B1 (en) 1998-07-09 2002-09-20 Oreal PHOTOPROTECTOR COSMETIC COMPOSITION CONTAINING AN ANIONIC SURFACTANT, COMPOUND FILTERING ULTRAVIOLET RADIATION AND CATIONIC OR ZPHITTERIONIC AMPHIPHILIC COMPOUND AND USE THEREOF
US6146664A (en) 1998-07-10 2000-11-14 Shaklee Corporation Stable topical ascorbic acid compositions
US6124362A (en) 1998-07-17 2000-09-26 The Procter & Gamble Company Method for regulating hair growth
US6071541A (en) 1998-07-31 2000-06-06 Murad; Howard Pharmaceutical compositions and methods for managing skin conditions
DE19835239A1 (en) * 1998-08-04 2000-02-24 Johnson & Johnson Gmbh Foaming oil preparation and its use
JP4017758B2 (en) 1998-08-04 2007-12-05 高砂香料工業株式会社 Cooling agent composition
GB9817817D0 (en) 1998-08-14 1998-10-14 Unilever Plc Cosmetic composition
NZ509618A (en) 1998-08-20 2003-09-26 3M Innovative Properties Co A patch-in-a-bottle that provides a fluid composition, which is applied to a surface and subsequently dries to form a covering, such as a patch
JP3712868B2 (en) 1998-09-02 2005-11-02 株式会社カネボウ化粧品 Aerosol composition
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
AUPP583198A0 (en) * 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
US6087310A (en) 1998-09-23 2000-07-11 Castrol Limited Skin cleaning compositions and uses comprising a polymer latex emulsion
JP2002525298A (en) 1998-09-28 2002-08-13 メルク エンド カムパニー インコーポレーテッド Treatment of inflammatory diseases by administration of thrombin inhibitors
US6914057B1 (en) 1998-09-28 2005-07-05 The Research Foundation Of State University Of New York Inhibitor of cataract formation
US6607716B1 (en) 1998-09-29 2003-08-19 Tech Labs, Inc. Pediculicidal compositions, a kit, and methods of use
RU2134052C1 (en) 1998-10-07 1999-08-10 Нерушай Сергей Алексеевич Method and apparatus for aerosol application of perfumery liquids
US6287546B1 (en) 1998-10-09 2001-09-11 Colgate-Palmolive Company Shampoos with stabilizers
JP3876081B2 (en) 1998-10-22 2007-01-31 東洋エアゾール工業株式会社 Aerosol composition for foam formation
US6110477A (en) 1998-10-30 2000-08-29 Topix Pharmaceuticals Inc. Stabilization of ascorbic acid, ascorbic acid derivatives and/or extracts containing ascorbic acid for topical use
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US5980904A (en) 1998-11-18 1999-11-09 Amway Corporation Skin whitening composition containing bearberry extract and a reducing agent
US6344218B1 (en) 1998-11-23 2002-02-05 The Procter & Gamble Company Skin deodorizing and santizing compositions
DE19855097A1 (en) 1998-11-28 2000-05-31 Wella Ag Pigment-containing, foamable gel
US20010006654A1 (en) 1998-12-09 2001-07-05 L'oreal Compositions and methods for treating hair and skin using aqueous delivery systems
US6087317A (en) 1998-12-10 2000-07-11 Dow Corning Corporation Particle size stable silicone emulsions
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6262128B1 (en) 1998-12-16 2001-07-17 3M Innovative Properties Company Aqueous foaming compositions, foam compositions, and preparation of foam compositions
FR2787325B1 (en) * 1998-12-17 2001-01-26 Oreal NANOEMULSION BASED ON OXYETHYLENE OR NON-OXYETHYLENE SORBITAN FATTY ESTERS, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
FR2787728B1 (en) 1998-12-23 2001-01-26 Oreal NANOEMULSION BASED ON FATTY ESTERS OF PHOSPHORIC ACID, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS
AU769224B2 (en) 1998-12-28 2004-01-22 Taisho Pharmaceutical Co., Ltd. External preparation
JP2000191429A (en) 1998-12-28 2000-07-11 Kao Corp Foamable cosmetic
FR2787703B1 (en) 1998-12-29 2001-01-26 Oreal NANOEMULSION BASED ON ETHOXYL FATHER ETHERS OR ETHOXYL FATTY ESTERS, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
FR2788007B1 (en) 1999-01-05 2001-02-09 Oreal NANOEMULSION BASED ON BLOCK COPOLYMERS OF ETHYLENE OXIDE AND PROPYLENE OXIDE, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6270781B1 (en) 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors
FR2789371B1 (en) 1999-02-05 2001-04-27 Sofab DISTRIBUTOR OF CHEMICALLY UNSTABLE PRODUCTS
EP1025836A1 (en) 1999-02-08 2000-08-09 F. Hoffmann-La Roche Ag Cosmetic light screening composition
TWI262930B (en) * 1999-02-10 2006-10-01 Mitsui Chemicals Inc High-durability flexible polyurethane cold molded foam and process for producing the same
US6224888B1 (en) * 1999-02-12 2001-05-01 The Procter & Gamble Company Cosmetic compositions
US6423329B1 (en) 1999-02-12 2002-07-23 The Procter & Gamble Company Skin sanitizing compositions
JP3641152B2 (en) 1999-02-17 2005-04-20 株式会社ヤクルト本社 Topical skin preparation
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6305578B1 (en) 1999-02-26 2001-10-23 Wella Aktiengesellshaft Device for mixing, foaming and dispensing liquids from separate compressed-gas containers
IL129102A0 (en) * 1999-03-22 2000-02-17 J P M E D Ltd An emulsion
DE60031025T2 (en) 1999-03-31 2007-05-24 Firmenich S.A. Use of Cubebol as a flavoring agent
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6264964B1 (en) 1999-04-14 2001-07-24 Conopco, Inc. Foaming cosmetic products
US6479532B1 (en) 1999-04-16 2002-11-12 Fujisawa Pharmaceutical Co., Ltd. Antifungal compositions
US6284802B1 (en) 1999-04-19 2001-09-04 The Procter & Gamble Company Methods for regulating the condition of mammalian keratinous tissue
SK287653B6 (en) 1999-04-23 2011-05-06 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Non-aqueous pharmaceutical composition for dermal use
US6433003B1 (en) 1999-04-23 2002-08-13 Arthur M. Bobrove Method for treating hyperhidrosis in mammals
GB9909711D0 (en) 1999-04-27 1999-06-23 Unilever Plc Mousse forming hair treatment composition
FR2793479B1 (en) 1999-05-10 2001-06-29 Lir France Sa DOUBLE DISPENSER FOR FLUID OR PASTY PRODUCTS
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
US6168576B1 (en) * 1999-05-24 2001-01-02 Irene N. Reynolds Device for dispensing vaginal medication
US6518228B1 (en) 1999-05-27 2003-02-11 Clairol Incorporated Ultra-mild, clear, aqueous, foamable skin cleanser
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
ATE300274T1 (en) 1999-05-28 2005-08-15 Unilever Nv FOAMABLE SHOWER OIL COMPOSITION
JP2000351726A (en) 1999-06-08 2000-12-19 Lion Corp Aerosol preparation
JP2000354623A (en) 1999-06-14 2000-12-26 Shiigeru Kk Deodorant and deodorizing spray
GB9913951D0 (en) 1999-06-15 1999-08-18 Unilever Plc Mousse-forming shampoo compositions
US6113888A (en) 1999-06-15 2000-09-05 Neutrogena Corporation Self-tanning mousse
US6190365B1 (en) 1999-06-21 2001-02-20 Chun Lim Abbott Vaginal douche applicator and method of vaginal deodorization using the same
NL1012419C2 (en) * 1999-06-23 2000-12-28 Airspray Nv Aerosol for dispensing a liquid.
JP2001002526A (en) 1999-06-23 2001-01-09 Koike Kagaku Kk Foam aerosol composition
US6524594B1 (en) 1999-06-23 2003-02-25 Johnson & Johnson Consumer Companies, Inc. Foaming oil gel compositions
US6551604B1 (en) 1999-06-28 2003-04-22 The Procter & Gamble Company Skin care compositions
WO2001001949A1 (en) 1999-07-01 2001-01-11 Johnson And Johnson Consumer Companies, Inc. Cleansing compositions
US6762158B2 (en) 1999-07-01 2004-07-13 Johnson & Johnson Consumer Companies, Inc. Personal care compositions comprising liquid ester mixtures
FR2795643B1 (en) 1999-07-02 2004-06-11 Oreal FIRMING COSMETIC COMPOSITION INCLUDING AT LEAST ONE HYDROXYSTILBENE IN ASSOCIATION WITH ASCORBIC ACID
JP4058199B2 (en) 1999-07-06 2008-03-05 ポーラ化成工業株式会社 Warm feeling pack
WO2001005366A1 (en) 1999-07-15 2001-01-25 Playtex Products, Inc. Sunscreen aerosol composition
US6548074B1 (en) 1999-07-22 2003-04-15 Elizabeth Arden Co., Division Of Conopco, Inc. Silicone elastomer emulsions stabilized with pentylene glycol
FR2796925B1 (en) 1999-07-29 2001-10-05 Valois Sa DISPENSER WITH ARTICULATED DISPENSING HEAD
WO2001008681A1 (en) 1999-08-02 2001-02-08 First Horizon Pharmaceutical Corporation Methods of administration of glycopyrrolate compositions
US6303552B1 (en) 1999-08-04 2001-10-16 Napier International Technologies, Inc. Aerosol paint stripper compositions
DE19938757A1 (en) * 1999-08-16 2001-02-22 Beiersdorf Ag Cosmetic or dermatological preparations of the oil-in-water type
WO2001013956A2 (en) 1999-08-26 2001-03-01 Ganeden Biotech, Inc. Use of emu oil a carrier for antifungal, antibacterial, and antiviral medications
US6777591B1 (en) 1999-08-27 2004-08-17 Sembiosys Genetics Inc. Legume-like storage protein promoter isolated from flax and methods of expressing proteins in plant seeds using the promoter
US6479058B1 (en) 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6308863B1 (en) 1999-09-02 2001-10-30 Owens-Brockway Plastic Products Inc. Dual chamber package for pressurized products
JP4394775B2 (en) 1999-09-03 2010-01-06 株式会社ダイゾー Water-in-oil foam aerosol composition and method for producing the same
JP4045475B2 (en) * 1999-09-06 2008-02-13 東洋紡績株式会社 Nucleic acid / protein purification equipment
US6986883B2 (en) 1999-09-09 2006-01-17 Discus Dental, Inc. Increased peroxide content tooth bleaching gel
AU3887301A (en) 1999-09-20 2001-04-24 Procter & Gamble Company, The Article for the delivery of foam products
US6437006B1 (en) 1999-09-27 2002-08-20 American Cyanamid Company Pharmaceutical carrier formulation
US6528086B2 (en) * 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
FR2798849B1 (en) 1999-09-29 2001-11-23 Oreal COMPOSITION FOR WASHING KERATIN MATERIALS, BASED ON A DETERGENT SURFACE-ACTIVE AGENT, A DIALKYL DIALLYL AMMONIUM HOMOPOLYMER AND AN ACRYLIC TERPOLYMER
US6790435B1 (en) 1999-10-01 2004-09-14 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Antiperspirant compositions comprising microemulsions
US6667045B2 (en) 1999-10-01 2003-12-23 Joseph Scott Dahle Topical applications for skin treatment
FR2799369B1 (en) 1999-10-08 2001-12-21 Oreal COMBINATION OF ESCINE AND DEXTRAN SULFATE AND THE USE THEREOF
US6186367B1 (en) * 1999-10-19 2001-02-13 Valley Design Inc. Metered liquid squeeze dispenser
FR2799963B1 (en) 1999-10-22 2002-07-19 Oreal EMULSIONS CONTAINING AT LEAST ONE INSOLUBLE ORGANIC UV FILTER AND A NON-FILTERING ORGANOMODIFIED SILICONE
US6080394A (en) 1999-11-08 2000-06-27 Dow Corning Corporation Polar solvent-in-oil emulsions and multiple emulsions
US20030077301A1 (en) 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
UA66796C2 (en) 1999-12-27 2004-06-15 Univ Nat Pharmaceutical Composition "profesol foamy" for treating radiation lesions of skin
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
IL133969A0 (en) 2000-01-10 2001-04-30 Thixo Ltd Thixotropic compositions containing unsaturated oils and food products containing the same
US7001690B2 (en) 2000-01-18 2006-02-21 Valence Technology, Inc. Lithium-based active materials and preparation thereof
US6528033B1 (en) 2000-01-18 2003-03-04 Valence Technology, Inc. Method of making lithium-containing materials
FR2804016B1 (en) 2000-01-21 2006-07-28 Oreal NANEMULSION CONTAINING AMPHIPHILIC LIPIDS AND PEG ESTER AND USES THEREOF
FR2804015B1 (en) 2000-01-21 2005-12-23 Oreal NANEMULSION CONTAINING AMPHIPHILIC LIPIDS AND NONIONIC POLYMER AND USES THEREOF
US20020006435A1 (en) 2000-01-27 2002-01-17 Samuels Paul J. Transdermal anesthetic and vasodilator composition and methods for topical administration
FR2804666B1 (en) 2000-02-04 2002-06-14 Oreal DISPENSER FOR STORING AT LEAST TWO COMPONENTS AND SELECTIVE DISPENSING EITHER OF A SINGLE CONSTITUENT, EITHER OF THEIR MIXTURE, AND METHOD FOR THE IMPLEMENTATION THEREOF
US6780443B1 (en) 2000-02-04 2004-08-24 Takasago International Corporation Sensate composition imparting initial sensation upon contact
NL1014389C2 (en) 2000-02-15 2001-08-16 Dija Zeist Bv Tanning preparation for the skin.
US20040161447A1 (en) 2000-02-17 2004-08-19 Leonard Paul Liquid foam producing compositions and dispensing system therefor
CA2400161C (en) 2000-02-22 2015-11-24 Metacarta, Inc. Spatially coding and displaying information
ATE275378T1 (en) 2000-02-22 2004-09-15 Color Access Inc AQUEOUS COSMETIC JELLIES
DE10008837A1 (en) 2000-02-25 2001-08-30 Henkel Kgaa Dental cleaner containing propellant gas
DE10008896A1 (en) 2000-02-25 2001-08-30 Beiersdorf Ag Improving the solubility and compatibility of benzotriazole UV filters in oils, e.g. in cosmetics or dermatological compositions, by addition of dialkylnaphthalates
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
IL135222A (en) 2000-03-22 2005-06-19 Univ Ben Gurion Compositions containing molecular iodine
DE20006099U1 (en) * 2000-04-01 2000-07-06 MegaPlast GmbH & Co. KG, 78052 Villingen-Schwenningen Dosing pump dispenser with at least two dosing pumps
US6649571B1 (en) 2000-04-04 2003-11-18 Masi Technologies, L.L.C. Method of generating gas bubbles in oleaginous liquids
FR2807322B1 (en) 2000-04-10 2004-02-20 Oreal COMPOSITION, ESPECIALLY COSMETIC, COMPRISING ASCORBIC ACID IN ASSOCIATION WITH AN ASCORBIC ACID DERIVATIVE
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
JP2002012513A (en) 2000-04-24 2002-01-15 Kanebo Ltd Urea-containing whipped cosmetic
US6358541B1 (en) 2000-05-03 2002-03-19 David S. Goodman Topical preparation for the treatment of hair loss
US6410036B1 (en) * 2000-05-04 2002-06-25 E-L Management Corp. Eutectic mixtures in cosmetic compositions
AU2001257534A1 (en) 2000-05-05 2001-11-20 R.P. Scherer Technologies, Inc. Oil-in-water emulsion formulation containing hydroquinone and retinol
EP1286652B1 (en) 2000-05-08 2006-09-06 Pfizer Products Inc. Skin protectant spray compositions
US6433024B1 (en) 2000-05-08 2002-08-13 Karl F. Popp Topical anti-acne composition
FR2808685B1 (en) 2000-05-12 2004-10-08 Sanofi Synthelabo PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ANTI-INFLAMMATORY AGENTS
JP2001326952A (en) 2000-05-15 2001-11-22 Nec Corp Broadcast confirmation system, method and device for broadcast confirmation, and recording medium with broadcast confirmation program recorded thereon
FR2809010B1 (en) 2000-05-22 2002-07-12 Oreal NANOEMULSION BASED ON ANIONIC POLYMERS, AND ITS USES IN PARTICULAR IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS
JP4653282B2 (en) * 2000-05-23 2011-03-16 昭和薬品化工株式会社 Minocycline-containing composition
DE10028638A1 (en) 2000-06-09 2001-12-20 Schuelke & Mayr Gmbh Storage-stable composition useful in cosmetic and pharmaceutical compositions comprises combination of glycerol monoalkyl ether with antioxidant
AU2001268451A1 (en) 2000-06-13 2001-12-24 Fd Management, Inc. Cosmetic composition for stressed skin under extreme conditions
WO2002000820A1 (en) 2000-06-23 2002-01-03 Combe International Ltd. Stable foam for use in disposable wipe
US20020164381A1 (en) 2000-06-30 2002-11-07 Medicis Pharmaceutical Corporation Mitocidal compositions and methods
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
CA2313659A1 (en) 2000-07-06 2002-01-06 Barry J. Barclay B complex vitamin compositions that protect against cellular damage caused by ultraviolet light
DE10033414B4 (en) 2000-07-08 2004-02-19 Wella Aktiengesellschaft Clear, two-phase, foam-forming aerosol hair care product
FR2811564B1 (en) 2000-07-13 2002-12-27 Oreal NANOEMULSION CONTAINING NON-IONIC POLYMERS, AND ITS USES IN PARTICULAR IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
DE10035930A1 (en) 2000-07-21 2002-01-31 Clariant Gmbh fine emulsions
US20020035070A1 (en) 2000-07-26 2002-03-21 The Procter & Gamble Company Method of regulating hair growth using metal complexes of oxidized carbohydrates
FR2812191B1 (en) 2000-07-28 2003-10-17 Oreal USE OF PROSTAGLANDIN E2 RECEPTOR AGONISTS (EP-3) TO ATTENUATE, DECREASE OR STOP HAIR AND HAIR GROWTH IN COSMETIC PREPARATIONS
JP4166931B2 (en) 2000-08-02 2008-10-15 ポーラ化成工業株式会社 Fever foam cosmetic
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6514487B1 (en) * 2000-08-08 2003-02-04 Teresa Leigh Barr Foam and gel oat protein complex and method of use
WO2002015873A2 (en) 2000-08-22 2002-02-28 The Procter & Gamble Company Personal care compositions containing adhesive elastomeric polymer and inorganic colloid
US6299023B1 (en) 2000-08-24 2001-10-09 Miles Arnone Device for dispensing two substances in a user selectable ratio with replaceable cartridges
AU2001286578A1 (en) 2000-08-24 2002-03-04 Tim Ioannides Topical antioxidant having vitamin c and method of combination with topical agent by user
FR2813189B1 (en) 2000-08-31 2003-02-28 Oreal COSMETIC FOAMING CREAM FOR THE TREATMENT OF OILY SKIN
WO2002022086A2 (en) 2000-09-14 2002-03-21 Quantum Energy Technologies Application of water nanoclusters to skin
JP5082181B2 (en) 2000-09-21 2012-11-28 大正製薬株式会社 Lower rectal retention suppository
AUPR048600A0 (en) 2000-10-02 2000-10-26 Soltec Research Pty Ltd Pharmaceutical vehicle
DE10049147A1 (en) 2000-10-04 2002-04-25 Wella Ag Hair wax product with waxes, non-volatile oils and volatile, hydrophobic substances
FR2814959A1 (en) 2000-10-09 2002-04-12 Menarini France Atomiser for pharmaceutical products based on antiinflammatory agents comprises pressurized container, dosing pouch and metering valve
US6547063B1 (en) 2000-10-10 2003-04-15 The Procter & Gamble Company Article for the delivery of foam products
GB2367809A (en) 2000-10-12 2002-04-17 Bespak Plc Metering valve with collapsible chamber
FR2815616B1 (en) 2000-10-20 2003-01-24 Oreal DISTRIBUTION ASSEMBLY FOR THE EXTEMPORARY DISTRIBUTION OF TWO PRODUCTS
US6403069B1 (en) 2000-10-20 2002-06-11 Colgate-Palmolive Company High oil clear emulsion with elastomer
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
DE10058384B4 (en) 2000-11-24 2004-12-16 Wella Aktiengesellschaft Cosmetic or dermatological agent in the form of a creamy permanent foam or a stably foamed cream, its use and method for producing the agent
US6299032B1 (en) 2000-11-27 2001-10-09 George W. Hamilton Disposable actuator with cap opener for aerosol cans
WO2002043490A1 (en) 2000-11-28 2002-06-06 Avon Products, Inc. Foaming insect repellent compositions
US6969521B1 (en) 2000-11-28 2005-11-29 Avon Products, Inc. Aerosol insect repellent composition having low VOC content and method of applying same to the skin
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
US6774100B2 (en) 2000-12-06 2004-08-10 Imaginative Research Associates, Inc. Anhydrous creams, lotions and gels
GB0030068D0 (en) 2000-12-11 2001-01-24 Lawrence Malcolm Highway vehicular traffic flow control
JP3497466B2 (en) 2000-12-12 2004-02-16 高砂香料工業株式会社 Warming composition
US20060254597A1 (en) 2000-12-14 2006-11-16 40J's Llc Method of treatment of atrophic vaginitis by topical clitoral menthol or a related cooling compound
US6749860B2 (en) 2000-12-22 2004-06-15 Kimberly-Clark Worldwide, Inc. Absorbent articles with non-aqueous compositions containing botanicals
US20040079361A1 (en) 2001-01-17 2004-04-29 Clayton Colin D. Medicinal aerosols
US20030013692A1 (en) 2001-01-19 2003-01-16 Gullans Steven R. Methods of treating neurological disorders
BR0206980A (en) 2001-02-05 2004-07-06 Michael Albert Kamm Use of a smooth muscle tone modulator
DE10110336A1 (en) 2001-03-03 2002-09-12 Clariant Gmbh Surfactant-free cosmetic, dermatological and pharmaceutical agents
IL157734A0 (en) 2001-03-06 2004-03-28 Cellegy Pharma Inc Pharmaceutical compositions for the treatment of urogenital disorders
CN1527694A (en) 2001-03-07 2004-09-08 宝洁公司 Topical composition comprising a functional aromatic derivative cosmetic bonding agent
ES2224063T3 (en) 2001-03-26 2005-03-01 3M Innovative Properties Company DOSING VALVE FOR A DOSE INHALER MEASURES THAT HAVE IMPROVED FLOW.
CA2441893C (en) 2001-03-26 2015-01-20 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
NZ528377A (en) 2001-03-27 2005-05-27 Galen Chemicals Ltd Intravaginal drug delivery devices for the administration of an antimicrobial agent
CA2441730C (en) 2001-03-29 2008-11-18 The Dial Corporation Antibacterial compositions for skin care
JP2002302419A (en) 2001-03-30 2002-10-18 Aldeep Cosmetics Japan Inc Cosmetic composition
NZ529308A (en) 2001-04-05 2005-03-24 Collagenex Pharm Inc Tetracycline compounds comprising a tetracycline and a controlled release agent to provide delivery at a dose below that required for antibiotic activity
US6848597B2 (en) 2001-04-18 2005-02-01 James A. Vlodek Methods and apparatus for extruding foam through orifices
US6682726B2 (en) * 2001-04-30 2004-01-27 The Gillette Company Self-foaming shaving lotion
US20030053980A1 (en) 2001-04-30 2003-03-20 The Gillette Company Shaving compositions containing highly lubricious water soluble polymers
US20020187181A1 (en) 2001-05-14 2002-12-12 3M Innovative Properties Company System for delivering cosmetics and pharmaceuticals
ITMI20011019A1 (en) 2001-05-17 2002-11-17 Carlo Ghisalberti FURILIC SUBSTANCES FOR TOPICAL USE
WO2002096374A2 (en) 2001-05-31 2002-12-05 Upsher-Smith Laboratories, Inc. Dermatological compositions and methods comprising alpha-hydroxy acids or derivatives
US7270828B2 (en) 2001-06-20 2007-09-18 The Procter & Gamble Company Personal care composition comprising hydrophobic gel
JP2005501022A (en) 2001-06-20 2005-01-13 ザ プロクター アンド ギャンブル カンパニー Personal care composition comprising a polyol-in-silicone emulsion
FR2826292B1 (en) 2001-06-22 2004-01-23 Rhodia Chimie Sa OIL-IN-OIL EMULSIONS COMPRISING A SILICONE, DISPERSIONS OF SUCH EMULSIONS AND USE THEREOF
US6428772B1 (en) 2001-06-25 2002-08-06 Blistex Inc. Acne treatment composition with cooling effect
US6544562B2 (en) 2001-06-25 2003-04-08 Blistex Inc. Acne treatment including dual-package system
WO2003002082A1 (en) 2001-06-26 2003-01-09 The Procter & Gamble Company Pressurized anhydrous antiperspirant emulsions
JP2003012511A (en) 2001-06-27 2003-01-15 Rohto Pharmaceut Co Ltd Aerosol composition
KR100791757B1 (en) 2001-06-27 2008-01-04 가부시키가이샤 가네보케쇼힝 Mixer/extractor
WO2003005985A1 (en) 2001-07-13 2003-01-23 The Procter & Gamble Company Mousse forming compositions comprising quaternary ammonium agents
US20060194773A1 (en) 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
DE10134786A1 (en) 2001-07-17 2003-02-06 Beiersdorf Ag Foamable preparations
JP5137289B2 (en) 2001-08-03 2013-02-06 武田薬品工業株式会社 Stable emulsion composition
DE10138495B4 (en) 2001-08-04 2004-11-11 Beiersdorf Ag Foaming preparations and their use
JP2005504756A (en) 2001-08-08 2005-02-17 マリア・アントニア・ガルシア−オルメド・ドミンゲス Injectable foam formulations and novel pharmaceutical applications
US7091243B2 (en) 2001-08-09 2006-08-15 Croda, Inc. Anti-irritants
JP4707279B2 (en) 2001-08-09 2011-06-22 ポーラ化成工業株式会社 Cosmetics for massage with cool-down effect
IL160275A0 (en) 2001-08-11 2004-07-25 Aventis Pharma Ltd Pressurised aerosol dispenser
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030049218A1 (en) 2001-08-28 2003-03-13 Amit Patel Antiperspirant deodorant emulsion
DK1455888T3 (en) 2001-08-29 2009-08-24 Pharmakodex Ltd Topical administration device
US6709663B2 (en) 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
US6479060B1 (en) 2001-09-04 2002-11-12 Healthpoint, Ltd. Elegant hydrogenated castor oil ointments
FR2829693B1 (en) 2001-09-20 2004-02-27 Oreal FOAMING COSMETIC CREAM
DE10147820A1 (en) 2001-09-27 2003-04-10 Beiersdorf Ag Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations containing waxes or lipids which are solid and / or semi-solid at room temperature
US7931533B2 (en) * 2001-09-28 2011-04-26 Igt Game development architecture that decouples the game logic from the graphics logics
US20030185839A1 (en) 2001-10-05 2003-10-02 Podolsky Daniel K. Methods and compositions for treating dermal lesions
AU2002367745B2 (en) 2001-10-10 2007-05-10 Exxonmobil Research And Engineering Company Biodegradable non-toxic gear oil
US20030082120A1 (en) 2001-10-26 2003-05-01 Milstein Harold J. Method for reducing systemic effects of aging, effects of aging on the skin, and incidence of skin damage from sun exposure using antibiotics of the tetracycline family
US9283162B2 (en) 2001-10-26 2016-03-15 Taiyo Kagaku Co., Ltd. Composition for oily foamable aerosol
US7255869B2 (en) 2001-10-30 2007-08-14 The Procter & Gamble Company Anhydrous cosmetic compositions containing polyols
DE10154324A1 (en) 2001-11-06 2003-08-07 Merz Pharma Gmbh & Co Kgaa Topically applicable compositions with external active substance depot formation, their production and their use
DE10155956A1 (en) 2001-11-09 2003-05-22 Beiersdorf Ag Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations
WO2003041667A2 (en) 2001-11-13 2003-05-22 The Procter & Gamble Company Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care
DE10155792A1 (en) 2001-11-14 2003-05-22 Beiersdorf Ag Self-foaming, foam-like, post-foaming or foamable cosmetic or dermatological preparations containing siloxane elastomers
WO2004043469A1 (en) 2001-11-16 2004-05-27 Klysz Beatrice M Anti-aging skin care composition and uses thereof
DE10159002A1 (en) 2001-11-30 2003-06-18 Clariant Gmbh Use of multi-phase foaming agents from foam dispensers
FR2833246B1 (en) 2001-12-06 2005-06-24 Beatrice France Touteau DEVICE FOR SIMULTANEOUSLY ACTING TWO AEROSOLS CONTAINING TWO PRODUCTS TO BE MIXED AT THE TIME OF USE
US6531118B1 (en) 2001-12-11 2003-03-11 Avon Products, Inc. Topical compositions with a reversible photochromic ingredient
WO2003053292A1 (en) 2001-12-20 2003-07-03 Femmepharma, Inc. Vaginal delivery of drugs
US6765001B2 (en) 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US20030118515A1 (en) 2001-12-21 2003-06-26 Robert Jew Cosmetic composition containing carbon dioxide
SE0104421D0 (en) 2001-12-21 2001-12-21 Ponsus Pharma Ab New composition
US20030129259A1 (en) 2001-12-28 2003-07-10 Avon Products, Inc. Topical lightening compostitions and methods of use
JP4549625B2 (en) 2002-01-05 2010-09-22 株式會社アモーレパシフィック Finely emulsified particles containing ginseng saponin metabolites as active ingredients, a method for producing the same, and a cosmetic composition for preventing skin aging containing the same
US7192601B2 (en) 2002-01-18 2007-03-20 Walker Edward B Antimicrobial and sporicidal composition
US6992049B2 (en) 2002-01-31 2006-01-31 Exxonmobil Research And Engineering Company Lubricating oil compositions
NZ517094A (en) 2002-02-08 2005-03-24 Advanced Animal Technology Ltd Improvements in and relating to substance delivery device
US20050255065A1 (en) 2002-02-14 2005-11-17 Quimversion, S.L. Aluminium and hexamethylenetetramine complex and the applications thereof
US6589216B1 (en) 2002-02-20 2003-07-08 Abbott Research Group, Inc. Vaginal douches, vaginal douche applicators and methods of vaginal douching
US6682511B2 (en) 2002-02-21 2004-01-27 Robert Wallace Besoyan Brief protector
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US6691898B2 (en) 2002-02-27 2004-02-17 Fomo Products, Inc. Push button foam dispensing device
WO2003075851A2 (en) 2002-03-06 2003-09-18 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US20050281766A1 (en) 2002-03-11 2005-12-22 Avon Products, Inc. Method of improving the aesthetic appearance of epithelia
US6736860B2 (en) 2002-03-12 2004-05-18 Unilever Home & Personal Care Usa Division Of Conopco, Inc. Gradual permanent coloring of hair using dye intermediates dissolved in alkaline water with fatty alcohol
CA2422244A1 (en) 2002-03-14 2003-09-14 Homax Products, Inc. Aerosol systems and methods for mixing and dispensing two-part materials
WO2003078075A1 (en) 2002-03-19 2003-09-25 Airspray International B. V. Dispensing unit
US20030180347A1 (en) 2002-03-19 2003-09-25 W.F. Young, Incorporated Patch for the delivery of topical agents
JP4322124B2 (en) 2002-03-28 2009-08-26 伯東株式会社 Method for stabilizing bubbles in foam-containing cosmetics
ATE337718T1 (en) 2002-04-12 2006-09-15 Dreamwell Ltd CASSETTE BED SYSTEM
US8192749B2 (en) 2003-04-16 2012-06-05 Galderma Laboratories Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US8846039B2 (en) 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
US6875438B2 (en) 2002-04-27 2005-04-05 Aventis Pharma Deutschland Gmbh Preparations for topical administration of substances having antiandrogenic activity
CA2384922C (en) 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
AU2003243205A1 (en) 2002-05-06 2003-11-17 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating mucositis and fungal infection
MXPA04011179A (en) 2002-05-10 2005-02-17 Unilever Nv Hair conditioning compositions.
JP2004025435A (en) 2002-05-10 2004-01-29 Toko:Kk Tapping device
US6783027B2 (en) 2002-05-15 2004-08-31 The Procter & Gamble Company Metered-dose underarm product and package
US20030215472A1 (en) 2002-05-16 2003-11-20 Bonda Craig A Methods and compositions employing a dialkyl amide
KR20050007553A (en) 2002-05-20 2005-01-19 콜라제넥스 파마슈티칼스, 인크 Methods of treating allergic reactions
JP4050094B2 (en) 2002-05-28 2008-02-20 株式会社三谷バルブ Metering valve mechanism and aerosol products
US6723309B1 (en) 2002-06-10 2004-04-20 Jeffrey Alan Deane Hair cleansing conditioner
FR2840903B1 (en) 2002-06-13 2005-01-28 Oreal GLUCOSE AND VITAMIN F DERIVATIVE, COMPOSITIONS COMPRISING THE SAME, AND USES FOR IMPROVING THE CONDITION OF HAIR AND HAIR
US7763587B2 (en) 2002-06-13 2010-07-27 L'oreal S.A. Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process
US7163669B2 (en) 2002-06-19 2007-01-16 J.M. Huber Corporation Cosmetic compositions comprising calcium silicates
EP1547937B1 (en) 2002-06-26 2010-12-08 Daizo Co., Ltd. Packaging container for discharge of plurality of contents, packaging product including the packaging container and process for producing the packaging product
JP2004026605A (en) 2002-06-27 2004-01-29 Asahi Fiber Glass Co Ltd Greige goods for glass fiber yarn and glass fiber yarn made using this
US20040002550A1 (en) 2002-06-28 2004-01-01 Mercurio Anthony Fred Post foaming compositions
US6785629B2 (en) 2002-07-02 2004-08-31 Agilent Technologies, Inc. Accuracy determination in bit line voltage measurements
JP3833972B2 (en) 2002-07-08 2006-10-18 古河電気工業株式会社 Wire harness assembly system
US7137536B2 (en) 2002-07-22 2006-11-21 Seaquist Perfect Dispensing Foreign, Inc. Inverted aerosol dispenser
DE10233330B4 (en) 2002-07-22 2007-04-26 Sasol Germany Gmbh Microemulsion containing UV photoprotective filter and / or anti-dandruff agent
US6897195B2 (en) 2002-07-24 2005-05-24 Nanjing Zhongshi Chemical Co. Composition of menthol and menthyl lactate, its preparation method and its applications as a cooling agent
US20020182162A1 (en) 2002-08-07 2002-12-05 Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for enhanced hair growth
FR2843373B1 (en) 2002-08-12 2005-03-04 Jean Augustin DEVICE FOR PACKAGING AND APPLYING A PRODUCT IN FLUID FORM
US7939170B2 (en) 2002-08-15 2011-05-10 The Rockefeller University Water soluble metal and semiconductor nanoparticle complexes
EA008150B1 (en) 2002-08-26 2007-04-27 С. Л. А. Фарма Аг Pharmaceutical composition
US6770607B2 (en) 2002-09-12 2004-08-03 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Viscoelastic cleansing gel with micellar surfactant solutions
US7906473B2 (en) 2002-09-13 2011-03-15 Bissell Homecare, Inc. Manual spray cleaner
GB0221697D0 (en) 2002-09-18 2002-10-30 Unilever Plc Novel compouds and their uses
US6968982B1 (en) 2002-09-18 2005-11-29 Burns Caleb E S Multiple-mist dispenser
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
US6949037B2 (en) 2002-09-27 2005-09-27 Richard A. Enos Quick-release fastener for releasably attaching lacrosse stick head to shaft
FR2845672B1 (en) 2002-10-09 2006-02-10 Airlessystems FLUID PRODUCT DISPENSER
US8232304B2 (en) 2002-10-24 2012-07-31 G & R Pharmaceuticals, Llc Antifungal formulations
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8900554B2 (en) * 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US20080031907A1 (en) 2002-10-25 2008-02-07 Foamix Ltd. Cosmetic and pharmaceutical foam
US20080206161A1 (en) 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20050271596A1 (en) 2002-10-25 2005-12-08 Foamix Ltd. Vasoactive kit and composition and uses thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20050069566A1 (en) 2003-08-04 2005-03-31 Foamix Ltd. Foam carrier containing amphiphilic copolymeric gelling agent
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20120156144A1 (en) 2002-10-25 2012-06-21 Foamix Foamable Compositions, Kits and Methods for Hyperhidrosis
MXPA05004278A (en) 2002-10-25 2005-10-05 Foamix Ltd Cosmetic and pharmaceutical foam.
US20060233721A1 (en) 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
US20160158261A1 (en) 2002-10-25 2016-06-09 Foamix Pharmaceuticals Ltd. Antibiotic Kit and Composition and Uses Thereof
US20050186142A1 (en) * 2002-10-25 2005-08-25 Foamix Ltd. Kit and composition of imidazole with enhanced bioavailability
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US20080317679A1 (en) 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20070292359A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20050205086A1 (en) * 2002-10-25 2005-09-22 Foamix Ltd. Retinoid immunomodulating kit and composition and uses thereof
US20070292355A1 (en) 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
AU2004266502B2 (en) 2002-10-25 2010-09-23 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
EP1556332B1 (en) 2002-10-28 2016-10-05 Givaudan SA Coolant solutions and compositions comprising the same
JP2004250435A (en) 2002-11-21 2004-09-09 Dai Ichi Seiyaku Co Ltd Composition for hair growth
JP4282311B2 (en) 2002-11-26 2009-06-17 三洋電機株式会社 Ice making equipment
US20070134167A2 (en) 2002-12-12 2007-06-14 Neubourg Skin Care Gmbh & Co. Kg Stable foam cream
GB0229071D0 (en) 2002-12-13 2003-01-15 Unilever Plc Cosmetic method and composition for enhancing attractiveness
US20040191196A1 (en) 2002-12-16 2004-09-30 Dov Tamarkin Novel conjugate compounds and dermatological compositions thereof
FR2848847B1 (en) 2002-12-18 2005-10-14 Coletica COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AN AQUEOUS INSOLUBLE ENZYME AND USES THEREOF
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
FR2848998B1 (en) 2002-12-20 2006-04-07 Oreal DISPENSING DEVICE HAVING MEANS FOR DISTRIBUTING TWO PRODUCTS IN VARIABLE PROPORTIONS
MXPA05007266A (en) 2003-01-02 2006-01-17 Femmepharma Holding Co Inc Pharmaceutical preparations for treatments of diseases and disorders of the breast.
WO2004064769A2 (en) 2003-01-21 2004-08-05 Hector Herrera Methods for making and using topical delivery agents
NZ541526A (en) 2003-01-24 2008-03-28 Stiefel Res Australia Pty Ltd Clindamycin phosphate foam
US20040151756A1 (en) 2003-02-04 2004-08-05 Richards Anthony P. Edible low density high surface area drug vehicle, method of manufacturing low density high surface area drug vehicle
US7517519B2 (en) 2003-02-06 2009-04-14 Cipla Limited Topical immunotherapy and compositions for use therein
WO2004071479A1 (en) 2003-02-12 2004-08-26 Connetics Australia Pty Ltd Film foaming hydroalcoholic foam
US6841547B2 (en) 2003-02-28 2005-01-11 Albert Einstein College Of Medicine Of Yeshevia University Method for decreasing low density lipoprotein
US20040175347A1 (en) 2003-03-04 2004-09-09 The Procter & Gamble Company Regulation of mammalian keratinous tissue using hexamidine compositions
GB0305010D0 (en) 2003-03-05 2003-04-09 Unilever Plc Changing colours
US6843390B1 (en) * 2003-03-17 2005-01-18 Joe G. Bristor Multiple fluid closed system dispensing device
US7357950B2 (en) 2003-03-21 2008-04-15 Elizabeth Anne Mazzio Topical treatment for dyshidrosis (pompholyx) and dry skin disorders
US7488757B2 (en) 2003-03-24 2009-02-10 Becton, Dickinson And Company Invisible antimicrobial glove and hand antiseptic
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
DE10315936A1 (en) 2003-04-03 2004-10-28 Ing. Erich Pfeiffer Gmbh Discharge device for at least one medium
GB0308585D0 (en) 2003-04-14 2003-05-21 Pz Cussons Int Ltd Cleaning composition
WO2004093895A1 (en) 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
US20040220187A1 (en) 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
DE10319771B4 (en) 2003-05-02 2005-03-17 Koenig & Bauer Ag System for inspecting a printed image
JP2004353084A (en) 2003-05-08 2004-12-16 Sanyo Electric Co Ltd Evaporator fixation member
FR2854821B1 (en) 2003-05-16 2006-12-08 Oreal ASSEMBLY FOR PACKAGING AND DISPENSING A PRODUCT, IN PARTICULAR IN THE FORM OF A SAMPLE
JP4232535B2 (en) 2003-05-20 2009-03-04 セイコーエプソン株式会社 Printer maintenance system, print control server, client, method related thereto and program related thereto
US7222802B2 (en) 2003-05-23 2007-05-29 Meadwestvaco Corporation Dual sprayer with external mixing chamber
AU2003275509A1 (en) 2003-05-25 2004-12-13 Eco Animal Health Ltd. Dimeticone-containing sustained formulation
US7186416B2 (en) 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
TR201807182T4 (en) 2003-05-30 2018-06-21 De Paoli Ambrosi Gianfranco The use of dimethyl sulfone in formulations for chemical skin / facial peels.
US20050208083A1 (en) 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
JP4018032B2 (en) 2003-06-17 2007-12-05 高砂香料工業株式会社 Hair and body cleaning composition
WO2004112780A1 (en) 2003-06-18 2004-12-29 Galderma S.A. Metronidazole-based green tinted topical pharmaceutical composition
CA2528344A1 (en) * 2003-06-19 2004-12-29 The Procter & Gamble Company Polyol-in-silicone emulsions
US6967012B2 (en) 2003-06-25 2005-11-22 General Motors Corporation Imide/amide hydrogen storage materials and methods
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
AU2004253410B2 (en) 2003-07-03 2008-08-21 Japan Science And Technology Agency Remedy for sarcoidosis and method of treating the same
US20070140999A1 (en) 2003-07-18 2007-06-21 Hill Dermaceuticals, Inc. Topical skin care composition containing refined peanut oil
WO2005009416A1 (en) 2003-07-24 2005-02-03 Ranbaxy Laboratories Limited Modified release compositions for minocycline
US7226230B2 (en) 2003-07-28 2007-06-05 Raymond Liberatore Spreader
US7735914B2 (en) * 2003-07-29 2010-06-15 L & P Property Management Company Ottoman recliner
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
DE602004011793T2 (en) 2003-09-05 2009-02-12 William Marsh Rice University, Houston FLUORESCENT SAFETY INKS AND MARKETS WITH CARBON NANOTONES
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
CN1886126A (en) 2003-09-25 2006-12-27 Dmi生物科学公司 Methods and products which utilize N-acyl-L-aspartic acid
US20050084551A1 (en) 2003-09-26 2005-04-21 Jensen Claude J. Morinda citrifolia-based oral care compositions and methods
FR2860143B1 (en) 2003-09-26 2008-06-27 Oreal COSMETIC COMPOSITION COMPRISING A SEQUENCE POLYMER AND A NON-VOLATILE SILICONE OIL
KR20060113907A (en) 2003-09-29 2006-11-03 에테나 헬스케어 인코포레이티드 - high alcohol content gel-like and foaming compositions
GB2406330B (en) 2003-09-29 2005-12-07 Bespak Plc A dispensing apparatus
CA2528818C (en) 2003-10-03 2010-08-10 Collegium Pharmaceutical, Inc. Topical aerosol foams
FR2860502B1 (en) 2003-10-07 2007-09-14 Valois Sas DOSING VALVE AND DEVICE FOR DISPENSING FLUID PRODUCT COMPRISING SUCH A VALVE
GB0323908D0 (en) * 2003-10-11 2003-11-12 Nupharm Lab Ltd Pharmaceutical foam formulation
WO2005034903A1 (en) 2003-10-14 2005-04-21 Showa Denko K.K. Agent for skin external use containing salt of ascorbic acid derivative, method for stabilizing the agent for skin external use, and stabilizer
FR2860976B1 (en) 2003-10-20 2006-02-10 Ravi Shrivastava NOVEL SYNERGISTIC COMPOSITIONS FOR IMPROVING THE BIODAVAILABILITY AND EFFICIENCY OF POLYUNSATURATED FATTY ACIDS FOR THE TREATMENT OF BRAIN FUNCTIONING DISORDERS.
US7419498B2 (en) 2003-10-21 2008-09-02 Nmt Medical, Inc. Quick release knot attachment system
CA2542145A1 (en) 2003-10-31 2005-05-19 The Procter & Gamble Company Skin care composition containing dehydroacetic acid and skin care actives
JP2007510757A (en) 2003-11-06 2007-04-26 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク How to treat eczema
US8157788B2 (en) 2003-11-06 2012-04-17 Paolo L. Manfredi Multi-site drug delivery platform
DE602004005073T2 (en) 2003-11-06 2007-06-21 Unilever N.V. IMPROVED COSMETIC COMPOSITION WITH VITAMIN B3, VITAMIN B6 AND AN ORGANIC ACID
AU2006246425B2 (en) 2003-11-06 2012-03-22 Genencor International, Inc. Personal care compositions and methods for their use
DE10354051A1 (en) 2003-11-17 2005-06-16 Beiersdorf Ag Dispensers containing cosmetic preparations containing aids for keeping the donor in motion
WO2005048966A1 (en) 2003-11-17 2005-06-02 The Procter & Gamble Company Antiperspirant composition and applicator therefor
CA2546195A1 (en) 2003-11-21 2005-06-02 Pfizer Products Inc. The use of anti biotics as vaccine adjuvants
US20050115988A1 (en) 2003-12-01 2005-06-02 Brian Law Multiple liquid foamer
US20050123496A1 (en) 2003-12-08 2005-06-09 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Self foaming non-aqueous personal wash cleansers with little or no surfactant
DE10361022A1 (en) 2003-12-23 2005-07-28 Merckle Gmbh Chem.-Pharm. Fabrik Topical preparations containing dimethyl sulfoxide and dexpanthenol
NZ548771A (en) 2003-12-30 2010-05-28 Gilead Sciences Inc Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
CA2555121A1 (en) * 2004-02-04 2005-08-25 Foamix Ltd. Cosmetic and pharmaceutical foam with solid matter
US7225518B2 (en) 2004-02-23 2007-06-05 Boston Scientific Scimed, Inc. Apparatus for crimping a stent assembly
JP4381169B2 (en) 2004-02-27 2009-12-09 花王株式会社 Hair cosmetics
WO2005084410A2 (en) * 2004-03-03 2005-09-15 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1725132A2 (en) 2004-03-18 2006-11-29 Bodypoint Designs, Inc. Pivoting side mount and quick release assembly for a pelvic stabilization device
DE102004016710B4 (en) 2004-04-05 2020-11-19 Greppmayr GmbH Foot care formulation
CA2556993C (en) 2004-04-08 2013-05-21 Novartis Ag Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides
JP2007532697A (en) 2004-04-19 2007-11-15 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー The beneficial effects of increased local blood flow
NL1026031C2 (en) 2004-04-23 2005-10-25 Airspray Nv Delivery assembly.
EP1768648A1 (en) 2004-04-28 2007-04-04 Foamix Ltd. Body cavity foams
JP2005314323A (en) 2004-04-30 2005-11-10 Sato Pharmaceutical Co Ltd Hair growth formulation
US20050244354A1 (en) 2004-04-30 2005-11-03 Sam Speron Oxygenated personal care products
US20050255048A1 (en) 2004-05-15 2005-11-17 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
US7083125B2 (en) 2004-05-17 2006-08-01 S.C. Johnson & Son, Inc. Detachable tube assembly
US7143909B2 (en) 2004-05-21 2006-12-05 Sonoco Development, Inc. Reconfigurable metered material dispenser
US8394394B2 (en) 2004-05-26 2013-03-12 L'oréal Mousse formulations
ITBO20040338A1 (en) 2004-05-28 2004-08-28 Progine Farmaceutici Srl VAGINAL NEBULIZATION DISPENSER
US20050268416A1 (en) 2004-06-03 2005-12-08 Sommers J E Foldable lotion applicator
JP4368250B2 (en) 2004-06-09 2009-11-18 ポーラ化成工業株式会社 Post-form dosage form of warm cosmetic
FR2871696B1 (en) 2004-06-17 2006-11-10 Galderma Sa TOPICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS
FR2871698B1 (en) 2004-06-17 2008-07-04 Galderma Sa SPRAY COMPOSITION COMPRISING AN ASSOCIATION OF PHARMACEUTICAL ASSETS AND AN OILY PHASE
US8211449B2 (en) 2004-06-24 2012-07-03 Dpt Laboratories, Ltd. Pharmaceutically elegant, topical anhydrous aerosol foam
JP4355264B2 (en) 2004-06-25 2009-10-28 ポーラ化成工業株式会社 Warm feeling non-water foam cosmetic
US7207655B2 (en) 2004-06-28 2007-04-24 Eastman Kodak Company Latency stirring in fluid ejection mechanisms
US6991789B2 (en) 2004-06-29 2006-01-31 Allergas, Inc. Methods of modulating intracellular degradation rates of toxins
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
UA93354C2 (en) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Topical antiviral formulations
US20060121073A1 (en) 2004-07-12 2006-06-08 Sandhya Goyal Topical gel formulation comprising insecticide and its preparation thereof
US7288692B2 (en) * 2004-07-14 2007-10-30 Exxonmobil Chemcial Patents Inc. Process for producing olefins
MXPA06014390A (en) 2004-07-19 2007-10-02 Warner Lambert Co Formulation for stimulating hair growth.
JP4557624B2 (en) 2004-07-29 2010-10-06 株式会社吉野工業所 Quantitative dispenser
WO2006010589A2 (en) 2004-07-29 2006-02-02 Mipharm S.P.A. Post foaming gel mousse
US20060029565A1 (en) 2004-08-09 2006-02-09 The Gillette Company Self-heating shave foam product
WO2006020695A2 (en) 2004-08-12 2006-02-23 Triaccess Technologies, Inc. Optical receiver with increased dynamic range
ES2429040T5 (en) 2004-08-31 2017-06-13 Stiefel Research Australia Pty Ltd Method and compositions of microemulsion and submicron emulsion
KR100623013B1 (en) 2004-09-04 2006-09-19 김영대 Nano-emulsion, the use thereof, and preparing method thereof
ES2729826T3 (en) 2004-09-23 2019-11-06 Arc Medical Devices Inc Pharmaceutical compositions and related methods to inhibit fibrous adhesions or inflammatory disease using low sulfate fucans
US8916050B2 (en) 2004-09-27 2014-12-23 Special Water Patents B.V. Methods and compositions for treatment of water
FR2875797B1 (en) 2004-09-30 2006-11-24 Oreal DISTRIBUTION ASSEMBLY FOR THE EXTENDED DISTRIBUTION OF TWO PRODUCTS
BRPI0404595A (en) 2004-10-26 2006-06-13 Natura Cosmeticos Sa oil-in-water nanoemulsion, cosmetic composition and cosmetic product comprising same, process for preparing said nanoemulsion
JP2006124347A (en) * 2004-10-29 2006-05-18 Bayer Cropscience Ag New method for producing phenyl 2-pyrimidinyl ketones and new intermediate therefor
DE102004052986A1 (en) 2004-11-02 2006-05-04 Lindal Ventil Gmbh Device for mixing two different components
US7350673B2 (en) 2004-11-19 2008-04-01 Glynntech, Inc. Metered dose squeeze dispenser
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
FR2880802B1 (en) 2005-01-14 2008-12-19 Sederma Soc Par Actions Simpli COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING EUGLENE EXTRACT
US20060194769A1 (en) 2005-01-25 2006-08-31 University Of Vermont And State Agricultural College Small molecules that reduce fungal growth
BRPI0607038A2 (en) 2005-01-28 2009-12-01 Basf Ag use of polymers cosmetic compositions for hair and skin and dermatological composition
US20060177392A1 (en) 2005-02-10 2006-08-10 William Walden Oil-based composition for acne
US20060193813A1 (en) 2005-02-11 2006-08-31 L'oreal Nanoemulsion containing a hydroxylated urea compound
EP1866033B1 (en) 2005-03-24 2017-04-19 Ensign Laboratories PTY LTD Sunscreen aerosol spray
GB0506141D0 (en) 2005-03-24 2005-05-04 Transphase Ltd A topical compostion and its uses
US20060222675A1 (en) 2005-03-29 2006-10-05 Sabnis Ram W Personal care compositions with color changing indicator
CA2610135A1 (en) 2005-04-19 2006-10-19 Foamix Ltd. Apparatus and method for releasing a measured amount of content from a container
CA2610662A1 (en) * 2005-05-09 2007-05-18 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9173835B2 (en) 2005-05-10 2015-11-03 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
WO2006122158A2 (en) 2005-05-10 2006-11-16 Xanthone Plus International, Llc Skin care compositions containing xanthones
ES2407407T3 (en) 2005-06-01 2013-06-12 Glaxosmithkline Intellectual Property Development Limited Vitamin formulation
US20060272199A1 (en) 2005-06-02 2006-12-07 Bmc Manufacturing, Llc Aqueous gel candle for use with a warming device
US8211874B2 (en) 2005-06-03 2012-07-03 Galderma Laboratories Inc. Inhibition of thrombin generation
AU2006339311A1 (en) 2005-06-07 2007-09-07 Foamix Ltd. Antibiotic kit and composition and uses thereof
WO2007085899A2 (en) 2005-07-06 2007-08-02 Foamix Ltd. Foamable arthropocidal composition for tropical application
US20070009607A1 (en) * 2005-07-11 2007-01-11 George Jones Antibacterial/anti-infalmmatory composition and method
US20070015738A1 (en) 2005-07-15 2007-01-18 Walker Stephen G Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells
ES2765895T3 (en) 2005-07-18 2020-06-11 Procter & Gamble Aerosol cream foam, method for treating hair and use
WO2007085902A2 (en) 2005-07-19 2007-08-02 Foamix Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20080152596A1 (en) 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
CN100531515C (en) * 2005-07-22 2009-08-19 鸿富锦精密工业（深圳）有限公司 Printing circuit board with modified power zone block
ATE410997T1 (en) 2005-07-22 2008-10-15 Wella Ag HAIR TREATMENT METHOD USING A DRY FOAM USED AS A MECHANICAL CARRIER
US7729372B2 (en) * 2005-07-27 2010-06-01 Sharp Corporation Communicating in a network that includes a medium having varying transmission characteristics
CA2618974C (en) 2005-08-09 2014-01-28 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
WO2007025244A2 (en) 2005-08-25 2007-03-01 Houle Philip R Treatment systems for delivery of sensitizer solutions
WO2007119099A2 (en) * 2005-09-12 2007-10-25 Foamix Ltd. Apparatus and method for releasing a measure of content from a plurality of containers
FR2890559B1 (en) 2005-09-13 2011-06-24 Galderma Sa DERMATOLOGICAL FOAMS BASED ON METRONIDAZOLE AND EMULSIONS FOR PREPARATION
DE202006004676U1 (en) * 2005-09-28 2007-02-08 Neubourg Skin Care Gmbh & Co. Kg Formulation, useful as foam skin cream and to treat e.g. dermatitis and psoriasis, comprises an aqueous emulsion, propellant gas, urea emulsion, hyaluronic acid, free fatty acid and at least two emulsions
EP2108360A3 (en) 2005-10-24 2010-06-09 Collegium Pharmaceutical, Inc. Topical Pharmaceutical Foam Composition
US20070134174A1 (en) 2005-11-03 2007-06-14 Christopher Irwin Personal care composition
JP2007131539A (en) 2005-11-08 2007-05-31 Koike Kagaku Kk Chilling foam cosmetic
US20070148194A1 (en) 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
JP4885529B2 (en) 2005-12-08 2012-02-29 住友重機械工業株式会社 Radiation detection unit and radiation inspection apparatus
US20070160548A1 (en) 2005-12-13 2007-07-12 Playtex Products, Inc. Moisturizing sunless tanning composition
US20070142263A1 (en) 2005-12-15 2007-06-21 Stahl Katherine D Color changing cleansing composition
US20070148112A1 (en) 2005-12-28 2007-06-28 Avon Products, Inc. Foaming, color-changing topical composition and method of imparting a cosmetic effect
AU2007207116B2 (en) 2006-01-19 2012-08-02 Disphar International B.V. Foam-forming composition
US20070166273A1 (en) 2006-01-19 2007-07-19 Krivulka Joseph J Skin treatment educational kit
CA2645073A1 (en) 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
US20070224143A1 (en) 2006-03-21 2007-09-27 Kamedis Ltd. Cosmetic and pharmaceutical foam carrier
KR20080098659A (en) 2006-03-22 2008-11-11 더 프록터 앤드 갬블 캄파니 Aerosol product comprising a foaming concentrate composition comprising particulate materials
US7252816B1 (en) 2006-03-29 2007-08-07 Dow Pharmaceutical Sciences Topical acne vulgairs medication with a sunscreen
BRPI0709674A2 (en) 2006-03-31 2011-12-06 Stiefel Res Australia Pty Ltd sparkling suspension gel
WO2008075207A2 (en) 2006-04-04 2008-06-26 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US20070264317A1 (en) 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
CA2653347A1 (en) 2006-05-31 2007-12-13 The Dial Corporation Alcohol-containing antimicrobial compositions having improved efficacy
JP4892282B2 (en) 2006-06-09 2012-03-07 アルプス電気株式会社 Lubricating composition for electrical contacts
WO2008110872A2 (en) 2006-06-23 2008-09-18 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US7826675B2 (en) * 2006-07-04 2010-11-02 Hewlett-Packard Development Company, L.P. Feature-aware image defect removal
WO2008038147A2 (en) 2006-07-05 2008-04-03 Foamix Ltd. Foamable vehicle comprising dicarboxylic acid or dicarboxylic acid ester and pharmaceutical compositions thereof
US9023863B2 (en) * 2006-07-14 2015-05-05 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
EP1889609B1 (en) 2006-07-18 2019-05-22 Meda AB Immune response modifier foam formulations
US20080031908A1 (en) * 2006-07-25 2008-02-07 L'oreal Oily cosmetic composition in aerosol form
JP2008040899A (en) 2006-08-08 2008-02-21 Fuji Xerox Co Ltd Printing controller, program, and method
MX2009002536A (en) 2006-09-08 2009-04-14 Foamix Ltd Colored or colorable foamable composition and foam.
ES2315123B1 (en) 2006-09-25 2009-12-30 Divasa-Farmavic, S.A. STABLE PHARMACEUTICAL COMPOSITIONS OF TETRACICLINES IN SOLUTION, PROCEDURE FOR OBTAINING AND USES.
HUP0600765A2 (en) 2006-10-06 2008-10-28 Istvan Piller Container for stable carbondioxide foam, process for producing stable carbondioxide foam and method for using of foam
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080206155A1 (en) 2006-11-14 2008-08-28 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
WO2008152444A2 (en) 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
CN102670424A (en) 2006-12-15 2012-09-19 宝洁公司 Skin care compositions
WO2008083158A2 (en) 2006-12-26 2008-07-10 Femmepharma Holding Company, Inc. Topical administration of danazol
US20080292560A1 (en) 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
JP2010515766A (en) 2007-01-16 2010-05-13 オイスターシェル エヌ．ブイ． Effervescent composition and use thereof for killing arthropods
WO2008097850A1 (en) 2007-02-02 2008-08-14 Warner Chilcott Company, Inc. Tretracycline compositions for topical administration
US20080188446A1 (en) 2007-02-02 2008-08-07 Warner Chilcott Company Inc. Tetracycline compositions for topical administration
PT103661B (en) 2007-02-23 2010-09-07 Hovione Farmaciencia S A MINOCYCINE PREPARATION PROCESS CRYSTALLINE
GB0703909D0 (en) 2007-02-28 2007-04-11 Neuropharm Ltd Treatment of anxiety disorders
FR2915891B1 (en) 2007-05-10 2012-05-11 Oreal FOAM COMPOSITION COMPRISING A SILICONE POLYMER
US9511016B2 (en) 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8617100B2 (en) 2007-09-04 2013-12-31 Foamix Ltd. Device for delivery of a foamable composition
US20090130029A1 (en) 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
CA2711703A1 (en) 2008-01-08 2009-07-16 Foamix Ltd. Sensation modifying topical composition foam
CA2712120A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8652443B2 (en) 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
ES2330291B1 (en) * 2008-02-29 2010-10-18 Lipotec Sa USEFUL PEPTIDES IN THE TREATMENT OF SKIN, MUCOSAS AND / OR LEATHER HAIR AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS.
RU2547441C2 (en) 2008-03-06 2015-04-10 Анакор Фармасьютикалз, Инк. Boron-containing small molecules as anti-inflammatory agents
US20120141384A1 (en) 2008-05-06 2012-06-07 Dov Tamarkin Antibacterial conjugated boronic acids and pharmaceutical compositions thereof
EP2312563B1 (en) 2008-08-07 2012-07-18 Sharp Kabushiki Kaisha Display device
EP2210588B1 (en) 2008-12-23 2011-03-09 Intendis GmbH Foamable composition essentially free of pharmaceutically active ingredients for the treatment of human skin
JP5213734B2 (en) 2009-01-22 2013-06-19 サンウエーブ工業株式会社 Cabinet with flap door
CA2752070C (en) 2009-02-12 2017-11-28 Precision Dermatology, Inc. Foamable benzoyl peroxide compositions for topical administration
PT2400951T (en) 2009-02-25 2018-11-26 Mayne Pharma Llc Topical foam composition
US20120164087A1 (en) 2009-04-24 2012-06-28 Carter Daniel C Human Serum Albumin-Based Topical Ointment for Treatment of Acne, Psoriasis, Egfr-Induced Toxicity, Premature Skin Aging and Other Skin Conditions
US20120087872A1 (en) * 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
PT104644B (en) 2009-06-26 2012-11-06 Hovione Farmaciencia S A Topical formulation containing a tetracycline and a method of treating skin infections using the same
US8255186B2 (en) 2009-07-09 2012-08-28 Air Liquide Large Industries U.S. Lp Presenting dynamic SCADA data
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US20110052506A1 (en) 2009-08-31 2011-03-03 Collegium Pharmaceutical, Inc. Stable Aerosol Topical Foams Comprising a Hypochlorite Salt
US20140121188A1 (en) 2009-10-02 2014-05-01 Foamix Ltd. Compositions for the improved treatment of acne and related disorders
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US20140186269A1 (en) 2013-01-03 2014-07-03 Foamix Ltd. Vehicle compositions essentially free of pharmaceutically active agents for the improved treatment of acne and related disorders
GB2474930B (en) 2009-10-02 2012-07-04 Foamix Ltd Topical tetracycline compositions
BR112012007473A2 (en) 2009-10-02 2019-05-07 Foamix Ltd tetracycline topical compositions and methods of use
WO2013136192A2 (en) 2012-03-15 2013-09-19 Foamix Ltd. Use of tetracycline compositions for wound treatment and skin restoration
US8735377B1 (en) 2010-02-04 2014-05-27 Susan Anna Sipos Methods of treating herpes zoster
US20110212035A1 (en) 2010-02-26 2011-09-01 Collegium Pharmaceutical, Inc. Emollient foams for treatment of dermatoses
US8623330B2 (en) 2010-03-18 2014-01-07 Precision Dermatology, Inc. Emollient foams for treatment of seborrheic dermatitis
EP2563336A4 (en) 2010-03-26 2014-07-23 Prec Dermatology Inc Aerosol foams comprising clindamycin phosphate
US20120070390A1 (en) 2010-04-21 2012-03-22 Phillips D Howard Topical drug delivery system with dual carriers
US20130053353A1 (en) 2010-05-04 2013-02-28 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses
ES2918299T3 (en) 2010-06-11 2022-07-15 Prec Dermatology Inc High oil content emollient spray foam compositions
WO2012007843A2 (en) 2010-07-12 2012-01-19 Foamix Ltd. Apparatus and method for releasing a unit dose of content from a container
CN103347517B (en) 2010-08-11 2018-10-02 德雷克塞尔大学 Treat the D of dyskinesia in Parkinson's disease3Dopamine-receptor stimulant
US20120064136A1 (en) 2010-09-10 2012-03-15 Nanobio Corporation Anti-aging and wrinkle treatment methods using nanoemulsion compositions
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
EP2665483B1 (en) 2011-01-19 2020-08-26 Laboratory Skin Care, Inc. Topical minocycline compositions and methods of using the same
US20140221320A1 (en) 2011-07-08 2014-08-07 The Research Foundation For The State University Of New York Topical minocycline ointment for suppression of allergic skin responses
JP2014532717A (en) 2011-11-03 2014-12-08 プレシジョン ダーマトロジー インコーポレイテッドＰｒｅｃｉｓｉｏｎ Ｄｅｒｍａｔｏｌｏｇｙ， Ｉｎｃ． Stable skin aerosol foam with reactive propellant
US8801680B2 (en) 2012-03-14 2014-08-12 Becton, Dickinson And Company Angled retracting sheath for safety needle
US9018236B2 (en) 2012-03-22 2015-04-28 Precision Dermatology, Inc. Cyclodextrin-based microemulsions, and dermatological uses thereof
CA2775393C (en) 2012-05-02 2014-04-29 Samy Saad Topical non-aqueous pharmaceutical formulations
JP2015525766A (en) 2012-07-13 2015-09-07 パラテック ファーマシューティカルズ インコーポレイテッド Tetracycline compounds for the treatment of neurodegenerative disorders
PT106679B (en) 2012-11-27 2015-03-25 Hovione Farmaciencia Sa TOPICAL FORMULATIONS OF TETRACYCLINES, THEIR PREPARATION AND USES
EP2961385A4 (en) 2013-02-28 2016-07-27 Prec Dermatology Inc Topical formulations of corticosteroids with enhanced bioavailability
US20140243300A1 (en) 2013-02-28 2014-08-28 Precision Dermatology, Inc. Controlling the Bioavailability of Active Ingredients in Topical Formulations
WO2014151347A1 (en) 2013-03-15 2014-09-25 Revance Therapeutics, Inc. Minocycline derivatives
EP3010487A4 (en) 2013-06-17 2016-12-07 Contract Pharmaceuticals Ltd Non-aerosol foams for topical administration
WO2015066717A1 (en) 2013-11-04 2015-05-07 BioPharmX, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
IN2013MU03646A (en) 2013-11-20 2015-07-31 Lupin Ltd
PT107433B (en) 2014-01-28 2018-12-04 Hovione Farm S A PARTICLE SIZE REDUCTION AND CONTROL PROCESS
WO2015153864A2 (en) 2014-04-02 2015-10-08 Hopkins Patricia T Methods for treating inflammatory conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679324A (en) * 1994-07-08 1997-10-21 The Procter & Gamble Co. Aerosol foamable fragrance composition
US20020182234A1 (en) * 2000-12-19 2002-12-05 Beiersdorf Aktiengesellschaft Self-foaming or foam-like preparations
US6902737B2 (en) * 2001-01-18 2005-06-07 L'oreal Translucent nanoemulsion, production method, and uses thereof in the cosmetic, dermatological and/or ophthalmological fields

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
WO2018086790A1 (en) * 2016-11-11 2018-05-17 Beiersdorf Ag Cleaning foam containing hydroxypropyl methylcellulose and xanthan gum

Also Published As

Publication number Publication date
US20170119665A1 (en) 2017-05-04
US20130183251A1 (en) 2013-07-18
US20100284938A1 (en) 2010-11-11
US20100040561A9 (en) 2010-02-18
US8435498B2 (en) 2013-05-07
US9492412B2 (en) 2016-11-15
US20050074414A1 (en) 2005-04-07
US8741265B2 (en) 2014-06-03
US7700076B2 (en) 2010-04-20
US20140227199A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
US9492412B2 (en) Penetrating pharmaceutical foam
CA2536482C (en) Penetrating pharmaceutical foam
US20200101164A1 (en) Cosmetic and pharmaceutical foam
CA2534372C (en) Foam carrier containing amphiphilic copolymeric gelling agent
US8114385B2 (en) Oleaginous pharmaceutical and cosmetic foam
ZA200503298B (en) Cosmetic and pharmaceutical foam

Legal Events

Date Code Title Description
AS Assignment

Owner name: FOAMIX PHARMACEUTICALS LTD., ISRAEL

Free format text: CHANGE OF NAME;ASSIGNOR:FOAMIX LTD.;REEL/FRAME:034476/0494

Effective date: 20140601

Owner name: FOAMIX LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAMARKIN, DOV;FRIEDMAN, DORON;EINI, MEIR;SIGNING DATES FROM 20041111 TO 20041117;REEL/FRAME:034268/0411

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: PERCEPTIVE CREDIT HOLDINGS II, LP, NEW YORK

Free format text: PATENT SECURITY AGREEMENT;ASSIGNOR:FOAMIX PHARMACEUTICALS LTD.;REEL/FRAME:052130/0966

Effective date: 20200309

AS Assignment

Owner name: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.), NEW JERSEY

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:PERCEPTIVE CREDIT HOLDINGS II, LP;REEL/FRAME:057531/0980

Effective date: 20210811